

CITATION REPORT

List of articles citing

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

DOI: 10.1056/nejmoa020047

New England Journal of Medicine, 2002, 347, 975-82.

Source: <https://exaly.com/paper-pdf/34119523/citation-report.pdf>

Version: 2024-04-09

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2282	Neonatal hepatitis and congenital infections. 140-154		1
2281	Direct Philosophical Influences on Psychology. 1975 , 15-35		
2280	Hepatocellular fat accumulation and low serum cholesterol in patients infected with HCV-3a. 2002 , 97, 2880-5		96
2279	Optimal clinical trial designs for immune-based therapies in persistent viral infections. 2002 , 1, 4		1
2278	Introduction to therapy of hepatitis C. 2002 , 36, S114-20		37
2277	Understudied populations with hepatitis C. 2002 , 36, S226-36		26
2276	Highly sensitive hepatitis C virus RNA detection methods: molecular backgrounds and clinical significance. 2002 , 25 Suppl 3, S23-9		87
2275	[The interferons: pharmacology, mechanism of action, tolerance and side effects]. 2002 , 23 Suppl 4, 449s-458s		25
2274	Front Matter. 2002 , iii		
2273	Motion - the available treatments for hepatitis C are cost effective: arguments for the motion. 2002 , 16, 705-9		4
2272	Hepatitis C. 2002 , 30, 37-40		
2271	Polymers--a synthetic or natural choice?. 2002 , 7, 1202-3		7
2270	Course and outcome of hepatitis C. 2002 , 36, S21-S29		526
2269	Use and interpretation of virological tests for hepatitis C. 2002 , 36, S65-S73		147
2268	Introduction to therapy of hepatitis C. 2002 , 36, S114-S120		53
2267	Optimal therapy of hepatitis C. 2002 , 36, S121-S127		123
2266	Retreatment of patients with chronic hepatitis C. 2002 , 36, S128-S134		30

2265	Monitoring of viral levels during therapy of hepatitis C. 2002 , 36, S145-S151	87
2264	Treatment of patients with hepatitis C and cirrhosis. 2002 , 36, S185-S194	56
2263	Understudied populations with hepatitis C. 2002 , 36, S226-S236	52
2262	Side effects of therapy of hepatitis C and their management. 2002 , 36, S237-S244	428
2261	Course and outcome of hepatitis C. 2002 , 36, S21-9	479
2260	Optimal therapy of hepatitis C. 2002 , 36, S121-7	128
2259	Monitoring of viral levels during therapy of hepatitis C. 2002 , 36, S145-51	63
2258	Side effects of therapy of hepatitis C and their management. 2002 , 36, S237-44	337
2257	Treatment of patients with hepatitis C and cirrhosis. 2002 , 36, S185-94	38
2256	Use and interpretation of virological tests for hepatitis C. 2002 , 36, S65-73	118
2255	Retreatment of patients with chronic hepatitis C. 2002 , 36, S128-34	21
2254	Combination treatment of IFNalpha2b and ribavirin in patients with chronic hepatitis C and persistently normal ALTs. 2003 , 48, 921-5	6
2253	Tyranny of algorithms in the treatment of patients with hepatitis C. 2003 , 38, 1593-4; author reply 1594-5	1
2252	Spontaneous viral clearance in patients with acute hepatitis C can be predicted by repeated measurements of serum viral load. 2003 , 37, 60-4	138
2251	Interferon alfa regulated gene expression in patients initiating interferon treatment for chronic hepatitis C. 2003 , 37, 610-21	89
2250	Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy. 2003 , 37, 600-9	223
2249	Extending combination therapy with peginterferon alfa-2b plus ribavirin for genotype 1 chronic hepatitis C late responders: a report of 9 cases. 2003 , 37, 1226-7	48
2248	Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon. 2003 , 37, 1351-8	203

2247	Triple therapy with amantadine in treatment-naïve patients with chronic hepatitis C: a placebo-controlled trial. 2003 , 37, 1359-67	54
2246	Diagnosing fibrosis in hepatitis C: is the pendulum swinging from biopsy to blood tests?. 2003 , 37, 972-4	96
2245	Viral kinetics in hepatitis C. 2003 , 37, 1257-9	14
2244	A multicenter study of recombinant human interleukin 12 for the treatment of chronic hepatitis C virus infection in patients nonresponsive to previous therapy. 2003 , 37, 1368-74	31
2243	Maintenance therapy with ribavirin in patients with chronic hepatitis C who fail to respond to combination therapy with interferon alfa and ribavirin. 2003 , 38, 66-74	73
2242	Can serum HBV-DNA be used as a primary end point to assess efficacy of new treatments for chronic hepatitis B?. 2003 , 38, 18-20	9
2241	Localization of hepatitis C virus in gastrointestinal mucosa: a possible reservoir for relapse. 2003 , 38, 775	7
2240	Ribavirin as maintenance therapy for hepatitis C patients: an interim peacekeeper?. 2003 , 38, 21-4	4
2239	Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. 2003 , 38, 645-52	621
2238	Obesity and its nurturing effect on hepatitis C. 2003 , 38, 557-9	26
2237	A pilot study of therapeutic vaccination with envelope protein E1 in 35 patients with chronic hepatitis C. 2003 , 38, 1289-96	101
2236	E1 therapeutic vaccination for chronic hepatitis C: all that glitters is not gold. 2003 , 38, 1092-4	1
2235	Projecting future complications of chronic hepatitis C in the United States. 2003 , 9, 331-8	450
2234	Hepatitis C virus therapy, hepatocyte drug metabolism, and risk for acute cellular rejection. 2003 , 9, 1159-65	61
2233	Treatment of patients with hepatitis C virus on the waiting list. 2003 , 9, S90-4	55
2232	Natural history and risk factors for progression of hepatitis C virus disease and development of hepatocellular cancer before liver transplantation. 2003 , 9, S14-20	23
2231	How can we identify better those with recurrent hepatitis C who will respond to therapy? What are the optimal treatment regimen and treatment duration?. 2003 , 9, S109-13	6
2230	Controversies in the management of hepatitis C virus infection after liver transplantation. 2003 , 9, 1129-44	24

2229	Antiviral Therapy for Hepatitis C. 2003 , 6, 445-453	5
2228	Update on chronic hepatitis C. 2003 , 29, 224-32	
2227	Treatment for chronic hepatitis C. 2003 , 5, 1-2	
2226	Hepatitis C antiviral treatment in special populations. 2003 , 2, 101-107	
2225	Hepatitis C in veterans. 2003 , 2, 108-115	9
2224	Alcohol and hepatitis C: Implications for disease progression and treatment. 2003 , 2, 125-131	
2223	Treatment of hepatitis C. 2003 , 2, 3-8	0
2222	Pegylated interferons: What role will they play in the treatment of chronic hepatitis C?. 2003 , 2, 17-23	2
2221	Pegylated interferons in combination with ribavirin for the treatment of chronic hepatitis C. 2003 , 2, 24-31	1
2220	Treatment of chronic hepatitis C in patients who have failed to respond to IFN or IFN and ribavirin combination therapy. 2003 , 2, 32-39	1
2219	Treatment of chronic hepatitis C: Improved combination therapy. 2003 , 2, 40-46	2
2218	Treatment of hepatitis B and C following nonliver organ transplants. 2003 , 2, 82-87	2
2217	New and modified interferon alfas: preclinical and clinical data. 2003 , 5, 108-13	22
2216	Zytokine. 2003 , 46, 203-210	
2215	Bekanntmachung des Arbeitskreises Blut des Bundesministeriums für Gesundheit und soziale Sicherung Hepatitis-C-Virus (HCV). 2003 , 46, 712-722	4
2214	When should decision-analytic modeling be used in the economic evaluation of health care?. 2003 , 4, 143-150	110
2213	Long-term ribavirin therapy in hepatitis C virus-positive renal transplant patients: effects on renal function and liver histology. 2003 , 42, 184-92	70
2212	Hepatitis C and renal disease: an update. 2003 , 42, 631-57	269

2211	Combined antiviral options for the treatment of chronic hepatitis C. 2003 , 60, 135-43	16
2210	The effect of ribavirin and IMPDH inhibitors on hepatitis C virus subgenomic replicon RNA. 2003 , 310, 333-42	153
2209	A replicon-based bioassay for the measurement of interferons in patients with chronic hepatitis C. 2003 , 110, 201-9	152
2208	Mechanisms of antiviral treatment efficacy and failure in chronic hepatitis C. 2003 , 59, 1-11	119
2207	GB virus C genotype determination in GB virus-C/HIV co-infected individuals. 2003 , 70, 141-9	45
2206	Suppression of HCV-specific T cells without differential hierarchy demonstrated ex vivo in persistent HCV infection. 2003 , 38, 1437-48	141
2205	Iron as a co-morbid factor in nonhemochromatotic liver disease. 2003 , 30, 137-44	80
2204	Quantification génomique : applications aux infections par le virus de l'hépatite C (HCV). 2003 , 2003, 35-37	
2203	Triple (interferon, ribavirin, amantadine) versus double (interferon, ribavirin) re-therapy for interferon relapser genotype 1b HCV chronic active hepatitis patients. 2003 , 25, 355-363	7
2202	Transition of care between paediatric and adult gastroenterology. Chronic viral hepatitis. 2003 , 17, 259-75	12
2201	Retreatment of hepatitis C non-responsive to interferon. A placebo controlled randomized trial of ribavirin monotherapy versus combination therapy with Ribavirin and Interferon in 121 patients in the Benelux [ISRCTN53821378]. 2003 , 3, 24	15
2200	Transjugular liver biopsy is safe and diagnostic for patients with congenital bleeding disorders and hepatitis C infection. 2003 , 9, 613-8	31
2199	Early viral kinetics on treatment with pegylated interferon-alpha-2a in chronic hepatitis C virus genotype 1 infection. 2003 , 10, 37-42	40
2198	The safety and tolerability of daily infigen plus ribavirin in the treatment of naïve chronic hepatitis C patients. 2003 , 10, 55-60	20
2197	Efficacy of prolonged 5 million units of interferon in combination with ribavirin for relapser patients with chronic hepatitis C. 2003 , 10, 111-7	8
2196	Twice-weekly administration of peginterferon-alpha-2b improves viral kinetics in patients with chronic hepatitis C genotype 1. 2003 , 10, 271-6	66
2195	Vogt-Koyanagi-Harada disease associated with interferon alpha-2b/ribavirin combination therapy. 2003 , 10, 467-70	29
2194	Hepatitis C virus-related cryoglobulinemic glomerulonephritis: long-term remission after antiviral therapy. 2003 , 63, 2236-41	66

2193	BHIVA guidelines: coinfection with HIV and chronic hepatitis C virus. 2003 , 4 Suppl 1, 52-62	10
2192	Review article: indicators and predictors of response to anti-viral therapy in chronic hepatitis C. 2003 , 17, 611-21	24
2191	Induction interferon and ribavirin for re-treatment of chronic hepatitis C patients unresponsive to interferon alone. 2003 , 17, 1197-204	3
2190	Systematic review: peginterferon vs. standard interferon in the treatment of chronic hepatitis C. 2003 , 18, 661-70	15
2189	RNA interference: on the road to an alternate therapeutic strategy!. 2003 , 13, 373-85	65
2188	The end of the needle is in sight. 2003 , 13, 343-5	
2187	Mutations in the NS5A and E2-PePHD regions of hepatitis C virus genotype 1b and response to combination therapy of interferon plus ribavirin. 2003 , 23, 426-33	17
2186	Efficacy of hepatitis C treatment may be enhanced by a longer interferon administration. 2003 , 23, 410-2	
2185	Effect of pegylation on pharmaceuticals. 2003 , 2, 214-21	2532
2184	GI clinical research 2002-2003: the year in review. 2003 , 1, 415-20	10
2183	Factors that influence the severity of recurrent hepatitis C virus following liver transplantation. 2003 , 7, 603-14	7
2182	Manejo terapéutico de la infección crónica por virus C. 2003 , 203, 443-444	
2181	Use and interpretation of hepatitis C virus diagnostic assays. 2003 , 7, 127-37	34
2180	Hepatitis:Actualice sus conocimientos sobre esta amenaza silenciosa. 2003 , 21, 19-25	
2179	Treatment strategies for hepatitis C: intervention prior to liver transplant, pre-emptively or after established disease. 2003 , 7, 631-50, vii	9
2178	Current therapy for hepatitis C: pegylated interferon and ribavirin. 2003 , 7, 149-61	94
2177	Antiviral and antiretroviral use in pregnancy. 2003 , 30, 731-49, vii	9
2176	Tratamiento de las hepatitis víricas. 2003 , 8, 6455-6468	

2175	[Interferon, ribavirin and amantadine in prior nonresponders to interferon and ribavirin therapy with chronic hepatitis C (genotype 1)]. <i>Gastroenterology & Hepatology</i> , 2003 , 26, 465-8	0.9	1
2174	Erythropoietin for ribavirin-induced anemia in hepatitis C: more answers but many more questions. 2003 , 98, 2344-2347		2
2173	Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa. 2003 , 98, 2491-2499		1
2172	The interferon sensitivity determining region in the era of combination therapies and the rational use of such therapies for patients with HCV genotype 1b infection. 2003 , 125, 1284-6		
2171	Side effects of therapy for chronic hepatitis C. 2003 , 124, 1711-9		212
2170	Developments in hepatitis C therapy during 2000-2002. 2003 , 8, 9-25		6
2169	Neuropsychiatric changes in HIV/hepatitis C coinfecting patients undergoing interferon therapy. 2003 , 14, 805-865		3
2168	Treatment of hepatitis C virus in the coinfecting patient. 2003 , 14, 525-795		1
2167	Macromolecular therapeutics: advantages and prospects with special emphasis on solid tumour targeting. 2003 , 42, 1089-105		227
2166	Peginterferon-alpha-2a (40kD) plus ribavirin: a review of its use in the management of chronic hepatitis C. 2003 , 63, 701-30		42
2165	Can we identify liver fibrosis in HCV-infected patients without a liver biopsy?. 2003 , 2, 145-151		4
2164	Weight-based dosing of pegylated interferon-alpha in chronic hepatitis C: just a marketing 'gag'?. 2003 , 35, 601-6		6
2163	Chimeric flaviviruses: novel vaccines against dengue fever, tick-borne encephalitis, and Japanese encephalitis. 2003 , 61, 469-509		76
2162	Peginterferon-alpha2a (40 kDa) for chronic hepatitis C. 2003 , 4, 541-51		11
2161	Suppression of HCV-specific T cells without differential hierarchy demonstrated ex vivo in persistent HCV infection. 2003 , 38, 1437-1448		225
2160	Management of hepatitis C. 2003 , 38 Suppl 1, S104-18		98
2159	Twelve weeks of follow-up is sufficient for the determination of sustained virologic response in patients treated with interferon alpha for chronic hepatitis C. 2003 , 39, 106-11		41
2158	Do we know how to achieve optimal response to Pegylated interferon alpha and Ribavirin?. 2003 , 39, 136-138		1

2157	Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. 2003 , 39, 389-96	248
2156	A randomized trial of consensus interferon in combination with ribavirin as initial treatment for chronic hepatitis C. 2003 , 39, 843-9	26
2155	Antiviral effect of ribavirin in early non-responders to interferon monotherapy assessed by kinetics of hepatitis C virus RNA and hepatitis C virus core antigen. 2003 , 39, 826-33	25
2154	Sustained virological response after a short course of treatment with interferon and ribavirin in two chronic hepatitis C patients. 2003 , 39, 655-6	10
2153	Viral hepatitis C. 2003 , 362, 2095-100	683
2152	Prospects for antiviral therapy. 2003 , 61, 511-53	15
2151	Pathophysiology of hepatitis C and HIV coinfection. 2003 , 14, 27S-48S; quiz 49S-51S	2
2150	Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections in health care workers (HCWs): guidelines for prevention of transmission of HBV and HCV from HCW to patients. 2003 , 27, 213-30	121
2149	Treatment of chronic hepatitis C in HIV-infected patients with interferon alpha-2b plus ribavirin. 2003 , 19, 1083-9	20
2148	Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa. 2003 , 98, 2491-9	185
2147	Good safety profile and efficacy of leucocyte interferon-alpha in combination with oral ribavirin in treatment-naïve patients with chronic hepatitis C: a multicentre, randomised, controlled study. 2003 , 17, 433-9	4
2146	Hepatitis C-HIV coinfection: current and future therapy. 2003 , 1, 433-9	
2145	Current and emerging therapeutic approaches to hepatitis C infection. 2003 , 1, 441-54	6
2144	[Antiviral treatment in liver cirrhosis due to hepatitis C virus]. <i>Gastroenterología Y Hepatología</i> , 2003 , 26, 303-6	0.9
2143	Clinical relevance of pharmacogenetics. 2003 , 35, 277-85	11
2142	Hepatitis C virus RNA levels during initial induction or standard interferon therapy: influence of continued treatment on sustained response. 2003 , 35, 180-5	3
2141	Hepatitis C virus (HCV) and lymphomagenesis. 2003 , 44, 1113-20	79
2140	Treatment of hepatitis C. The 2002 French consensus. 2003 , 52, 1784-7	49

2139	Chronic hepatitis C virus infection. 2003 , 289, 2413-7	75
2138	Immunology. A viral on/off switch for interferon. 2003 , 300, 1100-1	15
2137	Should treatment of hepatitis C in HIV-seropositive and HIV-seronegative patients with hemophilia include induction doses of interferon?. 2003 , 37, 463-4; author reply 464-5	
2136	Viramidine, a prodrug of ribavirin, shows better liver-targeting properties and safety profiles than ribavirin in animals. 2003 , 14, 145-52	50
2135	Monitoring response to antiviral therapy for patients with chronic hepatitis C virus infection by a core-antigen assay. 2003 , 41, 3881-4	16
2134	Hepatitis C virus (HCV) and human immunodeficiency virus (HIV) dynamics during HCV treatment in HCV/HIV coinfection. 2003 , 188, 1498-507	84
2133	Hematologic disorders associated with hepatitis C virus infection and their management. 2003 , 37, 533-41	79
2132	Pretreatment intrahepatic CD8+ cell count correlates with virological response to antiviral therapy in chronic hepatitis C virus infection. 2003 , 188, 1528-32	15
2131	Worsening of steatosis is an independent factor of fibrosis progression in untreated patients with chronic hepatitis C and paired liver biopsies. 2003 , 52, 288-92	227
2130	Hepatitis C virus therapies: current treatments, targets and future perspectives. 2003 , 14, 1-21	40
2129	Indications, patient selection and timing of referral for lung transplantation. 2003 , 22, 845-52	71
2128	Dinucleotide analogues as novel inhibitors of RNA-dependent RNA polymerase of hepatitis C Virus. 2003 , 47, 2674-81	7
2127	Initial binding of the broad spectrum antiviral nucleoside ribavirin to the hepatitis C virus RNA polymerase. 2003 , 278, 52471-8	34
2126	Implications of anemia in human immunodeficiency virus, cancer, and hepatitis C virus. 2003 , 37 Suppl 4, S293-6	7
2125	Predicting the therapeutic response in patients with chronic hepatitis C: the role of viral kinetic studies. 2004 , 53, 15-8	58
2124	A 50-year-old man with hepatitis C and cirrhosis needing liver transplantation. 2003 , 290, 3238-46	1
2123	Predicting antiviral treatment response in chronic hepatitis C: how accurate and how soon?. 2003 , 51, 487-91	16
2122	Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. 2003 , 300, 1145-8	679

2121 Hepatitis C virus. **2003**, 127-171

2120 Erythropoietin for ribavirin-induced anemia in hepatitis C: more answers but many more questions. **2003**, 98, 2344-7 7

2119 Mutations within the CD81-binding sites and hypervariable region 2 of the envelope 2 protein: correlation with treatment response in hepatitis C virus-infected patients. **2003**, 187, 982-7 14

2118 Comparison of 2 regimens that include interferon-alpha-2a plus ribavirin for treatment of chronic hepatitis C in human immunodeficiency virus-coinfected patients. **2003**, 36, 1564-71 12

2117 Outcomes of interferon alpha and ribavirin treatment for chronic hepatitis C in patients with normal serum aminotransaminases. **2003**, 52, 1644-8 34

2116 Immunization with hepatitis C virus-like particles protects mice from recombinant hepatitis C virus-vaccinia infection. **2003**, 100, 6753-8 135

2115 Promising candidates for the treatment of chronic hepatitis C. **2003**, 12, 1269-80 16

2114 Anemia in the treatment of hepatitis C virus infection. **2003**, 37 Suppl 4, S315-22 62

2113 Therapeutic management of extrahepatic manifestations in patients with chronic hepatitis C virus infection. **2003**, 42, 818-28 29

2112 Update on chronic hepatitis C in HIV/HCV-coinfected patients: viral interactions and therapy. **2003**, 17, 2279-90 35

2111 Pegylated IFN-alpha2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients. **2003**, 17, 1023-8 143

2110 [Combination therapy for chronic viral hepatitis C]. **2003**, 128, 370-4

2109 Clinical trial results of peginterferons in combination with ribavirin. **2003**, 23 Suppl 1, 35-46 18

2108 Implications of peginterferon use in special populations infected with HCV. **2003**, 23 Suppl 1, 47-52 4

2107 Hepatitis C virus RNA tests: performance attributes and their impact on clinical utility. **2003**, 3, 689-702 3

2106 Comparison of three commercially available assays for HCV RNA using the international unit standard: implications for management of patients with chronic hepatitis C virus infection in clinical practice. **2003**, 98, 1159-66 26

2105 Peginterferon alfa-2a plus ribavirin for chronic hepatitis C. *New England Journal of Medicine*, **2003**, 348, 259-60; author reply 259-60 59.2 6

2104 Chronic Viral Hepatitis. **2003**, 24, 399-410 3

2103	Hepatitis C virus in human immunodeficiency virus-infected individuals: an emerging comorbidity with significant implications. 2003 , 23, 149-66	22
2102	Hepatitis B in the human immunodeficiency virus-infected patient: epidemiology, natural history, and treatment. 2003 , 23, 125-36	104
2101	Viral kinetics in hepatitis C virus: special patient populations. 2003 , 23 Suppl 1, 29-33	11
2100	Diagnostic testing in hepatitis C virus infection: viral kinetics and genomics. 2003 , 23 Suppl 1, 3-11	4
2099	Treatment of chronic hepatitis C virus infection. 2003 , 17, 751-753	25
2098	Diagnostic Molecular Microbiology: Nucleic Acid Probes and Microbes. 2003 , 8, 137-144	
2097	Comprehensive review of hepatitis C for psychiatrists: risks, screening, diagnosis, treatment, and interferon-based therapy complications. 2003 , 9, 93-110	43
2096	Didanosine+avirin combination. 2003 , 17, 2665-2667	4
2095	A pilot study of the combination of cyclosporin A and interferon alfacon-1 for the treatment of hepatitis C in previous nonresponder patients. 2003 , 36, 352-5	14
2094	Intrafamilial transmission of HIV-1. 2003 , 17, 2673-4	
2093	The nature of interferon-alpha resistance in hepatitis C virus infection. 2003 , 16, 587-92	63
2092	Hepatitis B and C infection in children undergoing chemotherapy or bone marrow transplantation. 2003 , 25, 184-92	14
2091	Hepatitis C: update your knowledge of this silent stalker. 2003 , 33, 57-63; quiz 64	
2090	Chronic hepatitis C: updated Swedish consensus. 2003 , 35, 445-51	19
2089	Efficacy and tolerance of HCV treatment in HIV-HCV coinfecting patients: the potential interaction of PI treatment. 2003 , 4, 262-8	7
2088	Diagnostic Molecular Microbiology: Nucleic Acid Probes and Microbes. 2003 , 8, 137-144	
2087	Response to Soriano et al., Treatment of chronic hepatitis C virus infection. 2003 , 17, 2665-2667	1
2086	Chapter 22. Non-HIV antiviral agents. 2003 , 38, 213-228	1

2085	Hepatitis C in the HIV-Infected Person. 2003 , 138, 197-207	299
2084	Hepatitis C Virus (HCV). 2003 , 30, 239-250	2
2083	Current therapies for chronic hepatitis C. Drug combination achieves sustained response in more than half of patients. 2003 , 114, 48-52, 57-9, 62	5
2082	A rational use of laboratory tests in the diagnosis and management of hepatitis C virus infection. 2003 , 2, 76-83	9
2081	Helical Computed Tomography as a Test for Pulmonary Embolism. 2003 , 139, 956	
2080	Early prediction of nonresponders to treatment with interferon alpha-2b and ribavirin in patients with chronic hepatitis C. 2003 , 17, 483-7	6
2079	Peginterferon-based therapy for chronic hepatitis C virus infection in patients with normal alanine aminotransferase levels. 2003 , 139, W83	2
2078	Coronary artery disease and the acute coronary syndrome. 2003 , 139, W82	1
2077	Risk factors and secondary prevention in women with heart disease. 2003 , 139, 954; author reply 954-5	
2076	A decree against inappropriate medical care in Italy. 2003 , 139, 958	0
2075	[Therapy of viral hepatitis]. 2003 , 60, 651-6	
2074	Treatment of HCV-related liver diseases after renal transplantation: modern views. 2003 , 26, 373-82	3
2073	Therapy-induced antibodies against the antiviral and antiproliferative effects of interferons in patients with chronic hepatitis C virus infection. 2004 , 51, 359-69	2
2072	Diagnostic Evaluation of Elderly Patients with Mild Memory Problems. 2004 , 140, 72	
2071	[Hepatitis C]. 2004 , 61, 493-8	2
2070	Payment and the future of primary care. 2004 , 140, 70	0
2069	Hospice Benefits and Phase I Cancer Trials. 2004 , 140, 71	1
2068	Complementary and alternative medical education. 2004 , 140, 67; author reply 68-9	2

2067	Diagnostic evaluation of elderly patients with mild memory problems. 2004 , 140, 71; author reply 72	
2066	Effects of ribavirin on cytokine production of recall antigens and phytohemagglutinin-stimulated peripheral blood mononuclear cells. (Inhibitory effects of ribavirin on cytokine production). 2004 , 3, 104-7	11
2065	Prescribing practices for the treatment of hepatitis C in a Veterans Affairs medical center. 2004 , 61, 1479-82	
2064	Side effects of medical therapy for chronic hepatitis C. 2004 , 3, 5-10	30
2063	Hepatitis C: An Update for Occupational Health Nurses. 2004 , 52, 210-217	1
2062	Diagnosis and Treatment of Hepatitis C. 2004 , 97, 223-225	8
2061	Alzheimer disease: current concepts and emerging diagnostic and therapeutic strategies. 2004 , 140, 71	1
2060	Neutralising antibody, CTL and dendritic cell responses to hepatitis C virus: a preventative vaccine strategy. 2004 , 5, 41-56	19
2059	Smallpox Vaccination Risks and Public Policy. 2004 , 140, 67	
2058	Complementary and alternative medical education. 2004 , 140, 68	
2057	The future of primary care. 2004 , 140, 69	
2056	Risk stratification for noncardiac surgery. 2004 , 140, W2; author reply W3	1
2055	The management of chronic viral hepatitis: A Canadian consensus conference 2004. 2004 , 15, 313-26	10
2054	The management of chronic viral hepatitis: a Canadian consensus conference 2004. 2004 , 18, 715-28	41
2053	Complementary and Alternative Medical Education. 2004 , 140, 68	
2052	Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who responds less well?. 2004 , 140, 370-81	184
2051	Recent developments in target identification against hepatitis C virus. 2004 , 8, 295-307	7
2050	Treatment of chronic hepatitis C infection with peginterferons plus ribavirin. 2004 , 24 Suppl 2, 47-54	61

2049	[Treatment of hepatitis B and C -- current standards]. 2004 , 129 Suppl 2, S57-9	0
2048	Chronic hepatitis C. 2004 , 24 Suppl 2, 1-2	3
2047	Predictors of response to therapy for chronic hepatitis C. 2004 , 24 Suppl 2, 25-31	65
2046	Interferon for hepatitis C patients with psychiatric disorders. 2004 , 161, 2332; author reply 2332-4	5
2045	[Standard treatment of acute and chronic hepatitis C]. 2004 , 42, 714-9	24
2044	Histological response to interferon alfa-based therapies in hepatitis C. 2004 , 24 Suppl 2, 55-60	9
2043	Biologic immunomodulatory therapies in the vasculitic diseases. 2004 , 25, 595-607	3
2042	Is the current standard therapy for hepatitis C of peginterferon and ribavirin an option for patients coinfectd with HIV?. 2004 , 1, 70-1	
2041	Treatment with interferons (including pegylated interferons) in patients with hepatitis B. 2004 , 24 Suppl 1, 45-53	51
2040	Use of diagnostic testing for managing hepatitis C virus infection. 2004 , 24 Suppl 2, 9-18	28
2039	Interferon for hepatitis C patients with psychiatric disorders. 2004 , 161, 2331-2; author reply 2332-4	10
2038	Past, present, and future hepatitis C treatments. 2004 , 24 Suppl 2, 97-104	49
2037	Adaptive mutations producing efficient replication of genotype 1a hepatitis C virus RNA in normal Huh7 cells. 2004 , 78, 7904-15	116
2036	MxA and PKR expression in chronic hepatitis C. 2004 , 24, 659-63	15
2035	Treatments for hepatitis B. 2004 , 39, 1353-62	11
2034	Evaluation of the core antigen assay as a second-line supplemental test for diagnosis of active hepatitis C virus infection. 2004 , 42, 4054-9	21
2033	Hepatitis C virus quasispecies variability modulates nonstructural protein 5A transcriptional activation, pointing to cellular compartmentalization of virus-host interactions. 2004 , 78, 4617-27	24
2032	Sustained virological response in hepatitis C virus type 1b infected patients is predicted by the number of mutations within the NS5A-ISDR: a meta-analysis focused on geographical differences. 2004 , 53, 1345-51	115

2031	Synthesis of beta-enantiomers of N4-hydroxy-3'-deoxypyrimidine nucleosides and their evaluation against bovine viral diarrhoea virus and hepatitis C virus in cell culture. 2004 , 15, 43-55	14
2030	Disposition and metabolic profiles of [14C]viramidine and [14C]ribavirin in rat and monkey red blood cells and liver. 2004 , 48, 1872-5	24
2029	Benefit of interferon therapy in hepatocellular carcinoma prevention for individual patients with chronic hepatitis C. 2004 , 53, 425-30	125
2028	Epidemiology, Diagnosis, and Treatment of Chronic Hepatitis C. 2004 , 17, 229-238	
2027	Incidence and predictors of severe liver fibrosis in human immunodeficiency virus-infected patients with chronic hepatitis C: a European collaborative study. 2004 , 38, 128-33	249
2026	Antiretroviral therapy in patients with hepatitis and HIV: weighing risks and benefits. 2004 , 38 Suppl 2, S109-13	25
2025	Steatosis affects chronic hepatitis C progression in a genotype specific way. 2004 , 53, 406-12	204
2024	Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. 2004 , 292, 2839-48	626
2023	Iron regulates hepatitis C virus translation via stimulation of expression of translation initiation factor 3. 2004 , 190, 819-25	52
2022	Strengths and limitations of commercial tests for hepatitis C virus RNA quantification. 2004 , 42, 421-5	29
2021	Reduced numbers and impaired ability of myeloid and plasmacytoid dendritic cells to polarize T helper cells in chronic hepatitis C virus infection. 2004 , 190, 1919-26	187
2020	Incidence of thyroid dysfunction during interferon alfa-2b and ribavirin therapy in men with chronic hepatitis C: a prospective cohort study. 2004 , 164, 2371-6	45
2019	Long term clinical outcome of chronic hepatitis C patients with sustained virological response to interferon monotherapy. 2004 , 53, 1504-8	126
2018	Inhibition of hepatitis C virus replication by arsenic trioxide. 2004 , 48, 2876-82	29
2017	Impact of alpha interferon and ribavirin on the function of maturing dendritic cells. 2004 , 48, 3382-9	50
2016	Use of the MagNA pure LC automated nucleic acid extraction system followed by real-time reverse transcription-PCR for ultrasensitive quantitation of hepatitis C virus RNA. 2004 , 42, 4130-6	42
2015	Treatment of hepatitis C in HIV-infected patients: significant progress but not the final step. 2004 , 292, 2909-13	11
2014	Clinical review 169: Interferon-alpha-related thyroid disease: pathophysiological, epidemiological, and clinical aspects. 2004 , 89, 3656-61	97

2013	Management of hepatitis C. 2004 , 70, 51-69	14
2012	Prediction of relapse following treatment for hepatitis C: is whole blood more than the sum of its parts?. 2004 , 39, 1761-3	1
2011	Pegylated interferons. 2004 , 2, 113-127	1
2010	Hepatitis C virus genotype 5: epidemiological characteristics and sensitivity to combination therapy with interferon-alpha plus ribavirin. 2004 , 189, 1397-400	47
2009	Treatment of early diagnosed HCV infection in hemodialyzed patients with interferon-alpha. Treatment of hepatitis C. 2004 , 22, 344-50	19
2008	Can epoetin alfa maintain ribavirin doses in patients with hepatitis C virus on combination therapy?. 2004 , 1, 24-5	1
2007	Early HCV dynamics on Peg-interferon and ribavirin in HIV/HCV co-infection: indications for the investigation of new treatment approaches. 2004 , 18, 59-66	37
2006	Pegylated interferon alpha2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients. 2004 , 18, 67-73	64
2005	The bisexual bridge revisited: sexual risk behavior among men who have sex with men and women, San Francisco, 1998-2003. 2004 , 18, 1604-6	40
2004	Screening for HIV-specific T-cell responses using overlapping 15-mer peptide pools or optimized epitopes. 2004 , 18, 1595-8	34
2003	A single-nucleotide polymorphism in the human beta-defensin 1 gene is associated with HIV-1 infection in Italian children. 2004 , 18, 1598-600	110
2002	Verification of an assay for quantification of hepatitis C virus RNA by use of an analyte-specific reagent and two different extraction methods. 2004 , 42, 3581-8	24
2001	Chronic hepatitis virus infections in patients on renal replacement therapy. 2004 , 19, 1049-53	28
2000	Answer. 2004 , 53, 430-430	2
1999	Pegylated interferons. 2004 , 2, 113-127	
1998	Performance characteristics of a quantitative TaqMan hepatitis C virus RNA analyte-specific reagent. 2004 , 42, 3739-46	38
1997	A pilot study of interleukin-11 in subjects with chronic hepatitis C and advanced liver disease nonresponsive to antiviral therapy. 2004 , 99, 2359-64	20
1996	Safety of antitumour necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection. 2004 , 63 Suppl 2, ii18-ii24	110

1995	Treatment of chronic hepatitis C virus in the virginia department of corrections: can compliance overcome racial differences to response?. 2004 , 99, 866-72	55
1994	Chronic hepatitis C and normal ALT: considerations for treatment. 2004 , 99, 1706-7	4
1993	Hepatitis C virus (HCV) relapses after anti-HCV therapy are more frequent in HIV-infected patients. 2004 , 20, 351-3	36
1992	Thalassemia. 2004 , 2004, 14-34	165
1991	Atlas of the Liver. 2004 ,	
1990	Multicenter evaluation of the performance characteristics of the bayer VERSANT HCV RNA 3.0 assay (bDNA). 2004 , 42, 563-9	83
1989	Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. <i>New England Journal of Medicine</i> , 2004 , 350, 2265-71	59.2 485
1988	A descriptive study of the relationship between mood disorders and hepatitis C treatment compliance: does nursing play a role?. 2004 , 25, 715-22	9
1987	A 48-week duration of therapy with pegylated interferon alpha 2b plus ribavirin may be too short to maximize long-term response among patients infected with genotype-1 hepatitis C virus. 2004 , 189, 964-70	79
1986	Treatment of chronic hepatitis C in children. 2004 , 8, 639-43	9
1985	Ribavirin/interferon- β sequential treatment of recurrent hepatitis C after liver transplantation. 2004 , 17, 169-176	6
1984	Management of hepatitis C virus genotype 4. 2004 , 19, 1233-9	18
1983	Factors contributing to ribavirin-induced anemia. 2004 , 19, 1312-7	66
1982	Combination therapy of thymalfasin (thymosin-alpha 1) and peginterferon alfa-2a in patients with chronic hepatitis C virus infection who are non-responders to standard treatment. 2004 , 19 Suppl 6, S76-8	14
1981	Natural history and treatment of hepatitis C infection in children. 2004 , 19, S379-S381	2
1980	Diagnosis of hepatitis C: update 2004. 2004 , 19, S88-S93	1
1979	Treatment of chronic HCV infection in compensated and decompensated cirrhosis. 2004 , 19, S94-S98	
1978	Chronic hepatitis B or C in HIV-infected persons: pathogenesis and management. 2004 , 19, S138-S144	1

1977	Interactions between non-alcoholic fatty liver disease and hepatitis C viral infection. 2004 , 19, S253-S257	3
1976	Treatment of chronic hepatitis C in patients with drug dependence: time to change the rules?. 2004 , 99, 1167-75	90
1975	A randomized controlled trial of amantadine plus interferon-alpha2a vs. interferon-alpha2a alone in naive patients with chronic hepatitis C randomized according to the early virological response to interferon-alpha2a monotherapy. 2004 , 19, 339-47	11
1974	Increased circulating and intrahepatic T-cell-specific chemokines in chronic hepatitis C: relationship with the type of virological response to peginterferon plus ribavirin combination therapy. 2004 , 19, 551-62	30
1973	Review article: the evolving role of liver biopsy. 2004 , 20, 249-59	81
1972	Combination therapy for the treatment of hepatitis C in the veteran population: higher than expected rates of therapy discontinuation. 2004 , 20, 629-36	6
1971	Review article: pegylated interferons: chemical and clinical differences. 2004 , 20, 825-30	76
1970	The management of side-effects during therapy for hepatitis C. 2004 , 20, 917-29	42
1969	Meta-analysis: a randomized trial of peginterferon plus ribavirin for the initial treatment of chronic hepatitis C genotype 4. 2004 , 20, 931-8	71
1968	Interest of transjugular liver biopsy in adult patients with haemophilia or other congenital bleeding disorders infected with hepatitis C virus. 2004 , 125, 769-76	18
1967	CD56(+dim) and CD56(+bright) cell activation and apoptosis in hepatitis C virus infection. 2004 , 137, 408-16	30
1966	Human immunodeficiency and hepatitis virus infections and their associated conditions and treatments among people with haemophilia. 2004 , 10 Suppl 4, 205-10	38
1965	Hepatitis C infection in children with haemophilia: a pilot study. 2004 , 10, 722-6	8
1964	Same day outpatient transjugular liver biopsies in haemophilia. 2004 , 10, 727-31	20
1963	Changes in haemoglobin during interferon alpha-2b plus ribavirin combination therapy for chronic hepatitis C virus infection. 2004 , 11, 243-50	123
1962	Effects of interferon and ribavirin combination therapy on CD4+ proliferation, lymphocyte activation, and Th1 and Th2 cytokine profiles in chronic hepatitis C. 2004 , 11, 206-16	18
1961	Polymorphisms of NS5B protein relates to early clearance of hepatitis C virus by interferon plus ribavirin: a pilot study. 2004 , 11, 225-35	10
1960	Epoetin alfa treatment for acute anaemia during interferon plus ribavirin combination therapy for chronic hepatitis C. 2004 , 11, 191-7	13

1959	Mutations in the putative HCV-E2 CD81 binding regions and correlation with cell surface CD81 expression. 2004 , 11, 310-8	11
1958	Treatment of patients with HCV infection with or without liver biopsy. 2004 , 11, 536-42	16
1957	Chronic hepatitis C and no response to antiviral therapy: potential current and future therapeutic options. 2004 , 11, 287-96	15
1956	Effects of ribavirin combined with interferon-alpha 2b on viral kinetics during first 12 weeks of treatment in patients with hepatitis C virus genotype 1 and high baseline viral loads. 2004 , 11, 448-54	10
1955	Monitoring intrahepatic CD8+ T cells by fine-needle aspiration cytology in chronic hepatitis C infection. 2004 , 11, 342-8	8
1954	A randomized trial of prolonged high dose of interferon plus ribavirin for hepatitis C patients nonresponders to interferon alone. 2004 , 11, 543-51	9
1953	Hepatitis C: How should we manage the patient?. 2004 , 11 Suppl 1, 19-22	3
1952	Hepatitis C: What is the best treatment?. 2004 , 11 Suppl 1, 23-7	18
1951	Sustained suppression of hepatitis C virus by high doses of interferon and ribavirin in adult hemophilic patients. 2004 , 44, 790-4	13
1950	Lymphocyte T helper-specific reactivity in sustained responders to interferon and ribavirin with negatvation (seroreversion) of anti-hepatitis C virus. 2004 , 24, 413-8	8
1949	Randomized trial of three different regimens for 24 weeks for re-treatment of chronic hepatitis C patients who failed to respond to interferon-alpha monotherapy in Taiwan. 2004 , 24, 595-602	14
1948	Risk factors for hepatocellular carcinoma in Hepatitis C patients with sustained virologic response to interferon therapy. 2004 , 24, 603-10	53
1947	A primer on the molecular virology of hepatitis C. 2004 , 24, 519-25	19
1946	Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C in Saudi patients commonly infected with genotype 4. 2004 , 24, 568-74	67
1945	Modifications of haematological series in patients co-infected with human immunodeficiency virus and hepatitis C virus during treatment with interferon and ribavirin: differences between pegylated and standard interferon. 2004 , 10, 1067-74	5
1944	Host genetic determinants in hepatitis C virus infection. 2004 , 5, 237-45	101
1943	Modelling how ribavirin improves interferon response rates in hepatitis C virus infection. 2004 , 432, 922-4	307
1942	Severe hepatitis C infection in a renal transplant recipient following hepatitis C genotype mismatch transplant. 2004 , 4, 1375-8	19

1941	Biomedicines to reduce inflammation but not viral load in chronic HCV--what's the sense?. 2004 , 22, 517-23	34
1940	The case for hepatitis C arthritis. 2004 , 33, 375-87	62
1939	Performance attributes of the LCx HCV RNA quantitative assay. 2004 , 115, 207-15	14
1938	Focus on hepatocellular carcinoma. 2004 , 5, 215-9	472
1937	[Acute hepatitis C: early, delayed or immediate treatment?]. 2004 , 28, 126-8	1
1936	[Obesity and alcoholic and viral chronic liver disease]. 2004 , 28, 268-71	1
1935	[Is combined treatment with interferon alpha and ribavirin for 3 months enough in selected patients with a genotype 2 or 3 hepatitis C virus?]. 2004 , 28, 304-6	
1934	[Treatment of hepatitis C and drug addiction: is the development of "clinically significant" fibrosis a good decision-making criterion?]. 2004 , 28, 529-31	
1933	Management of hepatitis C patients: a French population-based study. 2004 , 28, 1101-5	4
1932	Influence of antiviral therapy in hepatitis C virus-associated cryoglobulinemic MPGN. 2004 , 43, 617-23	140
1931	Follow-up of adverse drug reactions from peginterferon alfa-2b-ribavirin therapy. 2004 , 24, 1546-53	24
1930	The phenomenology and treatment of interferon-induced depression. 2004 , 82, 175-90	173
1929	A prospective study on treatment of chronic hepatitis C with tailored and extended interferon-alpha regimens according to pretreatment virological factors. 2004 , 63, 25-32	17
1928	Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. 2004 , 25, 472-92	151
1927	Injection drug use and the hepatitis C virus: considerations for a targeted treatment approach--the case study of Canada. 2004 , 81, 428-47	40
1926	Cell-mediated immunity and the outcome of hepatitis C virus infection. 2004 , 58, 391-424	168
1925	Acute pancreatitis associated with interferon and ribavirin therapy in patients with chronic hepatitis C. 2004 , 49, 1000-6	26
1924	Hepatitis C virus infection and the brain. 2004 , 19, 351-6	9

1923	A significant reduction in serum alanine aminotransferase levels after 3-month iron reduction therapy for chronic hepatitis C: a multicenter, prospective, randomized, controlled trial in Japan. 2004 , 39, 570-4	55
1922	Types of human leukocyte antigen and decrease in HCV core antigen in serum for predicting efficacy of interferon-Alpha in patients with chronic hepatitis C: analysis by a prospective study. 2004 , 39, 674-80	3
1921	Interferon therapy for aged patients with chronic hepatitis C: improved survival in patients exhibiting a biochemical response. 2004 , 39, 1069-77	60
1920	How to avoid discontinuation of ribavirin in combination with interferon to maintain efficacy of treatment for chronic hepatitis C patients. 2004 , 39, 1125-6	
1919	Differences in epidemiology, liver disease and treatment response among HCV genotypes. 2004 , 29, 129-135	25
1918	[Hepatitis (Hep-Net) competence network]. 2004 , 45, 415-21	3
1917	Retreatment of patients with chronic hepatitis C not responding to interferon/ribavirin combination therapy with daily interferon plus ribavirin plus amantadine. 2004 , 116, 530-5	4
1916	Guidelines for stopping therapy in chronic hepatitis C. 2004 , 6, 17-21	16
1915	Fat, diabetes, and liver injury in chronic hepatitis C. 2004 , 6, 22-9	34
1914	Hepatocellular carcinoma: updates in primary prevention. 2004 , 6, 37-43	6
1913	New therapies for chronic hepatitis C virus infection. 2004 , 6, 77-86	15
1912	When to treat patients with chronic hepatitis C. 2004 , 6, 261-3	
1911	Update on viral kinetics and hcv antiviral therapy. 2004 , 3, 5-9	
1910	Adherence to antiviral therapy in chronic hepatitis C. 2004 , 3, 10-15	2
1909	Current status of immunomodulatory therapies in HCV infection. 2004 , 3, 16-22	2
1908	Maintenance therapies for hepatitis C. 2004 , 3, 23-29	2
1907	Recent peginterferon and ribavirin combination trials. 2004 , 3, 30-37	4
1906	Hematopoietic growth factors for acute myelogenous leukemia. 2004 , 3, 38-9	1

1905 Alcohol and hepatitis C: Implications for disease progression and treatment. **2004**, 3, 105-111

1904 Hepatitis C virus infection in United States correctional institutions. **2004**, 3, 112-118

4

1903 Hepatitis C virus among african-american persons. **2004**, 3, 129-135

1

1902 Acute hepatitis C infection: Can immunology teach us the right way to treat?. **2004**, 3, 148-156

2

1901 Nonresponders to Previous Chronic Hepatitis C Treatment. **2004**, 7, 469-475

1

1900 Current Treatment for Chronic Hepatitis C. **2004**, 7, 491-499

4

1899 Human immunodeficiency virus and hepatitis C virus coinfection: epidemiology, natural history, therapeutic options and clinical management. **2004**, 32, 33-46

79

1898 Use of PEG-interferon alfa-2a plus ribavirin as treatment for chronic HCV hepatitis in a child cured of ALL. **2004**, 43, 185

7

1897 Evidence that plasma concentration rather than dose per kilogram body weight predicts ribavirin-induced anaemia. **2004**, 11, 84-7

81

1896 Reversible myopathy during successful treatment with pegylated interferon and ribavirin for acute hepatitis C. **2004**, 11, 183-6

5

1895 Comparison of quality of life, work productivity and medical resource utilization of peginterferon alpha 2a vs the combination of interferon alpha 2b plus ribavirin as initial treatment in patients with chronic hepatitis C. **2004**, 11, 157-65

42

1894 Consensus conference on chronic viral hepatitis and HIV infection: updated Spanish recommendations. **2004**, 11, 2-17

46

1893 Pegylated interferon alpha-2b plus ribavirin in the treatment of post-liver transplant recurrent hepatitis C. **2004**, 18, 166-73

90

1892 HIV and HCV coinfection in haemophilia. **2004**, 10, 1-8

66

1891 Hepatitis C. Development of new drugs and clinical trials: promises and pitfalls. Summary of an AASLD hepatitis single topic conference, Chicago, IL, February 27-March 1, 2003. **2004**, 39, 554-67

51

1890 Treatment of chronic hepatitis C in HIV/HCV-coinfection with interferon alpha-2b+ full-course vs. 16-week delayed ribavirin. **2004**, 39, 989-98

58

1889 Diagnosis, management, and treatment of hepatitis C. **2004**, 39, 1147-71

1280

1888 Hepatitis C virus-infected patients report communication problems with physicians. **2004**, 39, 999-1007

101

1887	Defining the standard of care: randomized controlled trials for the treatment of hepatitis C in the HIV-infected person. 2004 , 39, 906-8	6
1886	Short-term interferon-alfa therapy for acute hepatitis C: a randomized controlled trial. 2004 , 39, 1213-9	132
1885	Low membrane protein sulfhydryls but not G6PD deficiency predict ribavirin-induced hemolysis in hepatitis C. 2004 , 39, 1248-55	26
1884	Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1. 2004 , 39, 1702-8	234
1883	Effects of antiviral therapy on the cellular immune response in acute hepatitis C. 2004 , 40, 87-97	120
1882	Pegylated interferon alpha therapy in acute hepatitis C: relation to hepatitis C virus-specific T cell response kinetics. 2004 , 39, 1721-31	141
1881	A prospective controlled study of interferon-based therapy of chronic hepatitis C in patients on methadone maintenance. 2004 , 40, 120-4	135
1880	Long-term follow-up after successful interferon therapy of acute hepatitis C. 2004 , 40, 98-107	62
1879	Genetic manipulations utilizing albumin and alpha-fetoprotein promoter/enhancers affect both hepatocytes and oval cells. 2004 , 40, 759; author reply 760	6
1878	Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1. 2004 , 40, 760-1; author reply 761	2
1877	No hepatic iron overload 12 years after liver transplantation for hereditary hemochromatosis. 2004 , 40, 762; author reply 762	11
1876	Reply. 2004 , 40, 761-761	1
1875	Reply. 2004 , 40, 762-762	
1874	Reply. 2004 , 40, 760-760	2
1873	Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. 2004 , 40, 1260-5	233
1872	Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy. 2004 , 40, 1450-8	119
1871	Viral kinetics during antiviral therapy in patients with chronic hepatitis C and persistently normal ALT levels. 2004 , 40, 1442-9	34
1870	Tinkering and tailoring with HCV therapy: can we get away with less?. 2004 , 40, 1249-51	5

1869	Prevention and treatment of hepatocellular carcinoma. 2004 , 10, S111-4	18
1868	Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C. 2004 , 10, 199-207	123
1867	Predictive value of early HCV RNA quantitation for sustained response in nonresponders receiving daily interferon and ribavirin therapy. 2004 , 72, 46-51	5
1866	High rate of spontaneous clearance of acute hepatitis C virus genotype 3 infection. 2004 , 73, 387-91	89
1865	The predictive value of core antigen testing for the management of hepatitis C patients receiving pegylated interferon/ribavirin treatment. 2004 , 73, 392-6	17
1864	Genetic variability of hepatitis C virus in chronically infected patients with viral breakthrough during interferon-ribavirin therapy. 2004 , 74, 41-53	30
1863	Laparoscopic splenectomy reverses thrombocytopenia in patients with hepatitis C cirrhosis and portal hypertension. 2004 , 8, 120-6	65
1862	Cell culture and animal models for human viral hepatitis. 2004 , 28, 61-67	2
1861	Medical treatment of viral pneumonia including SARS in immunocompetent adult. 2004 , 49, 262-73	78
1860	A cell-based beta-lactamase reporter gene assay for the identification of inhibitors of hepatitis C virus replication. 2004 , 334, 344-55	49
1859	Protein-dynamics of the putative HCV receptor CD81 large extracellular loop. 2004 , 14, 1765-9	7
1858	Treatment of chronic viral hepatitis. 2004 , 18 Suppl, 113-20	5
1857	Histological findings, genotype distribution and percentage of patients fulfilling the treatment criteria among patients with chronic hepatitis C virus infection in a single Swedish centre. 2004 , 39, 164-7	7
1856	Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. <i>New England Journal of Medicine</i> , 2004 , 351, 1206-17	59.2 904
1855	Rapporto costo-efficacia della terapia peginterferone α 2a + ribavirina in confronto a interferone α 2b + ribavirina in pazienti affetti da epatite cronica di tipo C precedentemente non trattati. 2004 , 6, 105-114	3
1854	Hepatitis C treatment eligibility in an urban population with and without HIV coinfection. 2004 , 18, 239-45	35
1853	Cost effectiveness of peginterferon alpha-2a plus ribavirin versus interferon alpha-2b plus ribavirin as initial therapy for treatment-naive chronic hepatitis C. 2004 , 22, 257-65	55
1852	Cost effectiveness of peginterferon alpha-2a plus ribavirin versus interferon alpha-2b plus ribavirin as initial therapy for treatment-naive chronic hepatitis C. 2004 , 22, 477-8; author reply 478-9	2

1851	Peginterferon-2a (40kD) plus ribavirin: a new treatment option takes flight in chronic hepatitis C. 2004 , 20, 1-4	
1850	Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. 2004 , 140, 346-55	2231
1849	Recent advances in the management of the child who has hemophilia. 2004 , 18, 1249-76, viii	8
1848	Future trends in managing hepatitis C. 2004 , 33, S51-61	17
1847	Nonresponders to hepatitis C virus antiviral therapy: pegylated interferons and beyond. 2004 , 33, 527-47, viii	6
1846	Effectiveness of interferon alpha-2b and ribavirin combination therapy in the treatment of naive chronic hepatitis C patients in clinical practice. 2004 , 2, 425-31	21
1845	Role of epoetin alfa in maintaining ribavirin dose. 2004 , 33, S25-35	18
1844	Hepatitis viruses and human immunodeficiency virus (HIV) co-infection: pathogeny and treatments. 2004 ,	
1843	Treating hepatitis C: the state of the art. 2004 , 33, S1-9	9
1842	Treatment of relapsers after combination therapy for chronic hepatitis C. 2004 , 33, 513-26, viii	4
1841	Controversies in the management of hepatitis C patients with advanced fibrosis and cirrhosis. 2004 , 2, 183-97	16
1840	Adherence to combination therapy: influence on sustained virologic response and economic impact. 2004 , 33, S11-24	22
1839	Treatment of chronic hepatitis B: who to treat, what to use, and for how long?. 2004 , 2, 839-48	24
1838	[Treatment of hepatitis C in nonresponders to ribavirin and/or interferon]. <i>Gastroenterologia Y Hepatologia</i> , 2004 , 27, 24-6	0.9
1837	Hepatitis C virus antiviral therapy in patients with cirrhosis. 2004 , 33, 549-62, ix	6
1836	Antiviral therapy for treatment naïve patients with hepatitis C virus. 2004 , 33, 497-511, viii	6
1835	[Necrotic lesion in a patient with hepatitis C virus liver disease under treatment with pegylated interferon]. 2004 , 22, 497-8	1
1834	A general approach to the management of chronic hepatitis C. 2004 , 33, 463-77, vii	1

1833	Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. <i>New England Journal of Medicine</i> , 2004 , 351, 451-9	59.2	753
1832	Treatment of the hepatitis C virus in patients coinfectd with HIV. 2004 , 33, 479-96, vii-viii		2
1831	Foreword. 2004 , 36, S333		1
1830	Pharmacokinetics of pegylated interferons: what is misleading?. 2004 , 36 Suppl 3, S334-9		39
1829	Early virologic response with pegylated interferons. 2004 , 36 Suppl 3, S340-3		7
1828	Treatment of cirrhotic patients in the pegylated interferon era. 2004 , 36 Suppl 3, S344-8		6
1827	Weight-based dosing: which impact on efficacy and safety of therapy?. 2004 , 36 Suppl 3, S349-53		6
1826	Hepatitis C virus core and nonstructural proteins induce fibrogenic effects in hepatic stellate cells. 2004 , 126, 529-40		200
1825	Antiviral action of ribavirin in chronic hepatitis C. 2004 , 126, 703-14		238
1824	Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. 2004 , 126, 1015-23; discussion 947		393
1823	Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. 2004 , 126, 1302-11		471
1822	Chronic hepatitis C with normal aminotransferase levels. 2004 , 126, 1409-15		33
1821	Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients. 2004 , 127, 1347-55		284
1820	Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. 2004 , 127, 1724-32		190
1819	Reported risk factors are useless in detecting HCV-positive subjects in the general population. 2004 , 36, 547-50		2
1818	Natural history of initially mild chronic hepatitis C. 2004 , 36, 646-54		38
1817	Randomised double-blinded trial evaluating silymarin for chronic hepatitis C in an Egyptian village: study description and 12-month results. 2004 , 36, 752-9		45
1816	Efficacy and safety of two-dose regimens of peginterferon alpha-2a compared with interferon alpha-2a in chronic hepatitis C: a multicenter, randomized controlled trial. 2004 , 99, 1298-305		66

1815	Cost-effectiveness of combination peginterferon alpha-2a and ribavirin compared with interferon alpha-2b and ribavirin in patients with chronic hepatitis C. 2004 , 99, 1490-6	49
1814	Management of chronic hepatitis C in patients co-infected with HIV: focus on safety considerations. 2004 , 27, 7-24	10
1813	Treatment of hepatitis C in solid organ transplantation. 2004 , 64, 489-98	8
1812	Challenges in the management of HIV and hepatitis C virus co-infection. 2004 , 64, 693-700	8
1811	Peginterferon-alpha-2a (40kD) plus ribavirin: a review of its use in hepatitis C Virus And HIV co-infection. 2004 , 64, 2823-43	10
1810	Serum levels of hepatitis C virus core antigen as a marker of infection and response to therapy. 2004 , 99, 1738-43	19
1809	Hepatitis Prevention and Treatment. 2004 ,	
1808	[The era of antiretroviral therapy... and the era of hepatitis C virus coinfection]. 2004 , 123, 460-2	
1807	Coinfection VIH-VHC : Quelle prise en charge ?. 2004 , 6, 151-163	
1806	Pharmacokinetics and safety of virmidine, a prodrug of ribavirin, in healthy volunteers. 2004 , 44, 265-75	44
1805	Interferon alfa-2b [correction of alpha-2b]and ribavirin for patients with chronic hepatitis C and normal ALT. 2004 , 99, 1700-5	34
1804	Chronic viral hepatitis. 2004 , 45-58	
1803	Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. <i>New England Journal of Medicine</i> , 2004 , 351, 438-50	59.2 1079
1802	Peginterferon-alpha(2b) and ribavirin. 2004 , 2, 17-25	15
1801	New antiviral therapies for hepatitis C. 2004 , 2, 235-43	
1800	Hepatitis C drug discovery: in vitro and in vivo systems and drugs in the pipeline. 2004 , 2, 375-88	2
1799	Neuropsychiatric side effects of HCV therapy and their treatment: focus on IFN alpha-induced depression. 2004 , 33, S35-50	22
1798	Increased sensitivity of the Roche COBAS AMPLICOR HCV test, version 2.0, using modified extraction techniques. 2004 , 6, 225-30	3

1797	Hepatitis C and treatment with pegylated interferon and ribavirin. 2004 , 36, 1874-7	5
1796	Direct fluorometric measurement of hepatitis C virus helicase activity. 2004 , 567, 253-8	45
1795	A comparison of HCV antibody testing in drug-free and methadone maintenance treatment programs in the United States. 2004 , 73, 227-36	18
1794	Involvement of p38 signaling pathway in interferon-alpha-mediated antiviral activity toward hepatitis C virus. 2004 , 321, 722-7	30
1793	[Mutation analysis of ISDR and V3 domains of hepatitis C virus NS5A region before interferon therapy with or without ribavirin]. 2004 , 52, 505-10	17
1792	Expression, purification, and characterization of rat interferon-beta, and preparation of an N-terminally PEGylated form with improved pharmacokinetic parameters. 2004 , 34, 229-42	38
1791	A candidate vaccine based on the hepatitis C E1 protein: tolerability and immunogenicity in healthy volunteers. 2004 , 22, 3080-6	58
1790	TaqMan amplification system with an internal positive control for HCV RNA quantitation. 2004 , 31, 227-34	67
1789	Oral lichen planus, hepatitis C virus, and HIV: no association in a cohort study from an area of high hepatitis C virus endemicity. 2004 , 51, 364-70	15
1788	Combination therapy with amantadine and interferon in naïve patients with chronic hepatitis C: meta-analysis of individual patient data from six clinical trials. 2004 , 40, 478-83	35
1787	Hepatitis C virus Core Antigen as a predictor of non-response in genotype 1 chronic hepatitis C patients treated with peginterferon alpha-2b plus ribavirin. 2004 , 40, 527-32	22
1786	The impact of peginterferon alfa-2a plus ribavirin combination therapy on health-related quality of life in chronic hepatitis C. 2004 , 40, 675-81	92
1785	Treatment of recurrent hepatitis C after liver transplantation: a pilot study of peginterferon alfa-2b and ribavirin combination. 2004 , 40, 669-74	187
1784	Reduction of relapse rates by 18-month treatment in chronic hepatitis C. A Benelux randomized trial in 300 patients. 2004 , 40, 689-95	34
1783	Association of serum interleukin-8 with virologic response to antiviral therapy in patients with chronic hepatitis C. 2004 , 40, 845-52	22
1782	Monitoring response to antiviral treatment by serum hepatitis C virus core antigen: too early to take shortcuts?. 2004 , 40, 536-8	13
1781	Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. 2004 , 40, 993-9	346
1780	Optimizing PEG-interferon and ribavirin combination therapy for patients infected with HCV-2 or HCV-3: is the puzzle completed?. 2004 , 40, 1032-5	11

1779	A randomized, controlled trial of triple antiviral therapy as initial treatment of chronic hepatitis C in HIV-infected patients. 2004 , 41, 312-8	6
1778	Hepatitis viruses and human immunodeficiency virus co-infection: pathogenesis and treatment. 2004 , 41, 156-66	20
1777	Peginterferon alfa-2b plus ribavirin for naïve patients with genotype 1 chronic hepatitis C: a randomized controlled trial. 2004 , 41, 474-81	83
1776	Evaluation of amantadine in chronic hepatitis C: a meta-analysis. 2004 , 41, 462-73	60
1775	Induction therapy in chronic hepatitis C: dī-vu with pegylated interferons?. 2004 , 41, 488-90	6
1774	Hepatitis C treatment update. 2004 , 117, 344-52	63
1773	[A pluridisciplinary point of view of hepatitis C virus infections]. 2004 , 33, 544-9	
1772	A reporter-based assay for identifying hepatitis C virus inhibitors based on subgenomic replicon cells. 2004 , 116, 27-33	30
1771	Tratamiento de la infecci3n por VHB y VHC. 2004 , 9, 674-680	
1770	Peginterferon alfa-2a: a review of approved and investigational uses. 2004 , 26, 991-1025	57
1769	?HCV?C????????????????????HCV???v2.0(?????)???. 2004 , 45, 223-223	2
1768	Evaluation of common liver problems. 2004 , 94, 149-56	1
1767	Treatment of hepatitis C in children. 2004 , 23, 257-8	5
1766	Factors associated with successful referral for clinical care of drug users with chronic hepatitis C who have or are at risk for HIV infection. 2004 , 37, 1367-75	48
1765	Daily versus thrice-weekly interferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected persons: a multicenter randomized controlled trial. 2004 , 35, 464-72	20
1764	Dr. Hendin and Colleagues Reply. 2004 , 161, 2330-2331	1
1763	Management of acute hematogenous osteomyelitis in children. 2004 , 23, 255-7	34
1762	Liver fibrosis stage predicts early treatment outcomes with peginterferon plus ribavirin in HIV/hepatitis C virus co-infected patients. 2004 , 18, 1602-4	2

1761	Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon alpha2b and ribavirin: an open-label series. 2004 , 77, 190-4	151
1760	Diagnosis and treatment of hepatitis C. 2004 , 97, 223-5	10
1759	Hepatitis C virus (HCV) core antigen assay to detect ongoing HCV infection in thai injection drug users. 2004 , 42, 1631-6	16
1758	Mania during treatment of chronic hepatitis C with pegylated interferon and ribavirin. 2004 , 161, 429-35	44
1757	Ultralow-dose alpha-interferon plus ribavirin for the treatment of active hepatitis C in renal transplant recipients. 2004 , 77, 1894-6	52
1756	Hepatitis C: an emerging epidemic. 2004 , 6, 589-605	0
1755	New hopes for HIV and HCV coinfection in 2004. 2004 , 5, 232-51	7
1754	Successful long-term application of highly purified natural interferon-alpha (multiferon) after preceding interferon approaches in a chronic hepatitis C patient with thrombocytopenia. 2004 , 36, 395-9	4
1753	Knowledge of chronic hepatitis C among East London primary care physicians following the Department of Health's educational campaign. 2004 , 97, 331-6	30
1752	Severe, generalized nummular eczema secondary to interferon alfa-2b plus ribavirin combination therapy in a patient with chronic hepatitis C virus infection. 2004 , 140, 215-7	37
1751	Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients. 2004 , 18, F27-36	277
1750	Serious ophthalmic pathology compromising vision in HCV/HIV co-infected patients treated with peginterferon alpha-2b and ribavirin. 2004 , 18, 1805-9	19
1749	The prostate as a reservoir for HIV-1. 2004 , 18, 1600-2	24
1748	Risk factors for hepatic decompensation in patients with HIV/HCV coinfection and liver cirrhosis during interferon-based therapy. 2004 , 18, F21-5	110
1747	Possible autoimmune thrombocytopenia associated with pegylated interferon-alpha2a plus ribavirin treatment for hepatitis C. 2004 , 38, 84-6	18
1746	Advances in hepatitis B and C. 2004 , 17, 449-59	7
1745	Pegylated interferon alpha-2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients. 2004 , 18, 131	
1744	Subnormal rise of erythropoietin in patients receiving interferon and ribavirin combination therapy for hepatitis C. 2004 , 38, 595-8	12

1743	Care of patients with hepatitis C and HIV co-infection. 2004 , 18, 1-12	156
1742	Can HIV-1 superinfection compromise antiretroviral therapy?. 2004 , 18, 132-4	13
1741	Viral infection and antiviral therapy in the neonatal intensive care unit. 2004 , 18, 259-74	1
1740	Pegylated interferon alpha 2b and ribavirin in HIV/hepatitis C virus-co-infected non-responders and relapsers to IFN-based therapy. 2004 , 18, 75-9	36
1739	Management of hepatitis C after transplantation: a long way from success. 2004 , 16, 1131-3	6
1738	Hepatocellular carcinoma: paradigm of preventive oncology. 2004 , 10, 67-73	11
1737	Long-term outcome of hepatitis C infection after bone marrow transplantation. 2004 , 103, 1618-24	143
1736	The epidemiology of chronic hepatitis C infection in survivors of childhood cancer: an update of the St Jude Children's Research Hospital hepatitis C seropositive cohort. 2004 , 103, 2460-6	82
1735	Testing for hepatitis C virus infection should be routine for persons at increased risk for infection. 2004 , 141, 715-7	66
1734	Screening for hepatitis C virus infection: a review of the evidence for the U.S. Preventive Services Task Force. 2004 , 140, 465-79	76
1733	Chronic viral hepatitis. 2004 , 15, 145-58, x-xi	4
1732	Ascending multiple-dose pharmacokinetics of viramidine, a prodrug of ribavirin, in adult subjects with compensated hepatitis C infection. 2005 , 45, 275-85	12
1731	The use of growth factors to manage the hematologic side effects of PEG-interferon alfa and ribavirin. 2005 , 39, S9-13	48
1730	Peginterferon alpha/ribavirin combination therapy for the treatment of hepatitis C infection. 2005 , 28, 317-28	4
1729	Update on viral hepatitis in 2004. 2005 , 21, 300-7	4
1728	Diagnosis of liver cirrhosis: a comparison of modified ultrasound and laparoscopy in 100 consecutive patients. 2005 , 39, 529-32	11
1727	High rates of uninsured among HCV-positive individuals. 2005 , 39, 826-30	22
1726	Risk factors for symptomatic mitochondrial toxicity in HIV/hepatitis C virus-coinfected patients during interferon plus ribavirin-based therapy. 2005 , 40, 47-52	72

1725	Perspectives on HIV/hepatitis C virus co-infection, illicit drug use and mental illness. 2005 , 19 Suppl 3, S8-12	17
1724	Impact of adherence on the outcome of antiviral therapy for chronic hepatitis C. 2005 , 39, S23-7	40
1723	Early monitoring of ribavirin plasma concentrations may predict anemia and early virologic response in HIV/hepatitis C virus-coinfected patients. 2005 , 39, 401-5	67
1722	Efficacy of pegylated interferon alpha-2b for the treatment of chronic delta hepatitis in a patient co-infected with HIV. 2005 , 19, 2177-8	6
1721	Hematologic side effects of interferon and ribavirin therapy. 2005 , 39, S3-8	80
1720	Role of growth factors in the treatment of patients with HIV/HCV coinfection and patients with recurrent hepatitis C following liver transplantation. 2005 , 39, S14-22	11
1719	New paradigms in the management of HIV and hepatitis C virus coinfection. 2005 , 18, 550-60	11
1718	Ribavirin plus interferon versus interferon for chronic hepatitis C. 2005 , CD005445	14
1717	Partial splenic embolization as pretreatment for antiviral therapy in hepatitis C virus infection. 2005 , 17, 1153-5	30
1716	Validity of original studies in health technology assessment reports: significance of standardized assessment and reporting. 2005 , 21, 410-3	3
1715	Liver steatosis is an independent risk factor for treatment failure in patients with chronic hepatitis C. 2005 , 17, 149-53	33
1714	Rationale and design of the REPEAT study: a phase III, randomized, clinical trial of peginterferon alfa-2a (40 kDa) plus ribavirin in non-responders to peginterferon alfa-2b (12 kDa) plus ribavirin. 2005 , 17, 899-904	23
1713	Safe use of pegylated interferon/ribavirin in hepatitis C virus cirrhotic patients with hypersplenism after partial splenic embolization. 2005 , 17, 1157-64	50
1712	Hepatitis C infection: eligibility for antiviral therapies. 2005 , 17, 1185-9	17
1711	Clinical- and cost-effectiveness of pegylated interferon alfa in the treatment of chronic hepatitis C: a systematic review and economic evaluation. 2005 , 21, 47-54	29
1710	Estimating the mortality rate of hepatitis C using multiple data sources. 2005 , 133, 121-5	15
1709	Management of chronic hepatitis C in French departments of internal medicine and infectious diseases. 2005 , 133, 305-14	8
1708	Uptake and presentation of hepatitis C virus-like particles by human dendritic cells. 2005 , 105, 3605-14	76

1707	Biological and clinical basis for molecular studies of interferons. 2005 , 116, 1-23	15
1706	Efficacy of prolonged treatment following combination with ribavirin and interferon for chronic hepatitis type C: A pilot study. 2005 , 31, 211-6	2
1705	Emerging drugs for chronic hepatitis C. 2005 , 32, 146-53	11
1704	Traitements catabolisants. 2005 , 19, 25-29	3
1703	Synthesis of 5-haloethynyl- and 5-(1,2-dihalo)vinyluracil nucleosides: antiviral activity and cellular toxicity. 2005 , 13, 6015-24	9
1702	Inhibitors of HCV NS5B polymerase: synthesis and structure-activity relationships of N-1-heteroalkyl-4-hydroxyquinolon-3-yl-benzothiadiazines. 2005 , 15, 1577-82	43
1701	Peginterferon alfa-2a does not alter the pharmacokinetics of methadone in patients with chronic hepatitis C undergoing methadone maintenance therapy. 2005 , 77, 214-24	32
1700	Glutathione peroxidase, thioredoxin, and membrane protein changes in erythrocytes predict ribavirin-induced anemia. 2005 , 78, 422-32	23
1699	[Liver and rheumatism]. 2005 , 64, 26-31	1
1698	Virale hepatitis. 2005 , 21, 323-333	
1697	Molecular methods of hepatitis C genotyping. 2005 , 5, 507-20	36
1696	Hepatitis C virus infection. 2005 , 11, 86-94	80
1695	BHIVA guidelines on HIV and chronic hepatitis: coinfection with HIV and hepatitis C virus infection (2005). 2005 , 6 Suppl 2, 96-106	27
1694	Barriers to the treatment of hepatitis C. Patient, provider, and system factors. 2005 , 20, 754-8	154
1693	Undetectable phospho-STAT1 in peripheral blood mononuclear cells from patients with chronic hepatitis C who do not respond to interferon-alpha therapy. 2005 , 25, 987-93	6
1692	Antiviral therapy in advanced chronic liver disease due to hepatitis C virus infection: pilot study. 2005 , 20, 527-35	4
1691	Pegylated versus standard interferon-alpha in antiviral regimens for post-transplant recurrent hepatitis C: Comparison of tolerability and efficacy. 2005 , 20, 577-82	53
1690	Secondary prevention of hepatitis C virus-related hepatocellular carcinoma. 2005 , 20, 1475-7	3

1689	Reasons for non-treatment of hepatitis C in veterans in care. 2005 , 12, 81-5	71
1688	The rate of treatment of chronic hepatitis C in patients co-infected with HIV in an urban medical centre. 2005 , 12, 86-90	37
1687	Patient concerns regarding chronic hepatitis C infections. 2005 , 12, 51-7	22
1686	Prophylactic SSRI during interferon alpha re-therapy in patients with chronic hepatitis C and a history of interferon-induced depression. 2005 , 12, 96-100	75
1685	Therapeutic modalities in hepatitis C: challenges and development. 2005 , 12, 10-9	22
1684	Treatment of histologically mild hepatitis C virus infection with interferon and ribavirin: a multicentre randomized controlled trial. 2005 , 12, 58-66	18
1683	Future trends of HCV-related cirrhosis and hepatocellular carcinoma under the currently available treatments. 2005 , 12, 543-50	26
1682	Comparison of a 6-month course peginterferon alpha-2b plus ribavirin and interferon alpha-2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan. 2005 , 12, 283-91	63
1681	A randomized controlled trial of pegylated interferon alpha-2a (40 KD) or interferon alpha-2a plus ribavirin and amantadine vs interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C. 2005 , 12, 292-9	41
1680	Treatment of hepatitis C. 2005 , 12, 223-35	66
1679	Changing of hepatitis C virus genotype patterns in France at the beginning of the third millenium: The GEMHEP GenoCII Study. 2005 , 12, 405-13	117
1678	Factors associated with the initiation of alpha-interferon treatment in Medicaid patients diagnosed with hepatitis C. 2005 , 12, 176-85	16
1677	Safety and efficacy of peginterferon plus ribavirin in patients with chronic hepatitis C and bridging fibrosis or cirrhosis. 2005 , 12, 421-8	25
1676	Changes in epidemiological patterns of HCV infection and their impact on liver disease over the last 20 years in Greece. 2005 , 12, 551-7	37
1675	Clinical utility of viral load measurements in individuals with chronic hepatitis C infection on antiviral therapy. 2005 , 12, 465-72	32
1674	Hepatitis C virus RNA kinetics during the initial 12 weeks treatment with pegylated interferon-alpha 2a and ribavirin according to virological response. 2005 , 12, 473-80	27
1673	Amantadine in treatment of chronic hepatitis C virus infection?. 2005 , 12, 445-55	12
1672	Clinical usefulness of total hepatitis C virus core antigen quantification to monitor the response to treatment with peginterferon alpha-2a plus ribavirin*. 2005 , 12, 481-7	16

1671	Silymarin treatment of viral hepatitis: a systematic review. 2005 , 12, 559-67	122
1670	Weight loss during pegylated interferon and ribavirin treatment of chronic hepatitis C*. 2005 , 12, 531-5	30
1669	Higher doses of peginterferon alpha-2b administered twice weekly improve sustained virological response in difficult-to-treat patients with chronic hepatitis C: results of a pilot randomized study. 2005 , 12, 536-42	10
1668	Pathways of care and resource utilization in a national cohort of patients with transfusion-acquired hepatitis C. 2005 , 12, 618-26	4
1667	Hepatitis C infection among Dutch haemophilia patients: a nationwide cross-sectional study of prevalence and antiviral treatment. 2005 , 11, 270-5	22
1666	Prevalence of conditions associated with human immunodeficiency and hepatitis virus infections among persons with haemophilia, 2001-2003. 2005 , 11, 516-28	25
1665	Discontinuation of pegylated interferon plus ribavirin in patients who are not responding to therapy -- patients' views of early cessation of therapy. 2005 , 21, 43-7	1
1664	Short- and long-term effects of therapy with interferon-alpha and pegylated interferon-alpha/ribavirin on platelet plug formation and von Willebrand factor release in patients with chronic hepatitis C. 2005 , 21, 49-55	17
1663	Retinal toxicity during pegylated alpha-interferon therapy for chronic hepatitis C: a multifocal electroretinogram investigation. 2005 , 21, 723-32	23
1662	Dynamic decision analysis to determine optimal treatment duration in chronic hepatitis C. 2005 , 21, 539-47	3
1661	The safety of pegylated interferon alpha-2b in the treatment of chronic hepatitis B: predictive factors for dose reduction and treatment discontinuation. 2005 , 21, 1163-71	54
1660	Review article: an unexpected virus-host interaction--the hepatitis C virus-diabetes link. 2005 , 22 Suppl 2, 56-60	30
1659	The impact of past alcohol use on treatment response rates in patients with chronic hepatitis C. 2005 , 22, 701-6	20
1658	Pegylated interferon alfa-induced sarcoidosis: two sides of the same coin. 2005 , 152, 377-9	13
1657	Efficacy and tolerability of peginterferon alpha-2a with or without ribavirin in thalassaemia major patients with chronic hepatitis C virus infection. 2005 , 130, 644-6	56
1656	Treatment of chronic hepatitis C virus in allogeneic bone marrow transplant recipients. 2005 , 36, 709-13	38
1655	Bi-allelic presence of the interleukin-10 receptor 1 G330R allele is associated with cirrhosis in chronic HCV-1 infection. 2005 , 6, 242-7	20
1654	Mechanism of action of interferon and ribavirin in treatment of hepatitis C. 2005 , 436, 967-72	795

1653	The road to new antiviral therapies. 2005 , 5, 65-76	4
1652	Disposal of injection material used for the treatment of hepatitis C: comparison with insulin-dependent diabetes and thromboembolism. 2005 , 29, 64-69	1
1651	Treatment of chronic hepatitis C in patients unresponsive to interferon. Interest of re-treatment combining interferon induction therapy and ribavirin (a multicenter pilot study). 2005 , 29, 117-21	1
1650	[Psychiatric disorders during treatment of chronic hepatitis C]. 2005 , 29, 123-33	8
1649	[Acute hepatitis C in 2005]. 2005 , 29, 1149-56	1
1648	Applicability, tolerability and efficacy of preemptive antiviral therapy in hepatitis C-infected patients undergoing liver transplantation. 2005 , 5, 118-24	170
1647	Clinical performance of the LCx HCV RNA quantitative assay. 2005 , 123, 171-8	5
1646	Epoetin alfa for the treatment of combination therapy-induced hemolytic anemia in patients infected with hepatitis C virus. 2005 , 25, 862-75	
1645	Patient education and treatment strategies implemented at a pharmacist-managed hepatitis C virus clinic. 2005 , 25, 1230-41	23
1644	Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials. 2005 , 41, 289-98	244
1643	HCV persistence: cure is still a four letter word. 2005 , 41, 23-5	24
1642	High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C. 2005 , 41, 275-9	174
1641	Plasmacytoid dendritic cells in acute and chronic hepatitis C virus infection. 2005 , 41, 643-51	93
1640	Pushing the treatment envelope for chronic hepatitis C--is more necessarily better?. 2005 , 41, 234-6	1
1639	Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C. 2005 , 41, 832-5	158
1638	Peginterferon alfa-2b plus ribavirin treatment in children and adolescents with chronic hepatitis C. 2005 , 41, 1013-8	167
1637	T-cell response relative to genotype and ethnicity during antiviral therapy for chronic hepatitis C. 2005 , 41, 1365-75	46
1636	Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. 2005 , 42, 255-62	299

1635	Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection. 2005 , 42, 724-31	200
1634	PEGylated interferon alfa-2b and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis. 2005 , 52, 911-5	137
1633	HCV-hepatocellular carcinoma: new findings and hope for effective treatment. 2005 , 68, 130-48	12
1632	Liver transplantation in HIV-infected recipients. 2005 , 11, 76-81	38
1631	Management of pre-liver transplantation patients--part 1. 2005 , 11, 124-33	11
1630	Early viral kinetics and treatment outcome in combination of high-dose interferon induction vs. pegylated interferon plus ribavirin for naive patients infected with hepatitis C virus of genotype 1b and high viral load. 2005 , 75, 27-34	43
1629	Pegylated interferon and ribavirin therapy for chronic hepatitis C virus genotype 4 infection. 2005 , 77, 66-9	45
1628	Chemiluminescence enzyme immunoassay for monitoring hepatitis C virus core protein during interferon-alpha2b and ribavirin therapy in patients with genotype 1 and high viral loads. 2005 , 77, 77-82	9
1627	Evaluation of a total core antigen assay for the diagnosis of hepatitis C virus infection in hemodialysis patients. 2005 , 77, 502-8	32
1626	Management of chronic hepatitis C virus in patients with HIV. 2005 , 8, 433-41	4
1625	Clinical trials report. 2005 , 7, 9-10	
1624	Children with hepatitis C. 2005 , 7, 37-44	2
1623	Maintenance therapy for chronic hepatitis C. 2005 , 7, 50-3	13
1622	Treatment of HCV infection with pegylated interferons. 2005 , 4, 49-55	3
1621	Management of hematologic side effects: Impact on compliance and efficacy. 2005 , 4, 56-60	1
1620	Antiviral therapy in the liver transplant candidate and recipient. 2005 , 4, 75-82	
1619	HCV viral kinetics. 2005 , 4, 158-161	
1618	Hepatitis C Virus in patients with inherited bleeding disorders. 2005 , 4, 87-91	

1617	Management of hepatitis C virus in patients with porphyria cutanea tarda. 2005 , 4, 104-111	2
1616	Peginterferon alfa-2b treatment for patients affected by acute hepatitis C: presentation of six case reports. 2005 , 33, 30-2	6
1615	Peginterferon alpha-2a combination therapies in chronic hepatitis C patients who relapsed after or had a viral breakthrough on therapy with standard interferon alpha-2b plus ribavirin: a pilot study of efficacy and safety. 2005 , 50, 719-26	33
1614	Interferon alfacon-1 and ribavirin versus interferon alpha-2b and ribavirin in the treatment of chronic hepatitis C. 2005 , 50, 727-32	34
1613	Pegylated interferon alpha-2b, ribavirin and amantadine for chronic hepatitis C. 2005 , 50, 970-5	12
1612	Pegylated interferon alpha-2a with or without ribavirin in HCV/HIV coinfection: partially blinded, randomized multicenter trial. 2005 , 50, 1148-55	5
1611	Multiplex cytokine profiling of initial therapeutic response in patients with chronic hepatitis C virus infection. 2005 , 50, 1793-803	20
1610	High versus standard doses interferon-alpha in the treatment of naïve chronic hepatitis C patients in Taiwan: a 10-year cohort study. 2005 , 5, 27	20
1609	Kinetics of hepatitis C virus RNA load during pegylated interferon alpha-2a and ribavirin treatment in naïve genotype 1 patients. 2005 , 4, 9	4
1608	Treatment of chronic hepatitis C in Canadian prison inmates. 2005 , 19, 153-6	21
1607	Sarcoidosis associated with pegylated interferon alfa and ribavirin treatment for chronic hepatitis C: a case report and review of the literature. 2005 , 141, 865-8	63
1606	Interferon-alpha-induced changes in metallothionein expression in liver biopsies from patients with chronic hepatitis C. 2005 , 19, 481-6	12
1605	Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival. 2005 , 142, 105-14	229
1604	The prevalence of hepatitis C virus infection in Texas: implications for future health care. 2005 , 18, 3-6	14
1603	New approaches and therapeutic modalities for the treatment of patients with chronic hepatitis C. 2005 , 4, 144-150	2
1602	Current concepts in the management and treatment of hepatitis C in HIV-infected patients. 2005 , 4, 151-160	5
1601	Cost-efficacy analysis of peginterferon alfa-2b plus ribavirin compared with peginterferon alfa-2a plus ribavirin for the treatment of chronic hepatitis C. 2005 , 11, 687-94	20
1600	[Treatment of hepatitis C virus infection]. 2005 , 94, 721-6	2

1599	[Diagnosis of hepatitis B and C]. 2005 , 94, 66-72	0
1598	Hepatitis C Virus (HCV). 2005 , 32, 184-195	
1597	Transfusion Transmitted Disease: Hepatitis C Virus Infection and Liver Transplantation. 207-213	1
1596	Acute sensorineural hearing loss associated with peginterferon and ribavirin combination therapy during hepatitis C treatment: outcome after resumption of therapy. 2005 , 11, 5392-3	20
1595	[Drug therapy in chronic liver disease]. 2005 , 94, 1907-12	
1594	Integrating services for injection drug users infected with hepatitis C virus with methadone maintenance treatment: challenges and opportunities. 2005 , 40 Suppl 5, S339-45	68
1593	Treatment of hepatitis C in HIV/hepatitis C co-infected patients: what is the evidence?. 2005 , 16, 1-4	3
1592	Prospective multicenter study of eligibility for antiviral therapy among 4,084 U.S. veterans with chronic hepatitis C virus infection. 2005 , 100, 1772-9	156
1591	Treatment for hepatitis C virus infection among current injection drug users in Australia. 2005 , 40 Suppl 5, S325-9	47
1590	Hepatitis vírica aguda y crónica. 2005 , 51-86	
1589	Guidelines for the treatment of hepatitis C virus infection in injection drug users: status quo in the European Union countries. 2005 , 40 Suppl 5, S373-8	28
1588	Knowledge and attitudes about treatment for hepatitis C virus infection and barriers to treatment among current injection drug users in Australia. 2005 , 40 Suppl 5, S313-20	121
1587	Addressing tri-morbidity (hepatitis C, psychiatric disorders, and substance use): the importance of routine mental health screening as a component of a comanagement model of care. 2005 , 40 Suppl 5, S286-91	81
1586	New drug targets for HIV and hepatitis C virus coinfection. 2005 , 41 Suppl 1, S101-4	3
1585	Evidence-informed assessment and treatment of depression in HCV and interferon-treated patients. 2005 , 17, 471-6	16
1584	Hepatitis C virus infection among prisoners in the California state correctional system. 2005 , 41, 177-86	86
1583	In vitro studies of cross-resistance mutations against two hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061. 2005 , 280, 36784-91	177
1582	Management of HIV Infection in Persons Co-infected With Hepatitis. 2005 , 18, 295-309	

1581	Effect of ribavirin on intracellular and plasma pharmacokinetics of nucleoside reverse transcriptase inhibitors in patients with human immunodeficiency virus-hepatitis C virus coinfection: results of a randomized clinical study. 2005 , 49, 3997-4008	37
1580	Treating hepatitis C virus infection in active substance users. 2005 , 40 Suppl 5, S321-4	57
1579	Medical examinations at entry to treatment for drug abuse as an opportunity to initiate care for hepatitis C virus infection. 2005 , 40 Suppl 5, S297-303	6
1578	Suppression of haematopoiesis during therapy of chronic hepatitis C with different interferon alpha mono and combination therapy regimens. 2005 , 54, 1014-20	50
1577	Evaluation of the COBAS Hepatitis C Virus (HCV) TaqMan analyte-specific reagent assay and comparison to the COBAS Amplicor HCV Monitor V2.0 and Versant HCV bDNA 3.0 assays. 2005 , 43, 2133-40	30
1576	Peginterferon {alpha}-2b and ribavirin therapy in chronic hepatitis C genotype 4: impact of treatment duration and viral kinetics on sustained virological response. 2005 , 54, 858-66	128
1575	Liver injury and changes in hepatitis C Virus (HCV) RNA load associated with protease inhibitor-based antiretroviral therapy for treatment-naïve HCV-HIV-coinfected patients: lopinavir-ritonavir versus nelfinavir. 2005 , 41, 1186-95	35
1574	Role of viral kinetics under HCV therapy in HIV/HCV-coinfected patients. 2005 , 55, 824-7	6
1573	Effect of hepatitis C virus (HCV) genotype on HCV and HIV-1 disease. 2005 , 191, 4-10	56
1572	Chronic hepatitis C in patients with HIV/AIDS: a new challenge in antiviral therapy. 2005 , 56, 991-5	12
1571	Comparison of qualitative (COBAS AMPLICOR HCV 2.0 versus VERSANT HCV RNA) and quantitative (COBAS AMPLICOR HCV monitor 2.0 versus VERSANT HCV RNA 3.0) assays for hepatitis C virus (HCV) RNA detection and quantification: impact on diagnosis and treatment of HCV infections. 2005 , 43, 2590-7	32
1570	Review of the treatment of hepatitis C: where are we now?. 2005 , 6, 32-34	
1569	Randomized, placebo-controlled trial of nonpegylated and pegylated forms of recombinant human alpha interferon 2a for suppression of dengue virus viremia in rhesus monkeys. 2005 , 49, 4508-14	26
1568	Hepatitis C virus core protein and hepatitis activity are associated through transactivation of interleukin-8. 2005 , 192, 266-75	15
1567	Clinical trials of treatment for hepatitis C virus infection in HIV-infected patients: past, present, and future. 2005 , 41 Suppl 1, S63-8	8
1566	Response to interferon alfa is hepatitis B virus genotype dependent: genotype A is more sensitive to interferon than genotype D. 2005 , 54, 1009-13	182
1565	Effects of adding ribavirin to interferon to treat chronic hepatitis C infection: a systematic review and meta-analysis of randomized trials. 2005 , 165, 2206-12	26
1564	Aktuelle Diagnostik und Therapie der Hepatitis C. 2005 , 1, 55-72	

- 1563 Aktuelles und künftige Entwicklungen in der Therapie von Hepatitis B und C. **2005**, 31, 466-471
- 1562 Development of prophylactic and therapeutic vaccines against hepatitis C virus. **2005**, 4, 351-71 11
- 1561 Effect of alcohol use and highly active antiretroviral therapy on plasma levels of hepatitis C virus (HCV) in patients coinfecting with HIV and HCV. **2005**, 41 Suppl 1, S105-9 42
- 1560 Peptide-loaded chimeric influenza virosomes for efficient in vivo induction of cytotoxic T cells. **2005**, 17, 695-704 46
- 1559 Can Peg-IFN alpha-2a plus ribavirin be used to treat patients with chronic hepatitis C and normal alanine aminotransferase levels?. **2005**, 2, 130-1 1
- 1558 Pegylated IFNs for chronic hepatitis C: an update. **2005**, 2, 219-26 20
- 1557 Peginterferon Alfa-2b and ribavirin for 12 versus 24 weeks in HCV infection. *New England Journal of Medicine*, **2005**, 353, 1182-3; author reply 1182-3 59.2 4
- 1556 Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. *New England Journal of Medicine*, **2005**, 352, 2609-17 59.2 534
- 1555 Endovascular repair of abdominal aortic aneurysm. *New England Journal of Medicine*, **2005**, 353, 1181-2; author reply 1181-2 59.2 2
- 1554 Treatment of chronic hepatitis C in human immunodeficiency virus/hepatitis C virus-coinfecting patients in the era of pegylated interferon and ribavirin. **2005**, 25, 33-51 28
- 1553 Aktuelles und künftige Entwicklungen in der Therapie von Hepatitis B und C. **2005**, 31, 466-471
- 1552 Management and treatment of injection drug users with hepatitis C virus (HCV) infection and HCV/human immunodeficiency virus coinfection. **2005**, 25, 18-32 28
- 1551 Iron in nonhemochromatotic liver disorders. **2005**, 25, 461-72 100
- 1550 Therapie der Hepatitis C bei Drogenabhängigen. **2005**, 6, 137-141
- 1549 Current and future concepts in hepatitis C therapy. **2005**, 25, 72-83 48
- 1548 Review: Milstein Award lecture: interferons and cancer: where from here?. **2005**, 25, 511-27 31
- 1547 Pilot study of low-dose interleukin-2, pegylated interferon-alpha 2b, and ribavirin for the treatment of hepatitis C virus infection in patients with HIV infection. **2005**, 191, 686-93 9
- 1546 Chronic hepatitis C treatment patterns in African American patients: an update. **2005**, 100, 716-22 19

1545	High molecular weight adiponectin correlates with insulin sensitivity in patients with hepatitis C genotype 3, but not genotype 1 infection. 2005 , 100, 2717-23	49
1544	The spectrum of chronic hepatitis C virus infection in the Virginia Correctional System: development of a strategy for the evaluation and treatment of inmates with HCV. 2005 , 100, 313-21	10
1543	Antibody-mediated pure red cell aplasia due to epoetin alfa during antiviral therapy of chronic hepatitis C. 2005 , 100, 1415-9	45
1542	Insulin resistance plays a significant role in liver fibrosis in chronic hepatitis C and in the response to antiviral therapy. 2005 , 100, 1509-15	188
1541	Quasispecies heterogeneity within the E1/E2 region as a pretreatment variable during pegylated interferon therapy of chronic hepatitis C virus infection. 2005 , 79, 3071-83	74
1540	Benefit of hepatitis C virus core antigen assay in prediction of therapeutic response to interferon and ribavirin combination therapy. 2005 , 43, 186-91	34
1539	Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. 2005 , 51, 1867-73	415
1538	An in vitro model of hepatitis C virion production. 2005 , 102, 2579-83	96
1537	Spontaneous hepatic decompensation in patients coinfectd with HIV and hepatitis C virus during interferon-ribavirin combination treatment. 2005 , 41, 1806-9	35
1536	Normal functional capacity in circulating myeloid and plasmacytoid dendritic cells in patients with chronic hepatitis C. 2005 , 192, 497-503	110
1535	Factors Associated with Ribavirin-Induced Anemia. 2005 , 21, 207-212	
1534	Defective Jak-Stat activation in hepatoma cells is associated with hepatitis C viral IFN-alpha resistance. 2005 , 25, 528-39	43
1533	Cost of Hepatitis C Treatment in the Correctional Setting. 2005 , 11, 199-212	3
1532	Exacerbation of psoriasis due to peginterferon alpha-2b plus ribavirin treatment of chronic active hepatitis C. 2005 , 51, 167-9	25
1531	Liver-directed gamma interferon gene delivery in chronic hepatitis C. 2005 , 79, 13412-20	22
1530	Full-breadth analysis of CD8+ T-cell responses in acute hepatitis C virus infection and early therapy. 2005 , 79, 12979-88	93
1529	Host cell targets in HCV therapy: novel strategy or proven practice?. 2005 , 16, 69-90	9
1528	Integrating treatment for hepatitis C virus infection into an HIV clinic. 2005 , 40 Suppl 5, S362-6	24

1527	Interferon Methods and Protocols. 2005 ,	
1526	Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy. 2005 , 48, 372-80	242
1525	Management of chronic hepatitis C. 2005 , 81, 376-82	21
1524	Hepatitis C Viruss Immune Evasion Strategies. 2005 , 1, 223-235	
1523	Hepatitis C treatment in a Canadian federal correctional population: Preliminary feasibility and outcomes. 2005 , 1, 13-18	5
1522	Factors associated with interest in initiating treatment for hepatitis C Virus (HCV) infection among young HCV-infected injection drug users. 2005 , 40 Suppl 5, S304-12	92
1521	Clinical significance of in vitro replication-enhancing mutations of the hepatitis C virus (HCV) replicon in patients with chronic HCV infection. 2005 , 192, 1710-9	18
1520	Chronic hepatitis C virus infection in older adults. 2005 , 41, 1606-12	21
1519	Effectiveness and cost-effectiveness of initial combination therapy with interferon/peginterferon plus ribavirin in patients with chronic hepatitis C in Germany: a health technology assessment commissioned by the German Federal Ministry of Health and Social Security. 2005 , 21, 55-65	30
1518	Clinical impact of non-organ-specific autoantibodies on the response to combined antiviral treatment in patients with hepatitis C. 2005 , 40, 501-7	48
1517	Mutations conferring resistance to a hepatitis C virus (HCV) RNA-dependent RNA polymerase inhibitor alone or in combination with an HCV serine protease inhibitor in vitro. 2005 , 49, 4305-14	117
1516	Approaching treatment for hepatitis C virus infection in substance users. 2005 , 41 Suppl 1, S79-82	22
1515	Sarcoidosis in patients with chronic hepatitis C virus infection: analysis of 68 cases. 2005 , 84, 69-80	123
1514	Transmission of hepatitis C virus among HIV-positive homosexual men and response to a 24-week course of pegylated interferon and ribavirin. 2005 , 40, 41-6	116
1513	Treatment of hepatitis C virus in HIV patients: a review. 2005 , 19 Suppl 3, S166-73	8
1512	Prediction of treatment outcome in chronic hepatitis C patients based on early viral dynamics during high-dose induction interferon and ribavirin therapy. 2005 , 48, 230-8	7
1511	Hepatitis C virus genotype 1a NS5A pretreatment sequence variation and viral kinetics in African American and white patients. 2005 , 192, 1078-87	29
1510	Mass spectrometry for genotyping hepatitis C virus: a promising new approach. 2005 , 51, 1091-2	

1509	Immunogenicity and tolerability of intradermal administration of an HCV E1-based vaccine candidate in healthy volunteers and patients with resolved or ongoing chronic HCV infection. 2005 , 1, 61-5	29
1508	Hepatitis C virus treatment decision-making in the context of HIV co-infection: the role of medical, behavioral and mental health factors in assessing treatment readiness. 2005 , 19 Suppl 3, S190-8	13
1507	Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. 2005 , 365, 123-9	948
1506	Increased hepatocyte fas expression and apoptosis in HIV and hepatitis C virus coinfection. 2005 , 192, 1566-76	29
1505	Genetic diversity and evolution of hepatitis C virus in the Latin American region. 2005 , 34 Suppl 2, S1-7	142
1504	Recombinant interferon alpha treatment decreases heart rate variability indices and impairs exercise tolerance in patients with chronic hepatitis. 2005 , 59 Suppl 1, S163-8	6
1503	[Willing to undergo hepatitis C treatment in a sample of injection drug users in Toronto, Canada]. 2005 , 34, 1209-12	11
1502	Treatment of chronic hepatitis C infection: one step at a time. 2005 , 5, 524-6	16
1501	Global epidemiology of hepatitis C virus infection. 2005 , 5, 558-67	2085
1500	Hepatitis C. 2005 , 12, 74-85	
1499	Hepatitis B and C viruses in infants and young children. 2005 , 16, 296-305	44
1498	Regulating intracellular antiviral defense and permissiveness to hepatitis C virus RNA replication through a cellular RNA helicase, RIG-I. 2005 , 79, 2689-99	724
1497	Update on chronic hepatitis C. 2005 , 3, 507-20	21
1496	Treatment of hepatitis C in the patient with decompensated cirrhosis. 2005 , 3, S106-12	14
1495	Use of virologic assays in the diagnosis and management of hepatitis C virus infection. 2005 , 9, 371-82, v	29
1494	Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. 2005 , 129, 522-7	119
1493	Treatment of hepatitis C in patients who have decompensated cirrhosis. 2005 , 9, 473-86, viii	11
1492	Chronic hepatitis C: genotypes 4 to 9. 2005 , 9, 411-26, vi	40

1491	Effect of significant histologic steatosis or steatohepatitis on response to antiviral therapy in patients with chronic hepatitis C. 2005 , 3, 604-9	85
1490	Prevalence and treatment of hepatitis C virus genotypes 4, 5, and 6. 2005 , 3, S97-S101	154
1489	Use of growth factors with antiviral therapy for chronic hepatitis C. 2005 , 9, 439-51, vii	23
1488	Management of the hematologic complications of hepatitis C therapy. 2005 , 9, 601-16, vi	35
1487	Management of hepatitis C virus in special populations: patient and treatment considerations. 2005 , 3, 311-8	27
1486	Advances in gastrointestinal pharmacotherapy. 2005 , 3, 1167-79	5
1485	Chronic hepatitis C in African Americans. 2005 , 9, 427-38, vii	9
1484	Antiviral therapies in children: has their time arrived?. 2005 , 52, 837-67, vii	18
1483	Treatment of hepatitis C after liver transplantation. 2005 , 9, 579-600, vi	31
1482	Ribavirin monotherapy for Hepatitis C virus infection in renal transplant recipient. 2005 , 1, 12-15	
1481	Peginterferon-alpha 2a for the treatment of hepatitis B infection. 2005 , 6, 1373-80	7
1480	Hepatitis C virus core protein inhibits mitochondrial electron transport and increases reactive oxygen species (ROS) production. 2005 , 280, 37481-8	310
1479	Treatment of hepatitis C: critical appraisal of the evidence. 2005 , 6, 399-408	17
1478	Regression of advanced non-splenic marginal zone lymphoma after treatment of hepatitis C virus infection. 2005 , 46, 1365-8	28
1477	Financial impact of two different ways of evaluating early virological response to peginterferon-alpha-2b plus ribavirin therapy in treatment-naïve patients with chronic hepatitis C virus genotype 1. 2005 , 23, 1043-55	15
1476	Pharmacological agents can ameliorate some of the neuropsychiatric adverse effects of interferon- α treatment. 2005 , 21, 18-22	
1475	Long-term follow-up of interferon monotherapy in 454 consecutive naïve patients infected with hepatitis C virus: multi-course interferon therapy may reduce the risk of hepatocellular carcinoma and increase survival. 2005 , 40, 688-96	22
1474	Human serum facilitates hepatitis C virus infection, and neutralizing responses inversely correlate with viral replication kinetics at the acute phase of hepatitis C virus infection. 2005 , 79, 6023-34	229

1473	Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. <i>New England Journal of Medicine</i> , 2005 , 352, 2682-95	59.2	1226
1472	Global transcriptional profiling demonstrates the combination of type I and type II interferon enhances antiviral and immune responses at clinically relevant doses. 2005 , 25, 632-49		28
1471	Highly sensitive hepatitis C virus RNA detection assays for decision of treatment (dis)continuation in patients with chronic hepatitis C. 2005 , 42, 605-6		6
1470	Long-term supportive cyclical re-treatment in HBeAg-negative IFN responders. 2005 , 42, 277-8		1
1469	Treatment of hepatitis C virus genotype 2 and 3 with pegylated interferon plus ribavirin. 2005 , 42, 275-6; author reply 276-7		32
1468	Reply. 2005 , 42, 276-277		32
1467	Etanercept as an adjuvant to interferon and ribavirin in treatment-naïve patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study. 2005 , 42, 315-22		222
1466	Towards more individualised management of hepatitis C virus patients with initially or persistently normal alanineaminotransferase levels. 2005 , 42, 266-74		46
1465	Second hepatitis C replication compartment indicated by viral dynamics during liver transplantation. 2005 , 42, 491-8		61
1464	Serum antibodies against the hepatitis C virus E2 protein mediate antibody-dependent cellular cytotoxicity (ADCC). 2005 , 42, 499-504		25
1463	Estimating the impact of hepatitis C virus therapy on future liver-related morbidity, mortality and costs related to chronic hepatitis C. 2005 , 42, 639-45		83
1462	Management of cirrhosis due to chronic hepatitis C. 2005 , 42 Suppl, S65-74		19
1461	Should we treat patients with chronic hepatitis C on the waiting list?. 2005 , 42, 456-62		27
1460	Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis C. 2005 , 42, 793-8		149
1459	Combined treatment with pegylated interferon (alpha-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation. 2005 , 43, 53-9		131
1458	Peginterferon alfa-2b and ribavirin for treatment-refractory chronic hepatitis C. 2005 , 43, 243-9		62
1457	GNB3 C825T polymorphism and response to interferon-alfa/ribavirin treatment in patients with hepatitis C virus genotype 1 (HCV-1) infection. 2005 , 43, 388-93		24
1456	A follow-up study to determine the value of liver biopsy and need for antiviral therapy for hepatitis C virus carriers with persistently normal serum aminotransferase. 2005 , 43, 599-605		62

1455	Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. 2005 , 43, 425-33	425
1454	International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C. 2005 , 43, 250-7	127
1453	HCV clearance and treatment outcome in genotype 1 HCV-monoinfected, HIV-coinfected and liver transplanted patients on peg-IFN-alpha-2b/ribavirin. 2005 , 43, 783-90	19
1452	Relationship between early HCV kinetics and T-cell reactivity in chronic hepatitis C genotype 1 during peginterferon and ribavirin therapy. 2005 , 43, 776-82	32
1451	Divining the role of liver biopsy in hepatitis C. 2005 , 43, 374-6	6
1450	Mutagenic effects of ribavirin in vivo. 2005 , 43, 553-5	13
1449	Rethinking hepatitis C viral kinetics: Insights into host-virus interactions in 'difficult-to-treat' groups and implications for novel treatment approaches. 2005 , 43, 748-50	2
1448	Recent highlights in the development of new antiviral drugs. 2005 , 8, 552-60	117
1447	Hepatitis C virus-related resistance mechanisms to interferon alpha-based antiviral therapy. 2005 , 32, 86-91	44
1446	A real-time Taqman method for hepatitis C virus genotyping. 2005 , 34, 115-21	23
1445	Depressive symptoms and viral clearance: In response. 2005 , 19, 273-274	3
1444	SOCS-1 inhibits expression of the antiviral proteins 2',5'-OAS and MxA induced by the novel interferon-lambdas IL-28A and IL-29. 2005 , 331, 543-8	77
1443	Blocking of interleukin-10 receptor--a novel approach to stimulate T-helper cell type 1 responses to hepatitis C virus. 2005 , 117, 57-64	80
1442	Combination therapy with pegylated interferon plus ribavirin in the treatment of hepatitis C virus-related thrombocytopenia. 2005 , 66, 247-53	1
1441	Therapy for treatment-refractory chronic hepatitis C virus genotype 1b infection: A retrospective analysis. 2005 , 66, 451-62	
1440	Clinical experience with nonstandard doses of interferon alfa-2b and ribavirin in the treatment of chronic hepatitis C infection: A retrospective analysis. 2005 , 66, 433-50	
1439	Hepatitis C virus, ER stress, and oxidative stress. 2005 , 13, 159-63	211
1438	Salient molecular features of hepatitis C virus revealed. 2005 , 13, 528-34	7

1437	Pegylated interferon and ribavirin for the recurrence of chronic hepatitis C genotype 1 in transplant patients. 2005 , 37, 3963-4	21
1436	[Efficacy and safety of pegylated-interferon plus ribavirin in HIV-infected patients co-infected with hepatitis C virus in clinical practice: a 32 cases observational follow-up]. 2005 , 26, 280-7	4
1435	Treatment of hepatitis C. 2005 , 118, 808-15	70
1434	[Recommendations of the CEVIHP/SEIP/AEP/PNS on antiretroviral treatment in HIV-infected children and teenagers]. 2005 , 23, 279-312	4
1433	[Prevalences of hepatitis virus coinfection and indications for chronic hepatitis C virus treatment and liver transplantation in Spanish HIV-infected patients. The GESIDA 29/02 and FIPSE 12185/01 Multicenter Study]. 2005 , 23, 340-8	32
1432	Viral hepatitis and hepatocellular carcinoma. 2005 , 3, 27	94
1431	Treatment of hepatitis C in special populations. 2005 , 9, 567-77, v	2
1430	[Advances in the diagnosis and treatment of hepatitis C virus infection in patients with and without HIV infection]. 2005 , 23, 32-40	4
1429	Peginterferon alpha-2a (40KD) plus ribavirin: a review of its use in the management of patients with chronic hepatitis C and persistently 'normal' ALT levels. 2005 , 65, 521-36	8
1428	Generalised Dermatitis Induced by Pegylated Interferon-alpha-2b in a Patient Infected with Genotype-1 Hepatitis C Virus : Presentation of a Case. 2005 , 25, 281-4	3
1427	Marcadores de replicaci3n del virus de la hepatitis C. 2005 , 4, 233-237	
1426	Viral kinetics in hepatitis C or hepatitis C/human immunodeficiency virus-infected patients. 2005 , 128, 313-27	83
1425	La protein is a potent regulator of replication of hepatitis C virus in patients with chronic hepatitis C through internal ribosomal entry site-directed translation. 2005 , 128, 449-62	18
1424	Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. 2005 , 128, 636-41	607
1423	Mathematical modeling of primary hepatitis C infection: noncytolytic clearance and early blockage of virion production. 2005 , 128, 1056-66	92
1422	Reply. 2005 , 128, 2178-2179	0
1421	Peginterferon-2a (40KD) and Ribavirin for 16 or 24 Weeks in Patients With Genotype 2 or 3 Chronic Hepatitis C. 2005 , 129, 522-527	349
1420	Interferon treatment in children with chronic hepatitis C: long-lasting remission in responders, and risk for disease progression in non-responders. 2005 , 37, 336-41	16

¹⁴¹⁹ Second thoughts about secondary analyses. **2005**, 37, 805-7; author reply 808-9

¹⁴¹⁸ Response to letter from Professor Peter Ferenci. **2005**, 37, 808-809

¹⁴¹⁷ Acute polymyositis during treatment of acute hepatitis C with pegylated interferon alpha-2b. **2005**, 37, 882-5 19

¹⁴¹⁶ The influence of hiv coinfection on the natural history of hcv infection. **2005**, 4, 131-137 2

¹⁴¹⁵ Chronic hepatitis C: management of treatment failures. **2005**, 3, S102-5 13

¹⁴¹⁴ Treatment of hepatitis C virus/HIV coinfection. **2005**, 9, 525-33, ix 1

¹⁴¹³ Approach to the management of patients with chronic hepatitis C who failed to achieve sustained virologic response. **2005**, 9, 453-71, vii-viii 16

¹⁴¹² Steatosis and chronic hepatitis C infection: mechanisms and significance. **2005**, 3, S92-6 9

¹⁴¹¹ Therapies for HIV and viral hepatitis coinfection. **2005**, 3, 81-9 1

¹⁴¹⁰ Therapy of hepatitis C in patients with HIV infection. **2005**, 3, 375-84 1

¹⁴⁰⁹ Thymalfasin for the treatment of chronic hepatitis C infection. **2005**, 3, 885-92 9

¹⁴⁰⁸ High-throughput cell-based screening for hepatitis C virus NS3/4A protease inhibitors. **2005**, 3, 385-92 13

¹⁴⁰⁷ Clinical role of serum and tissue matrix metalloprotease-9 expression in chronic HCV patients treated with pegylated IFN-alpha2b and ribavirin. **2005**, 25, 453-8 7

¹⁴⁰⁶ Neuropsychiatric adverse effects of interferon-alpha: recognition and management. **2005**, 19, 105-23 357

¹⁴⁰⁵ A randomized trial of pegylated interferon alpha-2b plus ribavirin in the retreatment of chronic hepatitis C. **2005**, 100, 2453-62 114

¹⁴⁰⁴ Optimal dosing frequency of pegylated interferon alfa-2b monotherapy for chronic hepatitis C virus infection. **2005**, 3, 610-5 6

¹⁴⁰³ Interferon-stimulated gene expression in black and white hepatitis C patients during peginterferon alfa-2a combination therapy. **2005**, 3, 499-506 23

¹⁴⁰² Modifications of T-lymphocyte subsets before and during interferon and ribavirin treatment for chronic hepatitis C infection. **2005**, 18, 197-204 4

1401	Efficacy of short-term interferon therapy for patients infected with hepatitis C virus genotype 2a. 2005 , 100, 862-7	14
1400	Erythropoietic response to anemia in chronic hepatitis C patients receiving combination pegylated interferon/ribavirin. 2005 , 100, 299-307	50
1399	Effect of ethanol on innate antiviral pathways and HCV replication in human liver cells. 2005 , 2, 89	44
1398	Novel type I interferon IL-28A suppresses hepatitis C viral RNA replication. 2005 , 2, 80	66
1397	Comparative analysis of hepatitis C virus phylogenies from coding and non-coding regions: the 5' untranslated region (UTR) fails to classify subtypes. 2006 , 3, 103	21
1396	Serendipitous identification of natural intergenotypic recombinants of hepatitis C in Ireland. 2006 , 3, 95	50
1395	Quasispecies: Concept and Implications for Virology. 2006 ,	43
1394	The Role of Peginterferon α 2a (40kD) Plus Ribavirin in the Management of Chronic Hepatitis C Mono-Infection. 2006 , 14, 303-320	
1393	HIV-related liver disease: infections versus drugs. 2006 , 35, 487-505	4
1392	Antiviral therapy for treatment naïve patients with hepatitis C virus. 2006 , 20, 99-113, vi-vii	6
1391	An artificial neural network approach to the drug efficacy of interferon treatments. 2006 , 7, 1017-24	38
1390	Approach to the management of patients with chronic hepatitis C who failed to achieve sustained virologic response. 2006 , 20, 115-35	4
1389	Gene therapy for viral hepatitis. 2006 , 6, 1263-78	5
1388	Provider-patient in-office discussions of response to hepatitis C antiviral therapy and impact on patient comprehension. 2006 , 4, 507-13	10
1387	Hepatitis C virus population dynamics during infection. 2006 , 299, 261-84	88
1386	Hepatic histologic response (HR) to combination therapy among HCV/HIV-coinfected individuals: interferon induces HR independent of sustained virologic response (SVR). 2006 , 22, 1091-8	5
1385	A study of low dose peginterferon alpha-2b with ribavirin for the initial treatment of chronic hepatitis C. 2006 , 101, 1268-73	11
1384	Long-term follow-up of previous hepatitis C virus positive nonresponders to interferon monotherapy successfully retreated with combination therapy: are they really cured?. 2006 , 101, 1811-6	22

1383	Efficacy and safety of pegylated interferon-alpha2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients. 2006 , 22, 315-20	16
1382	Replication and Pathogenesis of Hepatitis C Virus. 2006 , 125-147	1
1381	Treatment options for chronic hepatitis B and C infection in children. 2006 , 4, 583-91	2
1380	Present and future therapy for hepatitis C virus. 2006 , 4, 781-93	11
1379	Proteases in Gastrointestinal Tissues. 2006 ,	
1378	Hepatitis C Viral Proteases And Inhibitors. 2006 , 153-181	1
1377	Hepatitis C: cost of illness and considerations for the economic evaluation of antiviral therapies. 2006 , 24, 661-72	43
1376	Improving anti-hepatitis C virus therapy. 2006 , 6, 923-33	16
1375	Treatment of interferon-alpha for chronic hepatitis C. 2006 , 7, 1163-79	9
1374	Poor response to hepatitis C virus (HCV) therapy in HIV- and HCV-coinfected patients is not due to lower adherence to treatment. 2006 , 22, 393-400	22
1373	Treating viral hepatitis C: efficacy, side effects, and complications. 2006 , 55, 1350-9	474
1372	Peginterferon alfa-2a (40KD) plus ribavirin in chronic hepatitis C patients who failed previous interferon therapy. 2006 , 55, 1631-8	67
1371	Hepatitis C in Pregnancy and Mother-to-Infant Transmission of HCV. 2006 , 153-171	
1370	Current therapy of hepatitis C. 2006 , 65-9	1
1369	Histamine dihydrochloride: actions and efficacy in the treatment of chronic hepatitis C infection. 2006 , 4, 377-85	2
1368	Peripheral neurotoxicity of pegylated interferon alpha: a prospective study in patients with HCV. 2006 , 67, 781-5	28
1367	Dendritic cells pulsed with hepatitis C virus NS3 protein induce immune responses and protection from infection with recombinant vaccinia virus expressing NS3. 2006 , 87, 1-10	24
1366	High rate of spontaneous negativity for hepatitis C virus RNA after establishment of chronic infection in Alaska Natives. 2006 , 42, 945-52	41

1365	Ribavirina y análogos. <i>Gastroenterología Y Hepatología</i> , 2006 , 29, 129-134	0.9
1364	Hepatitis C screening and treatment outcomes in patients with substance use/dependence disorders. 2006 , 47, 112-21	27
1363	Natural course and treatment of hepatitis D virus infection. 2006 , 105, 869-81	32
1362	Aspectos actuales y perspectivas de futuro del tratamiento de las hepatitis virales. 2006 , 9, 4443-4449	
1361	Treating chronic hepatitis C with pegylated interferon alfa-2a (40 KD) and ribavirin in clinical practice. 2006 , 23, 397-408	74
1360	[Management of psychological disorders in patients with chronic hepatitis C]. 2006 , 32, 198-203	2
1359	Distribution of hepatitis C virus genotypes in the Middle East. 2006 , 10, 272-7	81
1358	A phase 2 study to evaluate the antiviral activity, safety, and pharmacokinetics of recombinant human albumin-interferon alfa fusion protein in genotype 1 chronic hepatitis C patients. 2006 , 44, 671-8	86
1357	New therapies: oral inhibitors and immune modulators. 2006 , 10, 867-80	3
1356	The economics of hepatitis C virus. 2006 , 10, 717-34	19
1355	Management of hepatitis C in the setting of liver transplantation. 2006 , 10, 321-37, ix	3
1354	Role of obesity, insulin resistance, and steatosis in hepatitis C virus infection. 2006 , 10, 793-819	14
1353	Treatment of hepatitis C infection. 2006 , 35, 463-86	10
1352	Optimizing treatment regimens in hepatitis C. 2006 , 10, 835-50	13
1351	Hepatitis B and C in children: current treatment and future strategies. 2006 , 10, 133-48, vii	28
1350	Selection and characterization of replicon variants dually resistant to thumb- and palm-binding nonnucleoside polymerase inhibitors of the hepatitis C virus. 2006 , 80, 6146-54	127
1349	Impact of naturally occurring variants of HCV protease on the binding of different classes of protease inhibitors. 2006 , 45, 1353-61	43
1348	Intérêt de la charge virale au cours de l'hépatite C. 2006 , 8, 79-84	2

1347	Chronic hepatitis C therapy: changing the rules of duration. 2006 , 4, 963-71	13
1346	Chronic hepatitis C in patients with persistently normal alanine transaminase levels. 2006 , 4, 645-52	66
1345	Treatment of relapsers after combination therapy for chronic hepatitis C. 2006 , 20, 137-53	1
1344	American Gastroenterological Association technical review on the management of hepatitis C. 2006 , 130, 231-64; quiz 214-7	312
1343	Peginterferon alfa-2b therapy in acute hepatitis C: impact of onset of therapy on sustained virologic response. 2006 , 130, 632-8	160
1342	Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. 2006 , 130, 1086-97	417
1341	Pegylated interferon alfa-2b plus ribavirin in the retreatment of interferon-ribavirin nonresponder patients. 2006 , 130, 1098-106	79
1340	Alcohol use and treatment of hepatitis C virus: results of a national multicenter study. 2006 , 130, 1607-16	124
1339	Optimizing outcomes in hepatitis C: is treatment beyond 48 weeks ever justified?. 2006 , 130, 1357-62	7
1338	Serum proteome to predict virologic response in patients with hepatitis C treated by pegylated interferon plus ribavirin. 2006 , 130, 2189-97	26
1337	Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. 2006 , 131, 451-60	311
1336	Hepatitis C virus genotypes and viral concentrations in participants of a general population survey in the United States. 2006 , 131, 478-84	125
1335	Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. 2006 , 131, 470-7	405
1334	Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study. 2006 , 131, 997-1002	348
1333	Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin. 2006 , 131, 1040-8	162
1332	Use of ribavirin in patients with chronic HCV genotype 1: when enough is really enough. 2006 , 131, 1339-41	5
1331	Psychiatric and substance use disorders in individuals with hepatitis C: epidemiology and management. 2006 , 66, 155-74	66
1330	Short-term therapy for patients with hepatitis C virus genotype 2 or 3 infection. 2006 , 66, 1807-15	22

1329	Psychiatric symptoms induced by antiviral therapy in chronic hepatitis C: comparison between interferon-alpha-2a and interferon-alpha-2b. 2006 , 26, 655-62		25
1328	[Thyroid alterations following treatment with pegylated interferon and ribavirin: differences between HIV-coinfected and non-coinfected patients]. 2006 , 24, 213-4		2
1327	[HIV and HCV coinfection]. 2006 , 24, 335-45; quiz 346		3
1326	[Expert recommendations for the diagnosis and treatment of chronic hepatitis C infection in the prison setting]. 2006 , 24, 568-75		1
1325	[Early virologic response value as predictive factor of sustained virologic response to treatment with interferon alpha-2b plus ribavirin in chronic hepatitis C patients with or without HIV coinfection]. 2006 , 127, 561-6		0
1324	[Applicability of hepatitis C virus kinetics in patients co-infected with HIV]. 2006 , 127, 574-5		
1323	[Expert recommendations for the diagnosis and treatment of chronic hepatitis C infection in the prison setting]. <i>Gastroenterología Y Hepatología</i> , 2006 , 29, 551-9	0.9	4
1322	Situación actual. Perspectivas y vacunación. <i>Gastroenterología Y Hepatología</i> , 2006 , 29, 96-100	0.9	
1321	Monitorización y biopsia. <i>Gastroenterología Y Hepatología</i> , 2006 , 29, 121-124	0.9	0
1320	Pacientes naïve con genotipo 1. <i>Gastroenterología Y Hepatología</i> , 2006 , 29, 135-138	0.9	
1319	Tratamiento de la hepatitis crónica C por genotipos 2 y 3: revisión sistemática. <i>Gastroenterología Y Hepatología</i> , 2006 , 29, 139-145	0.9	
1318	Tratamiento de pacientes genotipo 4. <i>Gastroenterología Y Hepatología</i> , 2006 , 29, 146-149	0.9	1
1317	Manejo de los efectos adversos del tratamiento. <i>Gastroenterología Y Hepatología</i> , 2006 , 29, 184-189	0.9	4
1316	Coste-efectividad de interferón pegilado alfa en el tratamiento de la hepatitis crónica por virus C. <i>Gastroenterología Y Hepatología</i> , 2006 , 29, 200-205	0.9	
1315	Enfermedades hepáticas. <i>Gastroenterología Y Hepatología</i> , 2006 , 29, 99-111	0.9	1
1314	2-(2-Thienyl)-5,6-dihydroxy-4-carboxypyrimidines as inhibitors of the hepatitis C virus NS5B polymerase: discovery, SAR, modeling, and mutagenesis. 2006 , 49, 1693-705		81
1313	Pegylation of IFN-alpha and antiviral activity. 2006 , 26, 849-53		13
1312	[Treatment of viral hepatitis (II). Treatment of chronic hepatitis C]. 2006 , 24, 518-25; quiz 526		1

1311	Discovery of conformationally constrained tetracyclic compounds as potent hepatitis C virus NS5B RNA polymerase inhibitors. 2006 , 49, 6950-3	101
1310	Overview of Clinical Applications of Type I Interferons. 2006 , 275-308	3
1309	Drug interactions between psychoactive substances and antiretroviral therapy in individuals infected with human immunodeficiency and hepatitis viruses. 2006 , 41, 1395-463	36
1308	Propagation of hepatitis C virus infection: Elucidating targets for therapeutic intervention. 2006 , 3, 471-477	
1307	Pegylated interferon plus ribavirin for recurrent Hepatitis C infection after liver transplantation in naïve and non-responder patients on a stable immunosuppressive regimen. 2006 , 38, 27-32	39
1306	Expert Consensus Conference. The screening for hepatitis C virus infection in adults in Italy, May 5-6, 2005. 2006 , 38, 445-51	10
1305	Analysis of prognostic factors in therapeutic responses to interferon in patients with chronic hepatitis C. 2006 , 148, 79-86	10
1304	Different viral kinetics between hepatitis C virus genotype 1 and 2 as on-treatment predictors of response to a 24-week course of high-dose interferon-alpha plus ribavirin combination therapy. 2006 , 148, 120-7	24
1303	The novel nucleoside analog R1479 (4'-azidocytidine) is a potent inhibitor of NS5B-dependent RNA synthesis and hepatitis C virus replication in cell culture. 2006 , 281, 3793-9	172
1302	Peginterferon and ribavirin for chronic hepatitis C. <i>New England Journal of Medicine</i> , 2006 , 355, 2444-51	379
1301	Perinatal hepatitis C virus infection: diagnosis and management. 2006 , 91, 781-5	50
1300	Antiviral treatment of hepatitis C. 2006 , 7, 2025-35	8
1299	Diagnosis of hepatic fibrosis in patients with chronic hepatitis C. 2006 , 10, 821-33	14
1298	Cost effectiveness of interferon alpha or peginterferon alpha with ribavirin for histologically mild chronic hepatitis C. 2006 , 55, 1332-8	80
1297	Hepatitis C virus non-structural protein NS5A interacts with FKBP38 and inhibits apoptosis in Huh7 hepatoma cells. 2006 , 580, 4392-400	49
1296	Evaluation of the anti-hepatitis C virus effects of cyclophilin inhibitors, cyclosporin A, and NIM811. 2006 , 343, 879-84	118
1295	Genetic predisposition of responsiveness to therapy for chronic hepatitis C. 2006 , 7, 697-709	30
1294	Cost-effectiveness of peginterferon alfa-2a (40kDa) plus ribavirin in patients with HIV and hepatitis C virus co-infection. 2006 , 36, 283-91	19

1293	Hepatitis C minimal residual viremia (MRV) detected by TMA at the end of Peg-IFN plus ribavirin therapy predicts post-treatment relapse. 2006 , 44, 83-7	43
1292	A phase I trial of an antisense inhibitor of hepatitis C virus (ISIS 14803), administered to chronic hepatitis C patients. 2006 , 44, 88-96	65
1291	Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. 2006 , 44, 97-103	356
1290	Treating patients with HCV genotype 1 and low viraemia: more than meets the eye. 2006 , 44, 4-7	6
1289	HCV virological assessment. 2006 , 44, S35-9	20
1288	Options for treatment of hepatitis C in HIV-infected persons. 2006 , 44, S40-3	11
1287	Assessment of efficacy of treatment in HCV: infection and disease. 2006 , 44, S56-9	4
1286	Quality of life and cost-effectiveness of anti-HCV therapy in HIV-infected patients. 2006 , 44, S60-4	8
1285	Treatment of viral hepatitis in HIV-coinfected patients-adverse events and their management. 2006 , 44, S114-8	14
1284	The face of future hepatitis C antiviral drug development: recent biological and virologic advances and their translation to drug development and clinical practice. 2006 , 44, 411-21	67
1283	Viral and metabolic factors influencing alanine aminotransferase activity in patients with chronic hepatitis C. 2006 , 44, 679-85	39
1282	Oxidative stress inhibits IFN-alpha-induced antiviral gene expression by blocking the JAK-STAT pathway. 2006 , 45, 271-9	77
1281	Biochemical and histological effects of 26 weeks of glycyrrhizin treatment in chronic hepatitis C: a randomized phase II trial. 2006 , 45, 539-46	66
1280	Aeromonas septicaemia: an uncommon complication following placement of transhepatic biliary drainage devices in Europe. 2006 , 62, 115-6	3
1279	No carriers of hepatitis C among operating room personnel in a university hospital setting in The Netherlands. 2006 , 62, 114-5	
1278	The burden of hepatitis C virus infection in children: estimated direct medical costs over a 10-year period. 2006 , 148, 353-8	81
1277	Model-based identification of cis-acting elements from microarray data. 2006 , 88, 452-61	18
1276	Hepatitis C virus serologic and virologic tests and clinical diagnosis of HCV-related liver disease. 2006 , 3, 35-40	73

1275	Molecular virology of hepatitis C virus (HCV): 2006 update. 2006 , 3, 29-34	58
1274	Antiviral therapy of HCV in the cirrhotic and transplant candidate. 2006 , 3, 75-8	2
1273	Weight-based combination therapy with peginterferon alpha-2b and ribavirin for naïve, relapser and non-responder patients with chronic hepatitis C. 2006 , 10, 311-6	8
1272	Efficacy and long-term follow up of combination therapy with interferon alpha and ribavirin for chronic hepatitis C in Korea. 2006 , 47, 793-8	6
1271	Systemic lupus erythematosus following virological response to peginterferon alfa-2b in a transplanted patient with chronic hepatitis C recurrence. 2006 , 12, 4253-5	9
1270	[Therapy of chronic hepatitis C]. 2006 , 95, 1451-7	1
1269	Treatment outcomes in a centralized specialty clinic for hepatitis C virus are comparable with those from clinical trials. 2006 , 20, 87-90	3
1268	Hepatitis C eradication and improvement of cryoglobulinemia-associated rash and membranoproliferative glomerulonephritis with interferon and ribavirin after kidney transplantation. 2006 , 20, 427-31	7
1267	Clinical recommendations for the use of recombinant human erythropoietin in patients with hepatitis C virus being treated with ribavirin. 2006 , 20, 479-85	21
1266	Analytical and biological variables influencing quantitative hepatitis C virus (HCV) measurement in HIV-HCV coinfection. 2006 , 20, 31-5	1
1265	Elderly patients are at greater risk of cytopenia during antiviral therapy for hepatitis C. 2006 , 20, 589-92	47
1264	Predictors of antiviral therapy in a post-transfusion cohort of hepatitis C patients. 2006 , 20, 107-11	11
1263	Ischemic colitis during pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. 2006 , 20, 661-3	39
1262	Erythropoietin and hepatitis C therapy: useful adjuvant therapy but remember to treat the patient and not just a number. 2006 , 20, 519-20	1
1261	Predictive factors for response to treatment of chronic hepatitis C. 2006 , 5, S24-S28	4
1260	Cost efficacy and cost-benefit of treatment of hepatitis C. 2006 , 5, S69-S73	2
1259	Treatment of chronic hepatitis C infection in cirrhotic patients. 2006 , 5, S36-S39	1
1258	Treatment of chronic hepatitis C in treatment-naïve patients. 2006 , 5, S32-S33	

1257 Treatment of hepatitis C patients who do not respond to treatment or relapse after treatment. **2006**, 5, S40-S41

1256 Induction therapy with twice-daily interferon-beta does not improve the therapeutic efficacy of consensus interferon monotherapy for chronic hepatitis C. **2006**, 55, 111-7 5

1255 Liver Diseases. **2006**, 151-201

1254 Hepatitis C. **2006**,

1253 Peginterferon α 2b in the treatment of hepatitis C. **2006**, 1, 279-292 1

1252 Hepatitis C virus and oxidative stress: a dangerous liaison. **2006**, 1, 223-232 4

1251 Peginterferon- α 2a in the treatment of chronic hepatitis C. **2006**, 1, 689-701

1250 Treatment of chronic hepatitis C in patients with glucose-6-phosphate dehydrogenase deficiency: is ribavirin harmful?. **2006**, 107, 3409-10 3

1249 Improved outcome in central nervous system aspergillosis. **2006**, 107, 3410-1; author reply 3411-2

1248 Albumin-interferon- α 2b in the treatment of chronic hepatitis C. **2006**, 1, 269-278 3

1247 Can therapy of hepatitis C affect the development of hepatocellular carcinoma?. **2006**, 4, 751-7 7

1246 Standard of Care for HCV/HIV-Coinfected Patients. **2006**, 18, 21-26

1245 The kinetics of hepatitis C virus. **2006**, 18, 339-42 13

1244 Pegylated interferons for the treatment of chronic hepatitis B. **2006**, 1, 85-94 4

1243 Greater CD4 T-cell gains after one year of antiretroviral therapy are associated with lower HIV-1 pol replication capacity. **2006**, 20, 2123-5 30

1242 Hepatitis C virus eradication followed by HBeAg to anti-HBe seroconversion after pegylated interferon-alpha2b plus ribavirin treatment in a patient with hepatitis B and C coinfection. **2006**, 18, 1019-22 13

1241 Chronic hepatitis C in HIV-infected patients: those who more need therapy are those who respond less. **2006**, 6, 57-88

1240 Hepatitis C knowledge among staff in U.S. drug treatment programs. **2006**, 36, 141-58 22

1239	Individualization of antiviral treatment regimens for chronic hepatitis C. 2006 , 18, 321-5	3
1238	Majority of patients with hepatitis C express physical, mental, and social difficulties with antiviral treatment. 2006 , 18, 381-8	22
1237	Similar compliance and effect of treatment in chronic hepatitis C resulting from intravenous drug use in comparison with other infection causes. 2006 , 18, 159-66	63
1236	Sexually transmitted acute infection with a clustered genotype 4 hepatitis C virus in HIV-1-infected men and inefficacy of early antiviral therapy. 2006 , 20, 233-40	98
1235	Clinical presentation and course of acute hepatitis C infection in HIV-infected patients. 2006 , 41, 31-6	103
1234	Interferon-induced depression in chronic hepatitis C: a review of its prevalence, risk factors, biology, and treatment approaches. 2006 , 40, 322-35	138
1233	Transplantation and viral hepatitis: major progress. 2006 , 11, 579-582	
1232	Relationships between cellular immune responses and treatment outcomes with interferon and ribavirin in HIV/hepatitis C virus co-infection. 2006 , 20, 345-51	12
1231	A guided tour through the antiviral drug field. 2006 , 1, 19-35	5
1230	Clinical virology of hepatitis C virus. 2006 , 1, 649-657	
1229	Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinic. 2006 , 20, 2361-9	112
1228	Update on viral hepatitis: 2005. 2006 , 22, 241-7	2
1227	Comparison of characteristics of treated and non-treated patients with Hepatitis C infection. 2006 , 15, 71-6	13
1226	Hepatitis C: who should be treated?. 2006 , 15, 77-9	0
1225	Treatment of chronic hepatitis C patients with persistently normal alanine aminotransferase levels with the combination of peginterferon alpha-2a (40 kDa) plus ribavirin: impact on health-related quality of life. 2006 , 21, 406-12	41
1224	Thyroid dysfunction in patients with chronic hepatitis C receiving a combined therapy of interferon and ribavirin: Incidence, associated factors and prognosis. 2006 , 21, 319-326	3
1223	Effect of combination therapy with ribavirin and high-dose interferon-alpha2b for 24 weeks in chronic hepatitis C. 2006 , 21, 308-12	4
1222	Pegylated interferon for treatment in hemodialysis patients with chronic hepatitis C. 2006 , 21, 491-4	6

1221	Alpha-tocopherol [corrected] and ascorbic acid attenuates the ribavirin [corrected] induced decrease of eicosapentaenoic acid in erythrocyte membrane in chronic hepatitis C patients. 2006 , 21, 1269-75	15
1220	Changes of soluble CD26 and CD30 levels correlate with response to interferon plus ribavirin therapy in patients with chronic hepatitis C. 2006 , 21, 1789-93	16
1219	Chronic hepatitis C virus infection in renal transplant: treatment and outcome. 2006 , 20, 677-83	38
1218	A randomized trial of 24- vs. 48-week courses of PEG interferon alpha-2b plus ribavirin for genotype-1b-infected chronic hepatitis C patients: a pilot study in Taiwan. 2006 , 26, 73-81	41
1217	Consensus interferon and ribavirin for patients with chronic hepatitis C and failure of previous interferon-alpha therapy. 2006 , 26, 319-25	25
1216	Definition and management of anemia in patients infected with hepatitis C virus. 2006 , 26, 389-98	65
1215	Sustained viral response prolonged survival of patients with C-viral hepatocellular carcinoma. 2006 , 26, 536-42	18
1214	Twenty-four weeks of interferon alpha-2b in combination with ribavirin for Japanese hepatitis C patients: sufficient treatment period for patients with genotype 2 but not for patients with genotype 1. 2006 , 26, 520-8	7
1213	Results of combination treatment with pegylated interferon and ribavirin in cirrhotic patients with hepatitis C infection. 2006 , 26, 650-9	20
1212	Anti-Golgi complex antibodies during pegylated-interferon therapy for hepatitis C. 2006 , 26, 1148-54	8
1211	Impact of liver steatosis on the antiviral response in the hepatitis C virus-associated chronic hepatitis. 2006 , 26, 1119-25	42
1210	Zinc is a negative regulator of hepatitis C virus RNA replication. 2006 , 26, 1111-8	41
1209	Anemia associated with antiviral therapy in chronic hepatitis C: incidence, risk factors, and impact on treatment response. 2006 , 26, 1079-86	29
1208	A 24-week course of high-dose interferon-alpha plus ribavirin for Taiwanese chronic hepatitis C patients with persistently normal or near-normal alanine aminotransferase levels. 2006 , 26, 1187-95	7
1207	Role of individualization of hepatitis C virus (HCV) therapy duration in HIV/HCV-coinfected individuals. 2006 , 7, 248-54	22
1206	Barriers to treatment of hepatitis C in HIV/HCV-coinfected adults with alcohol problems. 2006 , 30, 1520-6	46
1205	Molecular medicine, the Medicare drug benefit, and the need for cost control. 2006 , 54, 1442-6	9
1204	Treatment of hepatitis C virus infection in intravenous drug users. 2006 , 18, 183-92	3

1203	Quantitative HBV DNA levels as an early predictor of nonresponse in chronic HBe-antigen positive hepatitis B patients treated with interferon-alpha. 2006 , 13, 96-103	21
1202	A prospective assessment of an 'a la carte' regimen of PEG-interferon alpha2b and ribavirin combination in patients with chronic hepatitis C using biochemical markers. 2006 , 13, 182-9	13
1201	A rapid real-time PCR assay for determination of hepatitis C virus genotypes 1, 2 and 3a. 2006 , 13, 222-9	2
1200	Comparison of hepatitis C treatment patterns in patients with and without psychiatric and/or substance use disorders. 2006 , 13, 235-41	27
1199	Fibrosis progression in initially mild chronic hepatitis C. 2006 , 13, 297-302	52
1198	Sustained virological response rates and durability of the response to interferon-based therapies in hepatitis C patients treated in the clinical setting. 2006 , 13, 311-5	53
1197	Interferon gamma-1b for the treatment of fibrosis in chronic hepatitis C infection. 2006 , 13, 322-8	49
1196	Pilot study of interferon-alpha-ribavirin-interleukin-2 for treatment of nonresponder patients with severe liver disease infected by hepatitis C virus genotype 1. 2006 , 13, 139-44	7
1195	Peginterferon alfa-2a and ribavirin for chronic hepatitis C genotype 1 infections in black patients: safety, tolerability and impact on sustained virologic response. 2006 , 13, 371-6	15
1194	Clinical pathways for patients with newly diagnosed hepatitis C - what actually happens. 2006 , 13, 264-71	49
1193	Long-term effect of interferon alpha-2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis. 2006 , 13, 409-14	95
1192	Viral kinetics and early prediction of nonresponse to peg-IFN-alpha-2b plus ribavirin in HCV genotypes 1/4 according to HIV serostatus. 2006 , 13, 466-73	15
1191	Effects of bezafibrate in patients with chronic hepatitis C virus infection: combination with interferon and ribavirin. 2006 , 13, 441-8	37
1190	Sensitivity to antiviral therapy may change after liver transplantation in patients with chronic hepatitis C virus infection. 2006 , 13, 544-51	13
1189	Viral kinetics in the treatment of chronic hepatitis C. 2006 , 13, 499-504	22
1188	Re-treatment of chronic hepatitis C patients after relapse: efficacy of peginterferon-alpha-2a (40 kDa) and ribavirin. 2006 , 13, 435-40	31
1187	Site-specific mutation of the interferon sensitivity-determining region (ISDR) modulates hepatitis C virus replication. 2006 , 13, 582-90	26
1186	Treatment of hepatitis C virus and human immunodeficiency virus coinfection: from large trials to real life. 2006 , 13, 678-82	28

1185	Zidovudine use but not weight-based ribavirin dosing impacts anaemia during HCV treatment in HIV-infected persons. 2006 , 13, 683-9	92
1184	Accurate model predicting sustained response at week 4 of therapy with pegylated interferon with ribavirin in patients with chronic hepatitis C. 2006 , 13, 701-7	10
1183	HCV-related advanced fibrosis/cirrhosis: randomized controlled trial of pegylated interferon alpha-2a and ribavirin. 2006 , 13, 762-9	58
1182	Assessing evidence from clinical trials in chronic hepatitis C. 2006 , 13 Suppl 1, 1-5	3
1181	Evaluating the evidence from clinical trials in chronic hepatitis C. 2006 , 13 Suppl 1, 15-25	1
1180	Issues in designing and interpreting clinical trials of treatments for chronic hepatitis C. 2006 , 13 Suppl 1, 6-14	
1179	The results of a randomized trial looking at 24 weeks vs 48 weeks of treatment with peginterferon alpha-2a (40 kDa) and ribavirin combination therapy in patients with chronic hepatitis C genotype 1. 2006 , 13, 552-9	12
1178	Treatment rates in patients with chronic hepatitis C after liver biopsy. 2006 , 13, 783-6	16
1177	Peginterferon alpha-2b plus ribavirin for treatment of chronic hepatitis C with severe fibrosis: a multicentre randomized controlled trial comparing two doses of peginterferon alpha-2b. 2006 , 13, 811-20	34
1176	Pharmacokinetics of ribavirin in patients with hepatitis C virus. 2006 , 62, 710-4	39
1175	Predicting sustained virological response and anaemia in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) plus ribavirin. 2006 , 62, 699-709	68
1174	Peroxisome proliferator-activated receptor-alpha and -gamma mRNA levels are reduced in chronic hepatitis C with steatosis and genotype 3 infection. 2006 , 23, 107-14	100
1173	Long-term follow-up of chronic hepatitis C patients with sustained virological response to various forms of interferon-based anti-viral therapy. 2006 , 23, 507-11	61
1172	Review article: predicting response in hepatitis C virus therapy. 2006 , 23, 1043-54	53
1171	Sustained virological response to peginterferon plus ribavirin in chronic hepatitis C genotype 1 patients is associated with a persistent Th1 immune response. 2006 , 24, 117-28	16
1170	Effectiveness of interferon plus ribavirin combination in the treatment of naive patients with hepatitis C virus type 5. A French multicentre retrospective study. 2006 , 24, 593-600	28
1169	Rates and predictors of hepatitis C virus treatment in HCV-HIV-coinfected subjects. 2006 , 24, 585-91	38
1168	Comparison of simple tests for the non-invasive diagnosis of clinically silent cirrhosis in chronic hepatitis C. 2006 , 24, 797-804	19

1167	Review article: management of patients with chronic hepatitis C virus infection and "normal" alanine aminotransferase activity. 2006 , 24, 1133-49	35
1166	Cost-effectiveness of growth factors during hepatitis C anti-viral therapy. 2006 , 24, 1067-77	12
1165	A randomized trial of pegylated-interferon-alpha2a plus ribavirin with or without amantadine in the re-treatment of patients with chronic hepatitis C not responding to standard interferon and ribavirin. 2006 , 24, 1079-86	17
1164	Cost-utility analysis of different peg-interferon alpha-2b plus ribavirin treatment strategies as initial therapy for naïve Chinese patients with chronic hepatitis C. 2006 , 24, 1483-93	12
1163	Impact on adherence and sustained virological response of psychiatric side effects during peginterferon and ribavirin therapy for chronic hepatitis C. 2006 , 24, 1223-30	37
1162	Clinical significance of organ- and non-organ-specific autoantibodies on the response to anti-viral treatment of patients with chronic hepatitis C. 2006 , 24, 1563-73	28
1161	Treatment of chronic hepatitis C in patients with haemophilia: a review of the literature. 2006 , 12, 473-8	23
1160	PEGylation of native disulfide bonds in proteins. 2006 , 1, 2241-52	97
1159	Antiviral agents active against influenza A viruses. 2006 , 5, 1015-25	516
1158	Divergent activities of interferon-alpha subtypes against intracellular hepatitis C virus replication. 2006 , 34, 41-9	21
1157	Hepatic steatosis is a predictor of poor response to interferon alpha-2b and ribavirin combination therapy in Japanese patients with chronic hepatitis C. 2006 , 35, 19-25	24
1156	Lactoferrin inhibits lipid peroxidation in patients with chronic hepatitis C. 2006 , 36, 27-32	33
1155	First phase viral kinetic parameters and prediction of response to interferon alpha-2b/ribavirin combination therapy in patients with chronic hepatitis C. 2006 , 36, 94-9	8
1154	Virological effects and safety of combined double filtration plasmapheresis (DFPP) and interferon therapy in patients with chronic hepatitis C: A preliminary study. 2006 , 36, 167-75	15
1153	Global transcriptional effects of PEG-IFN-alpha and ribavirin on peripheral blood cells obtained from patients with chronic hepatitis C. 2006 , 36, 277-87	
1152	Identification of novel hepatitis C virus-specific cytotoxic T lymphocyte epitope in NS3 region. 2006 , 36, 294-300	4
1151	Sensitive and specific LC-MS/MS method for the simultaneous measurements of virmidine and ribavirin in human plasma. 2006 , 32, 17-23	27
1150	N-terminally PEGylated human interferon-beta-1a with improved pharmacokinetic properties and in vivo efficacy in a melanoma angiogenesis model. 2006 , 17, 179-88	119

1149	Benzimidazole derivatives bearing substituted biphenyls as hepatitis C virus NS5B RNA-dependent RNA polymerase inhibitors: structure-activity relationship studies and identification of a potent and highly selective inhibitor JTK-109. 2006 , 49, 4721-36	134
1148	Comparison of two PEG-interferon alpha-2b doses (1.0 or 1.5 microg/kg) combined with ribavirin in interferon-naïve patients with chronic hepatitis C and up to moderate fibrosis. 2006 , 13, 457-65	25
1147	A decrease in AFP level related to administration of interferon in patients with chronic hepatitis C and a high level of AFP. 2006 , 51, 808-12	41
1146	From trials to a real hospital setting: effectiveness of pegylated interferon-alpha-2b/ribavirin combination therapy for naïve chronic hepatitis C patients. 2006 , 51, 1619-26	13
1145	Successful treatment with novel triple drug combination consisting of interferon-gamma, interferon alfacon-1, and ribavirin in a nonresponder HCV patient to pegylated interferon therapy. 2006 , 51, 956-9	3
1144	Standard interferon-alpha in combination with ribavirin for hepatitis C patients with advanced liver disease and thrombocytopenia. 2006 , 118, 595-600	4
1143	Antiviral therapy for chronic hepatitis C: past, present, and future. 2006 , 41, 17-27	128
1142	Negative regulation of intracellular hepatitis C virus replication by interferon regulatory factor 3. 2006 , 41, 750-7	10
1141	Early decline of hemoglobin correlates with progression of ribavirin-induced hemolytic anemia during interferon plus ribavirin combination therapy in patients with chronic hepatitis C. 2006 , 41, 862-72	22
1140	Chronic Hepatitis B and C--current treatment and future therapeutic prospects. 2006 , 156, 391-6	3
1139	Antiviral treatment of hepatitis C: present status and future prospects. 2006 , 12, 227-32	20
1138	Management of patients with chronic hepatitis C infection. 2006 , 6, 20-6	16
1137	The metabolism, pharmacokinetics and mechanisms of antiviral activity of ribavirin against hepatitis C virus. 2006 , 63, 832-42	96
1136	[Virus persistence in hepatitis C: lifelong infection despite therapy?]. 2006 , 101, 378-83	2
1135	[Health economics of chronic infectious diseases: the example of hepatitis C]. 2006 , 49, 57-63	9
1134	[Individualised treatment of chronic hepatitis C]. 2006 , 47 Suppl 1, S20, S22-5	1
1133	Patients' experiences related to anti-viral treatment for hepatitis C. 2006 , 62, 148-55	31
1132	Synthesis of two photolabile poly(ethylene glycol) derivatives for protein conjugation. 2006 , 66, 167-176	10

1131	Inhibitors of HCV NS5B polymerase: synthesis and structure-activity relationships of N-alkyl-4-hydroxyquinolon-3-yl-benzothiadiazine sulfamides. 2006 , 16, 3367-70	33
1130	Pegylated interferon alpha-2b plus ribavirin for the treatment of chronic hepatitis C in HIV-coinfected patients. 2006 , 53, 36-42	38
1129	Treatment of hepatitis C cryoglobulinemia: mission and challenges. 2006 , 9, 497-507	8
1128	Psychiatric management of the hepatitis C patient. 2006 , 9, 508-19	22
1127	Therapie der Hepatitis C. 2006 , 1, 126-132	1
1126	Construction and characterization of an HCV-derived multi-epitope peptide antigen containing B-cell HVR1 mimotopes and T-cell conserved epitopes. 2006 , 49, 490-9	2
1125	Chronic hepatitis C: treatment of pegylated interferon/ribavirin nonresponders. 2006 , 8, 46-52	17
1124	The impact of race and ethnicity on the treatment of hepatitis C disease. 2006 , 5, 79-85	1
1123	Treatment of nonresponders to standard hepatitis C therapy. 2006 , 5, 108-113	
1122	Chronic hepatitis C: Treatment of pegylated interferon/ ribavirin nonresponders. 2006 , 5, 114-120	
1121	Future therapies for hepatitis C. 2006 , 5, 121-128	
1120	Genotypic variations around the world: Is hepatitis C virus evolving?. 2006 , 5, 142-149	3
1119	Coinfection with hepatitis C virus and HIV: The challenges of management. 2006 , 5, 154-161	
1118	HIV coinfection with hepatitis C and hepatitis B. 2006 , 8, 409-18	
1117	Structure and functions of hepatitis C virus proteins: 15 years after. 2006 , 51, 665-80	18
1116	Daily dose of interferon alpha-2b and ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection: a randomised controlled study. 2006 , 1, 113-8	1
1115	Antiretroviral therapy 2006: pharmacology, applications, and special situations. 2006 , 29, 431-58	10
1114	In vitro selected Con1 subgenomic replicons resistant to 2'-C-methyl-cytidine or to R1479 show lack of cross resistance. 2006 , 351, 349-59	125

1113	Hepatitis C virus genotype 1b chimeric replicon containing genotype 3 NS5A domain. 2006 , 355, 192-202	14
1112	Antifibrotic agents for liver disease. 2006 , 6, 12-9	50
1111	Management of hepatitis C in liver transplant recipients. 2006 , 6, 449-58	30
1110	Pegylated interferon alpha-2b for patients with HCV recurrence and graft fibrosis following liver transplantation. 2006 , 6, 825-33	28
1109	Hepatitis C recurrence after liver transplantation: Viral and histologic response to full-dose PEG-interferon and ribavirin. 2006 , 6, 2348-55	116
1108	Selective inhibitors of hepatitis C virus replication. 2006 , 71, 363-71	46
1107	[Complementary treatments of chronic viral hepatitis C]. 2006 , 30, 197-214	6
1106	High dose daily interferon-alpha induction and secondary adjunction of ribavirin in treatment-naive patients with chronic hepatitis C. A multicentric, randomised, controlled trial. 2006 , 30, 525-32	4
1105	[Antiviral treatments during cirrhosis]. 2006 , 30, 899-902	
1104	[Hepatitis C and liver transplantation: fibrosis progression and treatment. Or how to improve management]. 2006 , 30, 1281-95	3
1103	[Identifying improvement opportunities in the management of hepatitis C]. 2006 , 30, 154-60	4
1102	[Budget impact analysis of the treatment of chronic hepatitis C in a hospital]. 2006 , 30, 291-9	4
1101	Real-time multiplex PCR assay to quantify hepatitis C virus RNA in peripheral blood mononuclear cells. 2006 , 133, 195-204	12
1100	Management of Hematologic and Neuropsychiatric Side Effects in Treatment of Chronic HCV Infection. 2006 , 2, 38-45	2
1099	Antinociceptive and behavioral effects of ribavirin in mice. 2006 , 83, 230-8	12
1098	Therapeutic role of beta-interferons in multiple sclerosis. 2006 , 110, 35-56	70
1097	Variation in hepatitis C services may lead to inequity of health-care provision: a survey of the organisation and delivery of services in the United Kingdom. 2006 , 6, 3	30
1096	Organizational change in management of hepatitis C: evaluation of a CME program. 2006 , 26, 145-60	7

1095	Antiviral therapy for hepatitis C virus--associated mixed cryoglobulinemia vasculitis: a long-term followup study. 2006 , 54, 3696-706	198
1094	Diabetes in chronic liver disease: from old concepts to new evidence. 2006 , 22, 274-83	73
1093	Therapy of hepatitis B -- viral suppression or eradication?. 2006 , 43, S182-93	48
1092	Insulin resistance is associated with steatosis in nondiabetic patients with genotype 1 chronic hepatitis C. 2006 , 43, 64-71	147
1091	Limitation of combination therapy of interferon and ribavirin for older patients with chronic hepatitis C. 2006 , 43, 54-63	330
1090	Development and validation of two models for early prediction of response to therapy in genotype 1 chronic hepatitis C. 2006 , 43, 72-80	41
1089	Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET acute-HCV-II study. 2006 , 43, 250-6	195
1088	Therapy of hepatitis C: from empiricism to eradication. 2006 , 43, S207-20	142
1087	Progression of liver fibrosis among injection drug users with chronic hepatitis C. 2006 , 43, 788-95	82
1086	Interferon alpha-2b with and without ribavirin in the treatment of hepatitis B e antigen-positive chronic hepatitis B: a randomized study. 2006 , 43, 742-9	38
1085	S-Adenosylmethionine and betaine correct hepatitis C virus induced inhibition of interferon signaling in vitro. 2006 , 43, 796-806	61
1084	Pharmacodynamics of PEG-IFN alpha differentiate HIV/HCV coinfectd sustained virological responders from nonresponders. 2006 , 43, 943-53	75
1083	The clinical and physiological spectrum of interferon-alpha induced thyroiditis: toward a new classification. 2006 , 43, 661-72	137
1082	Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. 2006 , 43, 954-60	412
1081	Genomic response to interferon-alpha in chimpanzees: implications of rapid downregulation for hepatitis C kinetics. 2006 , 43, 961-72	96
1080	Caspase activation is required for antiviral treatment response in chronic hepatitis C virus infection. 2006 , 43, 1311-6	35
1079	Tailoring antiviral therapy in hepatitis C. 2006 , 43, 909-11	11
1078	Duration of peginterferon therapy in acute hepatitis C: a randomized trial. 2006 , 43, 923-31	116

1077	Impact of obesity on treatment of chronic hepatitis C. 2006 , 43, 1177-86	106
1076	Statins and hepatic steatosis: perspectives from the Dallas Heart Study. 2006 , 44, 466-71	133
1075	Correlation between beta-lipoprotein levels and outcome of hepatitis C treatment. 2006 , 44, 335-40	99
1074	Global transcriptional response to interferon is a determinant of HCV treatment outcome and is modified by race. 2006 , 44, 352-9	74
1073	Interleukin-29 uses a type 1 interferon-like program to promote antiviral responses in human hepatocytes. 2006 , 44, 896-906	305
1072	CD4+ immune escape and subsequent T-cell failure following chimpanzee immunization against hepatitis C virus. 2006 , 44, 736-45	64
1071	A simple noninvasive index for predicting long-term outcome of chronic hepatitis C after interferon-based therapy. 2006 , 44, 1086-97	97
1070	Controversies in the management of pediatric liver disease: Hepatitis B, C and NAFLD: Summary of a single topic conference. 2006 , 44, 1344-54	44
1069	HCV kinetics, quasispecies, and clearance in treated HCV-infected and HCV/HIV-1-coinfected patients with hemophilia. 2006 , 44, 1146-57	31
1068	Hepatitis C virus reinfection in injection drug users. 2006 , 44, 1139-45	128
1067	IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection. 2006 , 44, 1617-25	177
1066	Cost-effectiveness of hematologic growth factors for anemia occurring during hepatitis C combination therapy. 2006 , 44, 1598-606	42
1065	Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. 2006 , 44, 1543-54	296
1064	Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial. 2006 , 44, 1675-84	131
1063	Treatment of HCV recurrence: do the pretransplantation rules apply?. 2006 , 12, 1044-8	6
1062	Clinical and histological efficacy of pegylated interferon and ribavirin therapy of recurrent hepatitis C after liver transplantation. 2006 , 12, 1805-12	84
1061	Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load. 2006 , 78, 83-90	90
1060	Assessment of early virological response to antiviral therapy by comparing four assays for HCV RNA quantitation using the international unit standard: implications for clinical management of patients with chronic hepatitis C virus infection. 2006 , 78, 208-15	14

1059	Twenty-four hour kinetics of hepatitis C virus and antiviral effect of alpha-interferon. 2006 , 78, 365-71	11
1058	Pharmacokinetics, pharmacodynamics, and hepatitis C viral kinetics during antiviral therapy: the null responder. 2006 , 78, 446-51	21
1057	Modulation of epitope-specific anti-hepatitis C virus E2 (anti-HCV/E2) antibodies by anti-viral treatment. 2006 , 78, 1304-11	8
1056	DNA-based immunization breaks tolerance in a hepatitis C virus transgenic mouse model. 2006 , 2, 78-83	7
1055	Hepatitis C treatment in drug users: perception versus evidence. 2006 , 18, 129-30	12
1054	Injection site with generalized rash caused by pegylated interferon alpha 2a injection. 2006 , 212, 82-3	4
1053	Established and emerging therapies for the treatment of viral hepatitis. 2006 , 24, 160-73	11
1052	Sustained remission of chronic hepatitis C after acute hepatitis B superinfection. 2006 , 38, 818-21	9
1051	[Effectiveness of antiviral therapy in patients with chronic hepatitis C treated by private practice gastroenterologists]. 2006 , 44, 25-31	5
1050	[Socioeconomic characteristics, quality of life, and state of knowledge of patients with hepatitis C viral infection in Germany--socioeconomic aspects in hepatitis C]. 2006 , 44, 305-17	14
1049	[Three years of vertical networking in the German Network of Competence on Viral Hepatitis: what can we learn from the usage of different information tools?]. 2006 , 44, 15-23	1
1048	Serum islet cell autoantibodies during interferon alpha treatment in patients with HCV-genotype 4 chronic hepatitis. 2006 , 13, 11-5	1
1047	Looking to the future: new agents for chronic hepatitis B. 2006 , 101 Suppl 1, S19-25	11
1046	Prospect of Individualized Medicine in Chronic Hepatitis C Therapy by Pharmacogenomics. 2006 , 4, 157-167	3
1045	Hepatitis C virus infection in Scotland: epidemiological review and public health challenges. 2006 , 51, 8-15	52
1044	Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forward. 2006 , 12, 3661-97	235
1043	Association of pretreatment serum interferon gamma inducible protein 10 levels with sustained virological response to peginterferon plus ribavirin therapy in genotype 1 infected patients with chronic hepatitis C. 2006 , 55, 374-9	122
1042	Current HIV treatment guidelines--an overview. 2006 , 12, 1045-63	50

1041	Health-related quality of life before, during and after combination therapy with interferon and ribavirin in unselected Swedish patients with chronic hepatitis C. 2006 , 41, 577-85	27
1040	Multilaboratory comparison of hepatitis C virus viral load assays. 2006 , 44, 1726-32	45
1039	A novel ex vivo assay of interferon-based suppression, to predict the outcome of antiviral therapy for hepatitis C. 2006 , 193, 1365-70	3
1038	Real-time PCR assays for hepatitis C virus (HCV) RNA quantitation are adequate for clinical management of patients with chronic HCV infection. 2006 , 44, 2507-11	65
1037	Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease. 2006 , 50, 899-909	330
1036	Treatment of hepatitis C in HIV-coinfected patients. 2006 , 40, 479-89; quiz 582-3	17
1035	Replication of hepatitis C virus (HCV) RNA in mouse embryonic fibroblasts: protein kinase R (PKR)-dependent and PKR-independent mechanisms for controlling HCV RNA replication and mediating interferon activities. 2006 , 80, 7364-74	88
1034	Acute hepatitis C: a window of opportunity. 2006 , 42, 1671-3	4
1033	Vigorous hepatitis C virus-specific CD4+ and CD8+ T cell responses induced by protein immunization in the presence of Montanide ISA720 plus synthetic oligodeoxynucleotides containing immunostimulatory cytosine-guanine dinucleotide motifs. 2006 , 193, 563-72	13
1032	Ribavirin antagonizes the in vitro anti-hepatitis C virus activity of 2'-C-methylcytidine, the active component of valopicitabine. 2006 , 50, 3444-6	52
1031	Chronic hepatitis C virus management: 2000-2005 update. 2006 , 40, 74-82	41
1030	Rate of infectious complications during interferon-based therapy for hepatitis C is not related to neutropenia. 2006 , 42, 1674-8	58
1029	Acute hepatitis C virus infection in incarcerated injection drug users. 2006 , 42, 1663-70	40
1028	Eligibility for treatment of hepatitis C virus infection among young injection drug users in 3 US cities. 2006 , 42, 669-72	38
1027	Interferon (IFN)-gamma-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infection. 2006 , 194, 895-903	190
1026	Novel alpha interferon (IFN-alpha) variant with improved inhibitory activity against hepatitis C virus genotype 1 replication compared to IFN-alpha2b therapy in a subgenomic replicon system. 2006 , 50, 3984-91	8
1025	Leukotriene receptor antagonists as potential steroid sparing agents in a patient with serosal eosinophilic gastroenteritis. 2006 , 55, 1363-4	20
1024	Treatment of chronic hepatitis C in southern Taiwan. 2006 , 49, 99-106	62

1023	Treatment of chronic hepatitis C with interferon alone or combined with ribavirin in Japan. 2006 , 49, 112-8	20
1022	Comparison of serum hepatitis C virus (HCV) RNA and core antigen levels in patients coinfectd with human immunodeficiency virus and HCV and treated with interferon plus ribavirin. 2006 , 44, 417-22	10
1021	Hepatitis C: a review for primary care physicians. 2006 , 174, 649-59	76
1020	Viral etiology of hepatocellular carcinoma and HCV genotypes in Taiwan. 2006 , 49, 76-81	26
1019	Anticarcinogenic impact of interferon on patients with chronic hepatitis C: a large-scale long-term study in a single center. 2006 , 49, 82-90	24
1018	Thyroid dysfunction in patients with chronic hepatitis C receiving a combined therapy of interferon and ribavirin: incidence, associated factors and prognosis. 2006 , 21, 319-26	23
1017	General catalytic deficiency of hepatitis C virus RNA polymerase with an S282T mutation and mutually exclusive resistance towards 2'-modified nucleotide analogues. 2006 , 50, 4161-9	80
1016	Role of erythrocytes as a reservoir for ribavirin and relationship with adverse reactions in the early phase of interferon combination therapy for chronic hepatitis C virus infections. 2006 , 44, 3562-8	17
1015	Combined interferon and ribavirin therapy for chronic hepatitis C in Taiwan. 2006 , 49, 91-5	19
1014	Prolonged negative HCV-RNA status led to a good outcome in chronic hepatitis C patients with genotype 1b and super-high viral load. 2006 , 49, 362-9	1
1013	Disappointing results of combination therapy for HCV?. 2006 , 55, 1362-3	8
1012	High-affinity aptamers to subtype 3a hepatitis C virus polymerase display genotypic specificity. 2006 , 50, 3019-27	43
1011	Immunomodulatory activities of IFN-gamma1b in combination with type I IFN: implications for the use of IFN-gamma1b in the treatment of chronic HCV infections. 2006 , 26, 473-83	7
1010	Antiviral therapy decreases hepatic venous pressure gradient in patients with chronic hepatitis C and advanced fibrosis. 2006 , 101, 2269-74	129
1009	Targets of emerging therapies for viral hepatitis B and C. 2006 , 10, 833-50	6
1008	Diagnosis and treatment of chronic hepatitis C infection. 2006 , 332, 1013-7	55
1007	Steatosis in hepatitis C: the missing link to metabolic abnormalities?. 2006 , 101, 2616-8	6
1006	Hepatitis C in 6,865 patients 65 yr or older: a severe and neglected curable disease?. 2006 , 101, 1260-7	116

1005	Integrated psychiatric/medical care in a chronic hepatitis C clinic: effect on antiviral treatment evaluation and outcomes. 2006 , 101, 2254-62	102
1004	Review of models used to predict the future numbers of individuals with severe hepatitis C disease: therapeutic and cost implications. 2006 , 6, 627-39	4
1003	Viral nephropathy. 2006 , 2, 254-62	61
1002	Management and treatment of hepatitis C viral infection: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center program and the National Hepatitis C Program office. 2006 , 101, 2360-78	93
1001	Comparison of conventional PCR with real-time PCR and branched DNA-based assays for hepatitis C virus RNA quantification and clinical significance for genotypes 1 to 5. 2006 , 44, 729-37	80
1000	Hepatitis C virus infection in African Americans. 2006 , 42, 82-91	281
999	Treating HCV with ribavirin analogues and ribavirin-like molecules. 2006 , 57, 8-13	82
998	Antibodies neutralizing peginterferon alfa during retreatment of hepatitis C. <i>New England Journal of Medicine</i> , 2006 , 354, 1323-4	59.2 39
997	Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1. 2006 , 55, 529-35	216
996	Elevated expression and polymorphisms of SOCS3 influence patient response to antiviral therapy in chronic hepatitis C. 2008 , 57, 507-15	65
995	A functional SNP of interferon-gamma gene is important for interferon-alpha-induced and spontaneous recovery from hepatitis C virus infection. 2007 , 104, 985-90	98
994	Extracellular branched-chain amino acids, especially valine, regulate maturation and function of monocyte-derived dendritic cells. 2007 , 179, 7137-46	65
993	Plasmacytoid dendritic cells initiate a complex chemokine and cytokine network and are a viable drug target in chronic HCV patients. 2007 , 204, 2423-37	97
992	Impact of hepatitis C virus (HCV) genotypes on quantification of HCV RNA in serum by COBAS AmpliPrep/COBAS TaqMan HCV test, Abbott HCV realtime assay [corrected] and VERSANT HCV RNA assay. 2007 , 45, 3077-81	29
991	Patients with hepatitis C are best managed by a specialist in liver diseases. CON: The management of hepatitis C in a community-based practice. 2007 , 102, 1839-41	3
990	A balancing view: We cannot do it alone. 2007 , 102, 1841-3	8
989	Patients with hepatitis C are best managed by a specialist in liver diseases. PRO: Management of hepatitis C by liver disease specialists. 2007 , 102, 1837-9	1
988	Trend of depression and the use of psychiatric medications in U.S. Veterans with hepatitis C during interferon-based therapy. 2007 , 102, 2426-33	6

987	Hepatitis-C patients have reduced growth hormone (GH) secretion which improves during long-term therapy with pegylated interferon-alpha. 2007 , 102, 2724-31	14
986	Strategies for managing anemia in hepatitis C patients undergoing antiviral therapy. 2007 , 102, 880-9	77
985	Treatment of chronic hepatitis C virus in African Americans with genotypes 2 and 3. 2007 , 102, 761-6	47
984	Patients With Hepatitis C Are Best Managed by a Specialist in Liver Diseases. 2007 , 102, 1837-1837	1
983	Singin' the blues: the downside of hepatitis C virus treatment. 2007 , 102, 2434-6	1
982	Retreatment of chronic hepatitis C in previous non-responders and relapsers. 2007 , 8, 2491-503	0
981	Rate and predictors of treatment prescription for hepatitis C. 2007 , 56, 385-9	125
980	Rapid and early virological response to chronic hepatitis C treatment with IFN alpha2b or PEG-IFN alpha2b plus ribavirin in HIV/HCV co-infected patients. 2007 , 56, 1111-6	34
979	Impact of NS5A sequences of Hepatitis C virus genotype 1a on early viral kinetics during treatment with peginterferon- alpha 2a plus ribavirin. 2007 , 196, 998-1005	16
978	The kidney transplant recipient with hepatitis C infection: pre- and posttransplantation treatment. 2007 , 2, 563-75	59
977	Liver gene expression signature to predict response to pegylated interferon plus ribavirin combination therapy in patients with chronic hepatitis C. 2008 , 57, 516-24	164
976	Productivity improvements in hepatitis C treatment: impact on efficacy, cost, cost-effectiveness and quality of life. 2007 , 42, 867-77	10
975	A large-scale, multicentre, double-blind trial of ursodeoxycholic acid in patients with chronic hepatitis C. 2007 , 56, 1747-53	49
974	Pretreatment sequence diversity differences in the full-length hepatitis C virus open reading frame correlate with early response to therapy. 2007 , 81, 8211-24	101
973	New drugs for hepatitis C virus. 2007 , 1, 145-54	5
972	Recent progress in the development of inhibitors of the hepatitis C virus RNA-dependent RNA polymerase. 2007 , 7, 1302-29	103
971	Neuropsychiatric complications of interferons: classification, neurochemical bases, and management. 2007 , 19, 113-23	19
970	Prophylaxis and treatment of recurrent viral hepatitis after liver transplantation. 2007 , 22 Suppl 8, viii37-viii46	14

969	Pegylated interferon alfa-2a (40 kD) and ribavirin in haemodialysis patients with chronic hepatitis C. 2008 , 23, 721-5	46
968	How should hepatitis C be managed in patients aged 65 years and older?. 2007 , 4, 22-3	
967	Baseline factors prognostic of sustained virological response in patients with HIV-hepatitis C virus co-infection. 2007 , 21, 1555-9	26
966	Long-term effects of interferon-based therapy for chronic hepatitis C. 2007 , 72 Suppl 1, 16-23	29
965	Customizing treatment to patient populations. 2007 , 4 Suppl 1, S3-9	5
964	Immune reconstitution syndrome to <i>Strongyloides stercoralis</i> infection. 2007 , 21, 649-50	26
963	Care of patients coinfectd with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel. 2007 , 21, 1073-89	250
962	Utilizing nucleic acid amplification to identify acute HIV infection. 2007 , 21, 653-5	11
961	Predictive value of early virologic response in HIV/hepatitis C virus-coinfected patients treated with an interferon-based regimen plus ribavirin. 2007 , 44, 174-8	25
960	Analysis of ribavirin mutagenicity in human hepatitis C virus infection. 2007 , 81, 7732-41	77
959	Shortened therapy for hepatitis C virus genotype 2 or 3--is less more?. <i>New England Journal of Medicine</i> , 2007 , 357, 176-8	59.2 5
958	Changes in gene expression during pegylated interferon and ribavirin therapy of chronic hepatitis C virus distinguish responders from nonresponders to antiviral therapy. 2007 , 81, 3391-401	103
957	Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. <i>New England Journal of Medicine</i> , 2007 , 357, 124-34	59.2 469
956	The "C" of viral hepatitis in children. 2007 , 27, 295-311	14
955	Is re-treatment with peginterferon alpha-2a and ribavirin effective in patients with relapsed chronic hepatitis C?. 2007 , 4, 12-3	
954	Hepatitis C: the complications of immune dysfunction. 2007 , 3, 145-57	9
953	Genetics, genomics, and proteomics: implications for the diagnosis and the treatment of chronic hepatitis C. 2007 , 27, 13-27	48
952	Gene-gene and gene-environment interactions in interferon therapy for chronic hepatitis C. 2007 , 8, 1327-35	25

951	[Quality of care and health economics in occupationally acquired hepatitis C in German health care workers between 1993 and 2004]. 2007 , 132, 1743-7	1
950	Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO trial. 2007 , 23, 972-82	156
949	Changing treatment paradigms: hepatitis C virus in HIV-infected patients. 2007 , 21, 154-68	9
948	Prediction of efficient virological response to pegylated interferon/ribavirin combination therapy by NS5A sequences of hepatitis C virus and anti-NS5A antibodies in pre-treatment sera. 2007 , 51, 471-82	35
947	Natural history of anemia associated with interferon/ribavirin therapy for patients with HIV/HCV coinfection. 2007 , 23, 1-9	14
946	Evaluation of a pharmacist-managed hepatitis C care clinic. 2007 , 64, 632-6	24
945	The cost of treating ribavirin-induced anemia in hepatitis C: the impact of using recombinant human erythropoietin. 2007 , 23, 1463-72	6
944	Influence of the type of pegylated interferon on the onset of depressive and neuropsychiatric symptoms in HIV-HCV coinfecting patients. 2007 , 19, 138-45	45
943	Hematologic toxicity associated with interferon-based hepatitis C therapy in HIV type 1-coinfecting subjects. 2007 , 44, 1375-83	15
942	Hepatitis C Infection, Treatment Regimens, and Thyroid Function Abnormalities. 2007 , 17, 231-235	12
941	Monitoring the antiviral effect of alpha interferon on individual cells. 2007 , 81, 8814-20	35
940	Managing symptomatic drug-induced liver injury in HIV-hepatitis C virus-coinfecting patients: a role for interferon. 2007 , 45, 1386-92	6
939	An open, randomized, controlled, phase II, single centre, two-period cross-over study to compare the quality of life and toxicity experienced on PEG interferon with interferon-alpha2b in patients with multiple myeloma maintained on a steady dose of interferon-alpha2b. 2007 , 18, 1388-94	17
938	Influence of concomitant antiretroviral therapy on the rate of sustained virological response to pegylated interferon plus ribavirin in hepatitis C virus/HIV-coinfecting patients. 2007 , 60, 1347-54	41
937	Mathematical modeling of subgenomic hepatitis C virus replication in Huh-7 cells. 2007 , 81, 750-60	84
936	Molecular diagnostics of hepatitis C virus infection: a systematic review. 2007 , 297, 724-32	133
935	Ribavirin up-regulates the activity of double-stranded RNA-activated protein kinase and enhances the action of interferon-alpha against hepatitis C virus. 2007 , 196, 425-34	46
934	The nonstructural 5A protein of hepatitis C virus genotype 1b does not contain an interferon sensitivity-determining region. 2007 , 195, 432-41	27

933	Use of hematopoietic growth factors as adjuvant therapy for anemia and neutropenia in the treatment of hepatitis C. 2007 , 41, 268-75	8
932	Prediction of response to pegylated interferon and ribavirin in hepatitis C by polymorphisms in the viral core protein and very early dynamics of viremia. 2007 , 50, 361-8	50
931	Full-length genome sequences of hepatitis C virus subtype 4f. 2007 , 88, 2985-2990	15
930	Toll-like receptors 1 and 6 are involved in TLR2-mediated macrophage activation by hepatitis C virus core and NS3 proteins. 2007 , 82, 479-87	155
929	Viral determinants of resistance to treatment in patients with hepatitis C. 2007 , 20, 23-38	126
928	Bile acids promote the expression of hepatitis C virus in replicon-harboring cells. 2007 , 81, 9633-40	54
927	Early viral kinetics during treatment of chronic hepatitis C virus infection with pegylated interferon alpha plus ribavirin in Taiwan. 2007 , 50, 310-5	16
926	A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C. 2007 , 56, 553-9	222
925	Evaluation of a new-generation line-probe assay that detects 5' untranslated and core regions to genotype and subtype hepatitis C virus. 2007 , 128, 300-4	16
924	Hepatitis C in dialysed patients--what is the current optimal treatment?. 2007 , 30, 156-61	4
923	Sustained virological response in the antiviral therapy of chronic hepatitis C: is there a predictive value of interferon-induced depression?. 2007 , 53, 292-9	12
922	Eicosapentaenoic acid could permit maintenance of the original ribavirin dose in chronic hepatitis C virus patients during the first 12 weeks of combination therapy with pegylated interferon-alpha and ribavirin. A prospective randomized controlled trial. 2007 , 50, 439-46	5
921	Phenotypic and structural analyses of hepatitis C virus NS3 protease Arg155 variants: sensitivity to telaprevir (VX-950) and interferon alpha. 2007 , 282, 22619-28	73
920	Response prediction and treatment tailoring for chronic hepatitis C virus genotype 1 infection. 2007 , 45, 2439-45	16
919	Factors affecting serum concentrations of hepatitis C virus (HCV) RNA in HCV genotype 1-infected patients with chronic hepatitis. 2007 , 45, 2426-33	45
918	New natural intergenotypic (2/5) recombinant of hepatitis C virus. 2007 , 81, 4357-62	100
917	Contribution of insertions and deletions to the variability of hepatitis C virus populations. 2007 , 88, 2198-2203	18
916	Hepatitis C virus non-structural proteins responsible for suppression of the RIG-I/Cardif-induced interferon response. 2007 , 88, 3323-3333	32

915	Side effects of combination therapy of peginterferon and ribavirin for chronic hepatitis-C. 2007 , 46, 1827-32	28
914	Chronic hepatitis C virus infection: a review for pharmacists. 2007 , 47, 508-20; quiz 508-20	4
913	Biochemical and virologic parameters in patients co-infected with hepatitis C and HIV versus patients with hepatitis C mono-infection. 2007 , 333, 271-5	4
912	Acute and Chronic Viral Hepatitis. 369-446	
911	Neonatal Hepatitis and Congenital Infections. 232-246	3
910	Management of HIV/hepatitis C virus-coinfected patient non-responders to hepatitis C virus antiviral therapy and relapsers. 2007 , 2, 496-502	
909	Hepatitis C treatment candidacy and outcomes among 4318 US veterans with chronic hepatitis C virus infection: does a history of injection drug use matter?. 2007 , 41, 199-205	26
908	Early initiation of antiretroviral therapy: the current best way to reduce liver-related deaths in HIV/hepatitis C virus-coinfected patients. 2007 , 44, 551-6	29
907	Benefits and adverse effects of hepatitis C screening: early results of a screening program. 2007 , 13, 263-9	6
906	Hepatitis C viral kinetics during treatment of hepatitis C virus/HIV coinfecting patients. 2007 , 2, 489-95	
905	Management and therapy of chronic hepatitis C in HIV. 2007 , 2, 482-8	
904	ACOG Practice Bulletin No. 86: Viral hepatitis in pregnancy. 2007 , 110, 941-56	118
903	Hepatitis C in African Americans. 2007 , 41, 185-93	25
902	Hepatitis C in HIV-positive patients--treatment and liver disease outcomes. 2007 , 41, 75-87	10
901	Compliance with referral for hepatitis C evaluation among veterans. 2007 , 41, 927-31	2
900	Prevalence and therapeutic significance of anti-interferon antibodies in hepatitis C virus/HIV-co-infected patients. 2007 , 21, 652-3	2
899	Peginterferon alfa-2b and ribavirin combination therapy for chronic hepatitis C. 2007 , 2, 553-563	
898	Treatment of hepatitis C in potential lung transplant candidates. 2007 , 83, 1652-5	14

897	Hepatitis C virus infection: a current review. 2007 , 20, 21-5	1
896	Hpatites virales. 2007 , 4, 1-32	
895	Response to pegylated interferon alpha-2b and ribavirin in children with chronic hepatitis C. 2007 , 41, 111-4	27
894	HIV seroconversion complicated by Mycobacterium kansasii infection. 2007 , 21, 650-2	2
893	Hepatitis C in the HIV-infected patient. 2007 , 45 Suppl 2, S47-56; discussion S66-7	36
892	Differential antiviral effect of PEG-interferon-alpha-2b on HIV and HCV in the treatment of HIV/HCV co-infected patients. 2007 , 21, 1855-65	30
891	Cost-effectiveness of treatment for hepatitis C in an urban cohort co-infected with HIV. 2007 , 120, 272-9	19
890	Referral for chronic hepatitis C treatment from a drug dependency treatment setting. 2007 , 88, 49-53	38
889	Baseline findings from the third collaborative injection drug users study/drug users intervention trial (CIDUS III/DUIT). 2007 , 91 Suppl 1, S1-3	7
888	Personalized therapy for chronic viral hepatitis C in the naive patient: How can we optimize treatment duration as a function of viral genotype?. 2007 , 18, 510-5	3
887	Interferon-based treatment of chronic hepatitis C. 2007 , 89, 894-8	11
886	Subthreshold mania as predictor of depression during interferon treatment in HCV+ patients without current or lifetime psychiatric disorders. 2007 , 62, 349-55	22
885	Depression following pegylated interferon-alpha: characteristics and vulnerability. 2007 , 63, 131-5	85
884	Hepatitis C management by addiction medicine physicians: results from a national survey. 2007 , 33, 99-105	27
883	Serum-derived hepatitis C virus infectivity in interferon regulatory factor-7-suppressed human primary hepatocytes. 2007 , 46, 26-36	68
882	Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels. 2007 , 46, 403-10	242
881	Tolerability of Peg interferon-alpha2b and Ribavirin therapy in patients with chronic hepatitis C and glucose-6-phosphate dehydrogenase deficiency. 2007 , 46, 171-3	1
880	Health-related quality of life in patients with chronic hepatitis C and advanced fibrosis. 2007 , 46, 420-31	112

879	High predictive value of early viral kinetics in retreatment with peginterferon and ribavirin of chronic hepatitis C patients non-responders to standard combination therapy. 2007 , 46, 596-604	44
878	The treatment of chronic hepatitis C with peginterferon alfa-2a (40 kDa) plus ribavirin in haemodialysed patients awaiting renal transplant. 2007 , 46, 768-74	136
877	Early ribavirin pharmacokinetics, HCV RNA and alanine aminotransferase kinetics in HIV/HCV co-infected patients during treatment with pegylated interferon and ribavirin. 2007 , 47, 23-30	33
876	Virological response and safety outcomes in therapy-naïve patients treated for chronic hepatitis C with taribavirin or ribavirin in combination with pegylated interferon alfa-2a: a randomized, phase 2 study. 2007 , 47, 51-9	41
875	Oral resiquimod in chronic HCV infection: safety and efficacy in 2 placebo-controlled, double-blind phase IIa studies. 2007 , 47, 174-82	157
874	Phase 2 study of the combination of merimepodib with peginterferon-alpha2b, and ribavirin in nonresponders to previous therapy for chronic hepatitis C. 2007 , 47, 476-83	23
873	Anemia and clinical outcomes in hepatitis C. 2007 , 47, 7-9	4
872	The role of CCR5/CXCR3 expressing CD8+ cells in liver damage and viral control during persistent hepatitis C virus infection. 2007 , 47, 632-41	68
871	Peg-interferon alone or combined with ribavirin in HCV cirrhosis with portal hypertension: a randomized controlled trial. 2007 , 47, 484-91	84
870	Treatment of chronic HCV in advanced liver disease: unmet challenges, reason for optimism. 2007 , 47, 441-3	3
869	Which patients with genotype 1 chronic hepatitis C can benefit from prolonged treatment with the 'accordion' regimen?. 2007 , 47, 580-7	29
868	Economics of chronic hepatitis B and hepatitis C. 2007 , 47, 608-17	18
867	Efficacy and safety of peg-IFN alfa-2a with ribavirin for the treatment of HCV/HIV coinfecting patients who failed previous IFN based therapy. 2007 , 38, 32-8	27
866	Neutralizing antibodies in patients with chronic hepatitis C infection treated with (Peg)-interferon/ribavirin. 2007 , 39, 288-94	10
865	Infection of human hepatocyte chimeric mouse with genetically engineered hepatitis C virus and its susceptibility to interferon. 2007 , 581, 1983-7	49
864	[Exceptional pancytopenia secondary to treatment with pegylated interferon and ribavirin]. <i>Gastroenterología Y Hepatología</i> , 2007 , 30, 253	0.9
863	Tratamiento de las hepatitis virales. 2007 , 9, 5921-5930	
862	Other immune thrombocytopenias. 2007 , 44, S24-34	46

861	Current non-AIDS antiviral chemotherapy. 2007 , 5, 217-30	6
860	Outbreak of hepatitis C virus infection during sclerotherapy of varicose veins: long-term follow-up of 196 patients (4535 patient-years). 2007 , 46, 19-25	21
859	Randomized placebo controlled phase I/II trial of alpha-galactosylceramide for the treatment of chronic hepatitis C. 2007 , 47, 356-65	58
858	Triple therapy of initial high-dose interferon with ribavirin and amantadine for patients with chronic hepatitis C. 2007 , 37, 325-30	3
857	Efficacy of low dose long-term interferon monotherapy in aged patients with chronic hepatitis C genotype 1 and its relation to alpha-fetoprotein: A pilot study. 2007 , 37, 490-7	24
856	Immunopathogenesis of hepatitis C virus infection and hepatic fibrosis: New insights into antifibrotic therapy in chronic hepatitis C. 2007 , 37, 579-95	14
855	Appropriate use of interferon for treatment of chronic hepatitis B. 2007 , 37, S47-54	19
854	Double filtration plasmapheresis and interferon combination therapy for chronic hepatitis C patients with genotype 1 and high viral load. 2007 , 37, 701-10	44
853	Anti-hepatitis C virus activity of albinterferon alfa-2b in cell culture. 2007 , 37, 941-7	20
852	Liver disease in hepatitis C virus carriers identified at blood donation and their outcomes with or without interferon treatment: Study on 1019 carriers followed for 5-10 years. 2007 , 37, 994-1001	12
851	Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. 2007 , 132, 1767-77	565
850	Peginterferon alpha-2b plus ribavirin vs interferon alpha-2b plus ribavirin for chronic hepatitis C in HIV-coinfected patients. 2007 , 14, 228-38	43
849	Qualitative application of COBAS AMPLICOR HCV test version 2.0 assays in patients with chronic hepatitis C virus infection and comparison of clinical performance with version 1.0. 2007 , 23, 332-8	3
848	Reduced expression of Jak-1 and Tyk-2 proteins leads to interferon resistance in hepatitis C virus replicon. 2007 , 4, 89	19
847	Replicative homeostasis III: implications for antiviral therapy and mechanisms of response and non-response. 2007 , 4, 29	4
846	Genetic distance and heterogeneity between quasispecies is a critical predictor to IFN response in Egyptian patients with HCV genotype-4. 2007 , 4, 16	19
845	Viral Hepatitis. 819-956	
844	A systematic review of the cost-effectiveness of peginterferon alfa-2b in the treatment of chronic hepatitis C. 2007 , 7, 577-95	3

843	The effect of age on response to therapy with peginterferon alpha plus ribavirin in a cohort of patients with chronic HCV hepatitis including subjects older than 65 yr. 2007 , 102, 1383-91	63
842	The effect of multiple doses of peginterferon alfa-2b on the steady-state pharmacokinetics of methadone in patients with chronic hepatitis C undergoing methadone maintenance therapy. 2007 , 47, 604-12	16
841	Prediction of sustained virological response in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) and ribavirin. 2007 , 42, 247-55	41
840	Molecular Pathology in Clinical Practice. 2007 ,	3
839	Improving outcome in patients with hepatitis C virus genotype 4. 2007 , 102, 2582-8	17
838	Synergy of small molecular inhibitors of hepatitis C virus replication directed at multiple viral targets. 2007 , 81, 3005-8	29
837	Status presens of antiviral drugs and strategies: Part II: RNA VIRUSES (EXCEPT RETROVIRUSES). 2007 , 5, 59-112	1
836	Cyclophilin inhibitors in hepatitis C viral infection. 2007 , 16, 1345-54	39
835	Improving the treatment of hepatitis C infection in the UK. 2007 , 8, 183-91	1
834	Design of the PEDS-C trial: pegylated interferon +/- ribavirin for children with chronic hepatitis C viral infection. 2007 , 4, 661-73	27
833	[Ocular complications of hepatitis C treatment]. 2007 , 30, e20	4
832	Effect of sustained viral response on hepatic venous pressure gradient in hepatitis C-related cirrhosis. 2007 , 5, 932-7	106
831	Tolérance et adhérence au traitement de l'hépatite C. 2007 , 9, 221-225	
830	Understanding the pathogenesis and management of hepatitis B/HIV and hepatitis B/hepatitis C virus coinfection. 2007 , 11, 917-43, ix-x	15
829	Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment. 2007 , 5, 124-9	382
828	Aging liver and hepatitis. 2007 , 23, 889-903, viii	21
827	Impact of asian race on response to combination therapy with peginterferon alfa-2a and ribavirin in chronic hepatitis C. 2007 , 102, 2181-8	81
826	Therapy of interferon-induced depression in chronic hepatitis C with citalopram: a randomised, double-blind, placebo-controlled study. 2008 , 57, 531-6	91

825	Treatment of hepatitis C: don't put all your eggs in one basket!. 2007 , 132, 1611-5	8
824	Traitement des h�patites virales chroniques. 2007 , 16, 618-625	
823	[Does antiviral therapy improve the clinical course of cirrhosis due to hepatitis C virus infection?]. <i>Gastroenterologia Y Hepatologia</i> , 2007 , 30, 85-92	0.9
822	[Adaptive cell immune response against the hepatitis C virus infection]. 2007 , 129, 469-76	
821	[Toxicity of the treatment of chronic hepatitis C with peginterferon alpha (2a or 2b) plus ribavirin in patients not previously treated]. 2007 , 129, 612-4	
820	Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. 2007 , 132, 103-12	173
819	Mutagenic effect of ribavirin on hepatitis C nonstructural 5B quasispecies in vitro and during antiviral therapy. 2007 , 132, 921-30	73
818	SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders. 2007 , 132, 1270-8	277
817	Inhibition of T-cell inflammatory cytokines, hepatocyte NF-kappaB signaling, and HCV infection by standardized Silymarin. 2007 , 132, 1925-36	163
816	Serotonin-1A receptor gene HTR1A variation predicts interferon-induced depression in chronic hepatitis C. 2007 , 132, 1279-86	88
815	Mutation rate of the hepatitis C virus NS5B in patients undergoing treatment with ribavirin monotherapy. 2007 , 132, 1757-66	92
814	Ribavirin: is it a mutagen for hepatitis C virus?. 2007 , 132, 2050-2	23
813	HCV-specific T-cell response in relation to viral kinetics and treatment outcome (DITTO-HCV project). 2007 , 133, 1132-43	55
812	Hepatitis C virus triggers apoptosis of a newly developed hepatoma cell line through antiviral defense system. 2007 , 133, 1649-59	93
811	Pegylated interferon therapy in chronic hepatitis C: lights and shadows of an innovative treatment. 2007 , 39 Suppl 1, S88-95	6
810	Antiviral treatment of HCV-related cirrhosis. 2007 , 39 Suppl 1, S96-101	4
809	Pegylated interferon and ribavirin in re-treatment of responder-relapser HCV patients. 2007 , 39, 47-51	19
808	Changes in serum tryptophan during antiviral therapy with recombinant Interferon in chronic hepatitis C. 2007 , 1304, 362-366	

807	[The role and possibilities of natural interferon treatment in chronic hepatitis C: experience with natural interferon treatment for patients barred from combined antiviral therapy because of the STOP rule]. 2007 , 148, 1545-50	1
806	Interferon therapy for HCV-associated glomerulonephritis: meta-analysis of controlled trials. 2007 , 30, 212-9	34
805	Management of Chronic Hepatitis C: Consensus Guidelines. 2007 , 21, 25C-34C	53
804	Management and treatment of hepatitis C virus in patients with HIV and hepatitis C virus coinfection: A practical guide for health care professionals. 2007 , 18, 293-303	8
803	Ribonucleic Acid Viruses: Antivirals for Influenza A and B, Hepatitis C Virus, and Respiratory Syncytial Virus. 2007 , 373-417	2
802	Hepatitis C virus: virology, diagnosis and management of antiviral therapy. 2007 , 13, 2461-6	105
801	Retinal circulatory changes associated with interferon-induced retinopathy in patients with hepatitis C. 2007 , 48, 368-75	28
800	Using pegylated interferon alfa-2b and ribavirin to treat chronic hepatitis patients infected with hepatitis c virus genotype 1: are nonresponders and relapsers different populations?. 2007 , 11, 554-60	5
799	Determinazione quantitativa di HCV-RNA: valutazione comparativa dei saggi Abbott Real-Time e Versant bDNA v.3. 2007 , 22,	
798	Viruses and Viral Diseases. 2007 , 253-293	1
797	Effect of Ribavirin Alone or Combined with Silymarin on Carbon Tetrachloride Induced Hepatic Damage in Rats. 2007 , 2, 117739280700200	3
796	Treatment of hepatitis C virus infection. 2007 , 13, 1897-905	21
795	Long-term outcome after interferon therapy in patients with chronic hepatitis C.. 2007 , 6, 267-269	2
794	End-stage renal disease and hepatitis C infection: comparison of alanine aminotransferase levels and liver histology in patients with and without renal damage. 2007 , 6, 48-54	19
793	Antiviral therapy: Inhibition of Hepatitis C Virus expression by RNA interference directed against the NS5B region of the Viral Genome. 2007 , 6, 174-180	11
792	Hepatitis C virus eradication in intravenous drug users maintained with subcutaneous naltrexone implants. 2007 , 45, 111-7	52
791	A national French survey on the use of growth factors as adjuvant treatment of chronic hepatitis C. 2007 , 45, 377-83	25
790	Final results of a double-blind, placebo-controlled trial of the antifibrotic efficacy of interferon-gamma1b in chronic hepatitis C patients with advanced fibrosis or cirrhosis. 2007 , 45, 569-78	88

789	The effects of HCV infection and management on health-related quality of life. 2007 , 45, 806-16	141
788	Evaluation of a cyclophilin inhibitor in hepatitis C virus-infected chimeric mice in vivo. 2007 , 45, 921-8	89
787	Impact of disease severity on outcome of antiviral therapy in treatment-naïve patients with chronic hepatitis C. 2007 , 45, 1333-4; author reply 1334	2
786	Overestimation and underestimation of hepatitis C virus RNA levels in a widely used real-time polymerase chain reaction-based method. 2007 , 46, 22-31	132
785	Triphasic decline of hepatitis C virus RNA during antiviral therapy. 2007 , 46, 16-21	102
784	Predictors of response of US veterans to treatment for the hepatitis C virus. 2007 , 46, 37-47	191
783	Impact of weight-based ribavirin with peginterferon alfa-2b in African Americans with hepatitis C virus genotype 1. 2007 , 46, 982-90	65
782	Molecular insight of flow property for gas-water mixture (CO ₂ /CH ₄ -H ₂ O) in shale organic matrix. 2021 , 288, 119720	5
781	High-frequency power loss mechanisms in ultra-thin amorphous ribbons. 2021 , 519, 167469	3
780	Endovascular Treatment of Symptomatic Intracranial Vertebrobasilar Stenosis: A 10-Year Single Centre Experience Using Balloon-Expandable Coronary Artery Stents. 2021 , 30, 105431	
779	Your cheating heart is just afraid of ending up alone: Fear of being single mediates the relationship between attachment anxiety and infidelity. 2021 , 168, 110366	5
778	The perimeter generating function for nondirected diagonally convex polyominoes. 2021 , 344, 112213	
777	Immunodeficiencies: non-infectious manifestations. 2021 , 97 Suppl 1, S24-S33	0
776	A TAD Skeptic: Is 3D Genome Topology Conserved?. 2021 , 37, 216-223	14
775	Metabolomic understanding of the difference between unpruning and pruning cultivation of tea (<i>Camellia sinensis</i>) plants. 2021 , 140, 109978	2
774	Positron excess from cosmic ray interactions in galactic molecular clouds. 2021 , 29, 1-18	3
773	Bronchopneumopathie chronique obstructive et diabète dans le service de pneumologie du CHU de Brazzaville. 2021 , 13, 95	
772	Electrically tunable optical fiber device based on hollow-core fiber infiltrated with liquid crystal. 2021 , 318, 112500	5

771	The assembly of methanotrophic communities regulated by soil pH in a mountain ecosystem. 2021 , 196, 104883	3
770	Cost-effectiveness of hepatitis C virus screening, and subsequent monitoring or treatment among pregnant women in the Netherlands. 2021 , 22, 75-88	3
769	The Psychological Impact of COVID-19 Pandemic and Lockdown on Caregivers of People With Dementia. 2021 , 29, 27-34	67
768	A rapid and non-destructive detection of Escherichia coli on the surface of fresh-cut potato slices and application using hyperspectral imaging. 2021 , 171, 111352	2
767	Achieving WHO target of HCV control in Hong Kong: challenges and strategies. 2021 , 3, 276-282	
766	Effect of Hepatitis C Virus Infection on Heart Transplants in the Current Era. 2021 , 105, 2482-2489	
765	Emerging Management of Hepatitis C in Transplant. 2021 , 951-969	
764	Interferon alpha-based combinations suppress SARS-CoV-2 infection in vitro and in vivo.	3
763	Treatment progress and expansion in Japan: From interferon to direct-acting antiviral. 2021 , 3, 321-334	0
762	The A150V Polymorphism of Genotype 3 Hepatitis C Virus Polymerase Inhibits Interferon Alfa by Suppressing Protein Kinase R Activation. 2021 , 11, 1163-1175	0
761	Effectiveness of direct-acting antiviral drugs against hepatitis C virus: predictive factors of response to the treatment. 2021 , 16, 1949797	1
760	Effect of a genetically engineered interferon-alpha versus traditional interferon-alpha in the treatment of moderate-to-severe COVID-19: a randomised clinical trial. 2021 , 53, 391-401	16
759	Bayesian approach for predicting responses to therapy from high-dimensional time-course gene expression profiles. 2021 , 22, 132	1
758	Analysis of Different Types of Interferon-Associated Retinopathy in Patients with Chronic Hepatitis C Virus Infection Treated with Pegylated Interferon Plus Ribavirin. <i>Viruses</i> , 2021 , 13,	6.2 0
757	Prioritizing antiviral drugs against SARS-CoV-2 by integrating viral complete genome sequences and drug chemical structures. 2021 , 11, 6248	13
756	Neonatal Hepatitis and Congenital Infections. 2021 , 147-161	
755	Tertiary Prevention of HCC in Chronic Hepatitis B or C Infected Patients. 2021 , 13,	3
754	Feasible TLC-Spectro-Densitometry Technique for Simultaneous Determination of Two Hepatitis C Antiviral Drugs, Sofosbuvir and Simeprevir: Application to Combined Pharmaceutical Dosage Forms and Human Plasma. 2021 , 59, 576-583	1

- 753 Activation of plasmacytoid dendritic cells promotes AML-cell fratricide. **2021**, 12, 878-890 1
- 752 Drug-induced (medication-induced) depression in neurology practice. **2021**, 13, 104-110
- 751 Blinding in Clinical Trials for Chronic Liver Diseases. **2021**, 41, 163-171 0
- 750 A Review of Hepatitis B Virus and Hepatitis C Virus Immunopathogenesis. **2021**, 9, 409-418 0
- 749 Long-Term Outcomes and Evaluation of Hepatocellular Carcinoma Recurrence after Hepatitis C Virus Eradication by Direct-Acting Antiviral Treatment: All Kagawa Liver Disease Group (AKLDG) Study. **2021**, 13, 0
- 748 Curative Therapies for Hepatitis C Virus Infection in Patients with Kidney Disease.. **2021**, 2, 1316-1325
- 747 Covid-19da Kullantın İdarisi Hesapsal Algoritmalarıyla
- 746 Subtype-specific collaborative transcription factor networks are promoted by OCT4 in the progression of prostate cancer. **2021**, 12, 3766 3
- 745 The risk of hepatitis C virus recurrence in hepatitis C virus-infected patients treated with direct-acting antivirals after achieving a sustained virological response: A comprehensive analysis. **2021**, 41, 2341-2357 0
- 744 Sofosbuvir-Based Therapies Achieved Satisfactory Virological Response in Chinese Individuals with Genotypes 3 and 6 Infections: A Real-World Experience. **2021**, 14, 2297-2307 1
- 743 Dietary daidzein inhibits hepatitis C virus replication by decreasing microRNA-122 levels. **2021**, 298, 198404 3
- 742 aMAP score prediction of hepatocellular carcinoma occurrence and incidence-free rate after a sustained virologic response in chronic hepatitis C. **2021**, 51, 933-942 3
- 741 Optimal Timing of Administration of Direct-acting Antivirals for Patients With Hepatitis C-associated Hepatocellular Carcinoma Undergoing Liver Transplantation. **2021**, 274, 613-620 1
- 740 Viral hepatitis: Milestones, unresolved issues, and future goals. **2021**, 27, 4603-4638 3
- 739 Estimating the net value of treating hepatitis C virus using sofosbuvir-velpatasvir in India. **2021**, 16, e0252764 1
- 738 Roppeginterferon alfa-2b in patients with genotype 1 chronic hepatitis C: Pharmacokinetics, safety, and preliminary efficacy. **2021**, 5, 929-940 4
- 737 Effectiveness of Direct-Acting Antivirals in Treatment of Elderly Egyptian Chronic Hepatitis C Patients. **2021**, 12, 336-346 2
- 736 Evaluation of liver fibrosis using hepatic extracellular volume fraction by contrast-enhanced computed tomography before and after direct-acting antiviral therapy in patients with chronic hepatitis C infection: comparison with serological liver fibrosis markers. **2021**, 94, 20210045

735	Association of blood groups with hepatitis C viremia. 2021 , 28, 5359-5363	0
734	Safety and efficacy of sofosbuvir/ledipasvir and sofosbuvir/daclatasvir in the treatment of hepatitis C in patients with decompensated cirrhosis. 2021 , 33,	1
733	A Novel Small Molecule Inhibits Hepatitis C Virus Propagation in Cell Culture. 2021 , 9, e0043921	1
732	Hepatitis C treatment outcomes among patients treated in co-located primary care and addiction treatment settings. 2021 , 131, 108438	1
731	Curious effects of fluorine on medicinally active compounds. 2021 , 241-276	0
730	Hepatitis C. 2021 , 41-55	
729	The isolation of high-affinity ssDNA aptamer for the detection of ribavirin in chicken. 2021 , 13, 3110-3117	2
728	Interferon signaling. 214-225	1
727	Pharmacology and Mechanisms of Action of Antiviral Drugs: Ribavirin Analogs. 36-42	1
726	Polymer Therapeutics for Cancer: Current Status and Future Challenges. 1-65	105
725	New promises in the adjuvant, and palliative treatment of melanoma. 2007 , 135, 277-92	1
724	Interferon-Induced Effector Proteins and Hepatitis C Virus Replication. 2008 , 106-129	1
723	Interferon Treatment of Hepatitis C Virus Infection: From Basic Biology to Clinical Application. 2008 , 148-167	1
722	Hepatitis Virus Resistance. 2008 , 291-323	1
721	Managing the Side Effects of Therapy. 2012 , 171-182	1
720	Overview of Direct-Acting Antiviral Drugs and Drug Resistance of Hepatitis C Virus. 2019 , 1911, 3-32	52
719	Mechanisms of Hepatitis C Virus Drug Resistance. 2009 , 531-545	1
718	Mathematical modeling of HCV infection and treatment. 2009 , 510, 439-53	14

717	Treatment of Viral Hepatitis in Children - 2008. 2009 , 405-429	1
716	Hepatitis C and Hepatocellular Carcinoma. 2009 , 259-281	4
715	Prevention of hepatitis C virus infection and liver cancer. 2014 , 193, 113-33	13
714	HCV NS3/4A Protease Inhibitors and the Road to Effective Direct-Acting Antiviral Therapies. 2016 , 257-285	1
713	Harvoni: A Combination Therapy for Curing HCV. 2017 , 558-582	2
712	Antiviral Drugs (Other than Antiretrovirals). 2010 , 565-610	3
711	Chronic Viral Hepatitis. 2010 , 1593-1617	1
710	Hepatitis C. 2010 , 2157-2185	4
709	Natural History of Hepatitis C. 2005 , 129-141	1
708	Monitoring and Care of the Patient Before Liver Transplantation. 2005 , 473-489	0
707	Neuropathies with Systemic Vasculitis. 2005 , 2335-2404	11
706	Hepatitis C. 2006 , 665-686	2
705	The Journey to the Discovery of Boceprevir: an NS3-NS4 HCV protease inhibitor for the treatment of chronic hepatitis C. 2010 , 49, 1-36	21
704	PREVALENCE OF HEPATITIS C VIRUS (HCV) COINFECTION IN HIV INFECTED INDIVIDUALS IN SOUTH INDIA AND CHARACTERIZATION OF HCV GENOTYPES. 2009 , 27, 12-16	11
703	Hepatitis C infection: a clinical review. 2004 , 97, 364-73; quiz 374	25
702	Efficacy and safety of peginterferon-alpha2b and ribavirin combination therapy in children with chronic hepatitis C infection. 2008 , 27, 142-8	89
701	Alpha interferon inhibits translation mediated by the internal ribosome entry site of six different hepatitis C virus genotypes. 2005 , 86, 3047-3053	17
700	Antiviral effect of alpha-glucosidase inhibitors on viral morphogenesis and binding properties of hepatitis C virus-like particles. 2006 , 87, 861-871	37

699	Antiherpesvirus, Anti-Hepatitis Virus, and Anti-Respiratory Virus Agents. 2009 , 217-264	4
698	Molecular Microbiology. 54-90	4
697	Virus-induced type I IFN stimulates generation of immunoproteasomes at the site of infection. 2006 , 116, 3006-14	119
696	Tim-3 expression on PD-1+ HCV-specific human CTLs is associated with viral persistence, and its blockade restores hepatocyte-directed in vitro cytotoxicity. 2010 , 120, 4546-57	249
695	Pegylated IFN- α regulates hepatic gene expression through transient Jak/STAT activation. 2014 , 124, 1568-81	36
694	Antiviral completion rates and sustained viral response in hepatitis C patients with and without preexisting major depressive disorder. 2009 , 50, 500-5	16
693	A functional serotonin transporter gene polymorphism and depressive effects associated with interferon-alpha treatment. 2010 , 51, 137-48	27
692	Successful Anti-HCV Therapy of a Former Intravenous Drug User with Sofosbuvir and Daclatasvir in a Peritransplant Setting: A Case Report. 2016 , 17, 605-10	1
691	Current status and emerging challenges in the treatment of hepatitis C virus genotypes 4 to 6. 2015 , 3, 210-20	9
690	Rates of HCV treatment eligibility among HCV-monoinfected and HCV/HIV-coinfected patients in tertiary care referral centers. 2009 , 10, 25-32	14
689	Interleukin-28B genotype testing to determine response to the combination of pegylated-interferon and ribavirin for the treatment of hepatitis C virus. 2011 , 3, RRN1207	2
688	A novel unsupervised method to identify genes important in the anti-viral response: application to interferon/ribavirin in hepatitis C patients. 2007 , 2, e584	18
687	Hepatitis C virus diversity and evolution in the full open-reading frame during antiviral therapy. 2008 , 3, e2123	40
686	Genetic variability of hepatitis C virus before and after combined therapy of interferon plus ribavirin. 2008 , 3, e3058	14
685	Treatment of hepatitis C in children: a systematic review. 2010 , 5, e11542	26
684	Response prediction in chronic hepatitis C by assessment of IP-10 and IL28B-related single nucleotide polymorphisms. 2011 , 6, e17232	120
683	Dysregulation of IFN system can lead to poor response to pegylated interferon and ribavirin therapy in chronic hepatitis C. 2011 , 6, e19799	13
682	Generation of a cell culture-adapted hepatitis C virus with longer half life at physiological temperature. 2011 , 6, e22808	18

681	Interferon-alpha administration enhances CD8+ T cell activation in HIV infection. 2012 , 7, e30306	37
680	Sequence heterogeneity in NS5A of hepatitis C virus genotypes 2a and 2b and clinical outcome of pegylated-interferon/ribavirin therapy. 2012 , 7, e30513	16
679	Impact of obesity on the bioavailability of peginterferon- α and ribavirin and treatment outcome for chronic hepatitis C genotype 2 or 3. 2012 , 7, e37521	13
678	Selective hyper-responsiveness of the interferon system in major depressive disorders and depression induced by interferon therapy. 2012 , 7, e38668	20
677	The HCV non-nucleoside inhibitor Tegobuvir utilizes a novel mechanism of action to inhibit NS5B polymerase function. 2012 , 7, e39163	37
676	HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors. 2012 , 7, e39652	74
675	Kinetic and dynamic computational model-based characterization of new proteins in mice: application to interferon alpha linked to apolipoprotein A-I. 2012 , 7, e42100	2
674	Effect of different interferon α preparations on IP10 and ET-1 release from human lung cells. 2012 , 7, e46779	12
673	Correlation of viral loads with HCV genotypes: higher levels of virus were revealed among blood donors infected with 6a strains. 2012 , 7, e52467	17
672	Liver-targeting of interferon-alpha with tissue-specific domain antibodies. 2013 , 8, e57263	18
671	Baseline MELD score predicts hepatic decompensation during antiviral therapy in patients with chronic hepatitis C and advanced cirrhosis. 2013 , 8, e71262	11
670	Targeted deletion of FGL2 leads to increased early viral replication and enhanced adaptive immunity in a murine model of acute viral hepatitis caused by LCMV WE. 2013 , 8, e72309	16
669	Can antidepressants prevent pegylated interferon- α /ribavirin-associated depression in patients with chronic hepatitis C: meta-analysis of randomized, double-blind, placebo-controlled trials?. 2013 , 8, e76799	10
668	HCV genotypes, characterization of mutations conferring drug resistance to protease inhibitors, and risk factors among blood donors in S \tilde{a} Paulo, Brazil. 2014 , 9, e86413	24
667	In silico identification and evaluation of leads for the simultaneous inhibition of protease and helicase activities of HCV NS3/4A protease using complex based pharmacophore mapping and virtual screening. 2014 , 9, e89109	19
666	Impaired expression of type I and type II interferon receptors in HCV-associated chronic liver disease and liver cirrhosis. 2014 , 9, e108616	24
665	Individualized treatment of genotype 1 naïve patients: an Italian multicenter field practice experience. 2014 , 9, e110284	5
664	Suppression of dual specificity phosphatase I expression inhibits hepatitis C virus replication. 2015 , 10, e0119172	10

663	MicroRNAs as predictor markers for response to interferon treatment of chronic hepatitis C genotype-4 in Egyptian patients. 2015 , 10, e0121524	11
662	Benefit of Treatment Individualization in Patients with Chronic Hepatitis C Receiving Peginterferon Alfa-2a and Ribavirin in a Large Noninterventional Cohort Study. 2015 , 10, e0134839	3
661	24 versus 48 Weeks of Peginterferon Plus Ribavirin in Hepatitis C Virus Genotype 6 Chronically Infected Patients with a Rapid Virological Response: A Non-Inferiority Randomized Controlled Trial. 2015 , 10, e0140853	2
660	Impact of IL28B, APOH and ITPA Polymorphisms on Efficacy and Safety of TVR- or BOC-Based Triple Therapy in Treatment-Experienced HCV-1 Patients with Compensated Cirrhosis from the ANRS CO20-CUPIC Study. 2015 , 10, e0145105	4
659	Pretreatment Predictors of Response to PegIFN-RBV Therapy in Egyptian Patients with HCV Genotype 4. 2016 , 11, e0153895	7
658	Randomized Trial Evaluating the Impact of Ribavirin Mono-Therapy and Double Dosing on Viral Kinetics, Ribavirin Pharmacokinetics and Anemia in Hepatitis C Virus Genotype 1 Infection. 2016 , 11, e0155142	8
657	Anti-Viral Therapy and Decreased Sexual Desire in Patients with Chronic Hepatitis C. 2016 , 11, e0160450	6
656	Changing Epidemiology of Hepatitis C Virus Genotype among Patients with Human Immunodeficiency Virus/Hepatitis C Virus Co-Infection in China. 2016 , 11, e0161844	3
655	Genome-Wide Association Study Identifies ZNF354C Variants Associated with Depression from Interferon-Based Therapy for Chronic Hepatitis C. 2016 , 11, e0164418	7
654	Who Treats Patients with Diabetes and Compensated Cirrhosis. 2016 , 11, e0165574	7
653	Vitamin D Status and Virologic Response to HCV Therapy in the HALT-C and VIRASHEP-C Trials. 2016 , 11, e0166036	7
652	Real-life results of sofosbuvir based therapy in chronic hepatitis C -naïve and -experienced patients in Egypt. 2017 , 12, e0184654	9
651	Genotype distribution and treatment response among incarcerated drug-dependent patients with chronic hepatitis C infection. 2018 , 13, e0191799	3
650	Impact of direct-acting antiviral therapy for hepatitis C-related hepatocellular carcinoma. 2020 , 15, e0233212	9
649	Use of Ribavirin for Hepatitis C Treatment in the Modern Direct-acting Antiviral Era. 2018 , 6, 431-437	10
648	Herbal Medicines for Hepatitis C Virus Infection: The Exploratory Journey from Bench to Bedside Still Has a Long Way to Go. 2019 , 4, 9-18	1
647	Assessment of Knowledge, Attitudes, and Practices Regarding Chronic Hepatitis C Treatment and Its Challenges: A Survey of Internal Medicine Residents in a Community Hospital. 2018 , 11, 31-35	2
646	[Experiences in antiviral treatment of chronic viral hepatitis B and C in Hungary (1998-2004)]. 2007 , 148, 819-26	3

645	[Interferon in the treatment of viral hepatitis. The interferon was discovered 50 years ago]. 2007 , 148, 1539-43	1
644	[Successful elimination of hepatitis C virus after hepatic lobectomy in a patient with hepatocellular carcinoma]. 2008 , 149, 2143-8	0
643	[Influence of weight reduction on the effectiveness of combined peginterferon and ribavirin treatment in chronic HCV hepatitis]. 2008 , 149, 2189-92	2
642	[Silymarin in the treatment of chronic liver diseases: past and future]. 2008 , 149, 2413-8	16
641	[Side-effects of pegylated interferon plus ribavirin therapy with or without protease inhibitor direct acting antiviral agents during treatment of chronic hepatitis C virus infection]. 2011 , 152, 1997-2009	6
640	EFFICACY OF TREATMENT WITH PEGYLATED INTERFERON AND RIBAVIRIN IN PATIENTS WITH CHRONIC HCV INFECTION UNDER REAL LIFE CONDITIONS. 2014 , 21, 23-32	1
639	Eczema craquelé associated with antiviral treatment for chronic hepatitis C. 2017 , 92, 436-437	3
638	[The sustained response rates for chronic hepatitis C patients undergoing therapy with the several interferons and ribavirins supplied by Brazilian Health Ministry is comparable to those reported in the literature]. 2004 , 41, 3-9	9
637	Celiac disease onset after pegylated interferon and ribavirin treatment of chronic hepatitis C. 2004 , 41, 132-3	15
636	[Alpha-interferon versus peg-interferon associated to ribavirin in the treatment of genotype 1 hepatitis C virus and human immunodeficiency virus coinfecting patients]. 2009 , 46, 132-7	1
635	Effect of HFE gene polymorphism on sustained virological response in patients with chronic hepatitis C and elevated serum ferritin. 2012 , 49, 9-13	2
634	Prevalence of hepatitis C virus and HIV infection among injection drug users in two Mexican cities bordering the U.S. 2007 , 49, 165-72	46
633	Treatment of chronic hepatitis C in non-responsive patients with pegylated interferon associated with ribavirin and thalidomide: report of six cases of total remission. 2006 , 48, 109-12	6
632	[High prevalence of genotype 1 in individuals with hepatitis C in Belo Horizonte, MG]. 2008 , 41, 238-42	6
631	[Situation of lawsuits concerning the access to medical products by the Health Department of Santa Catarina State, Brazil, during the years 2003 and 2004]. 2010 , 15 Suppl 3, 3551-60	18
630	Treatment of hepatitis C virus infection with interferon and small molecule direct antivirals: viral kinetics and modeling. 2010 , 30, 131-48	54
629	[The efficiency of antiviral therapy in patients with chronic -hepatitis C infected with hepatitis C virus recombinants]. 2016 , 88, 101-105	3
628	Inhibition of hepatitis C virus (HCV) core protein- induced cell growth by non-structural protein 4A (NS4A) is mediated by mitochondrial dysregulation. 2008 , 8, 4-11	13

627	Hepatitis C virus genotypes in chronic hepatitis C patients and in first time blood donors in northeastern Bosnia and Herzegovina. 2009 , 9, 278-82	10
626	Genetic predictors of the response to the treatment of hepatitis C virus infection. 2015 , 15, 55-9	4
625	Dynamics of PBMC gene expression in hepatitis C virus genotype 1-infected patients during combined peginterferon/ribavirin therapy. 2016 , 7, 61325-61335	6
624	[Cytopenias and their correction during antiviral therapy of chronic hepatitis C in patients with genotype 1]. 2017 , 62, 174-178	2
623	Soluble Markers of Immune Activation Differentially Normalize and Selectively Associate with Improvement in AST, ALT, Albumin, and Transient Elastography During IFN-Free HCV Therapy. 2018 , 3, 149-163	21
622	No evidence for higher rates of hepatocellular carcinoma after direct-acting antiviral treatment: a meta-analysis. 2019 , 5,	11
621	Efficacy and safety profile of boceprevir- or telaprevir-based triple therapy or dual peginterferon alfa-2a or alfa-2b plus ribavirin therapy in chronic hepatitis C: the real-world PegBase observational study. 2017 , 30, 327-343	5
620	Efficacy of peginterferon alpha-2A and ribavirin combination therapy in treatment-naïve Estonian patients with chronic hepatitis C. 2012 , 20, 150-5	5
619	Risk prediction models for hepatocellular carcinoma in different populations. 2016 , 28, 150-60	5
618	Hepatitis C Virus: Efficacy of New DAAs Regimens. 2020 , 20, 143-149	12
617	A Primary Care-based Collaborative Hepatitis C Clinic: Clinical Structure and Virologic Outcomes with Direct Acting Antiviral Therapy. 2016 , 3, 70-78	1
616	Co-occurring Depression, Chronic Pain and Substance Use Disorders in People with Hepatitis C. 2016 , 3, 79-103	1
615	The Role of Physicians' Attitudes and the Provision of Hepatitis C Virus Treatment to People Who Inject Drugs. 2016 , 3, 104-112	2
614	Serum Serotonin Levels are Associated with Antiviral Therapy Outcomes in Patients with Chronic Hepatitis C. 2010 , 4, 132-141	6
613	Direct-acting antivirals and interferon-based therapy on hepatocellular carcinoma risk in chronic hepatitis-C patients. 2020 , 16, 675-686	5
612	Hepatitis C crónica: aspectos clínicos, serológicos y de tratamiento en dos centros de atención en Bogotá-Colombia. 2014 , 29, 424-432	2
611	[Efficacy of combined antiviral therapy with pegylated interferon alpha-2a and ribavirin for chronic hepatitis C infection in intravenous drug users]. 2010 , 138, 43-9	1
610	Meta-analysis of the Efficacy and Safety of Grazoprevir and Elbasvir for the Treatment of Hepatitis C Virus Infection. 2017 , 27, 150-160	1

609	Total clearance (CL/F) of ribavirin is the factor most influencing incidence of hemolytic anemia in interferon .ALPHA. plus ribavirin combination therapy. 2005 , 46, 107-118	4
608	Factors affecting efficacy of pegylated interferon alpha-2a in chronic hepatitis C patients with serotype 2. 2011 , 52, 236-243	3
607	Treatment Guidelines of Hepatitis C. 2012 , 53, 355-395	2
606	Protease inhibitors for the treatment of hepatitis C virus infection. 2017 , 5, Doc08	11
605	Current standards in the treatment of chronic hepatitis C. 2012 , 109, 352-8	16
604	Cost-effectiveness of non-invasive methods for assessment and monitoring of liver fibrosis and cirrhosis in patients with chronic liver disease: systematic review and economic evaluation. 2015 , 19, 1-409, v-vi	101
603	Impact of ribavirin dose reduction during treatment in chronic hepatitis C genotype 1 patients. 2012 , 18, 268-71	1
602	Efficacy of peginterferon and ribavirin is associated with the IL28B gene in Korean patients with chronic hepatitis C. 2012 , 18, 360-7	12
601	Is peginterferon and ribavirin therapy effective in Korean patients with chronic hepatitis C?. 2013 , 19, 26-8	4
600	High effectiveness of peginterferon alfa-2a plus ribavirin therapy in Korean patients with chronic hepatitis C in clinical practice. 2013 , 19, 60-9	5
599	No association between the IL28B SNP and response to peginterferon plus ribavirin combination treatment in Korean chronic hepatitis C patients. 2014 , 20, 177-84	4
598	KASL clinical practice guidelines: management of hepatitis C. 2014 , 20, 89-136	30
597	Predictors of spontaneous viral clearance and outcomes of acute hepatitis C infection. 2014 , 20, 368-75	11
596	Highly effective peginterferon 2a plus ribavirin combination therapy for chronic hepatitis C in hemophilia in Korea. 2015 , 21, 125-30	3
595	Sofosbuvir-based therapy for patients with chronic hepatitis C: Early experience of its efficacy and safety in Korea. 2015 , 21, 358-64	11
594	Barriers to treatment of failed or interferon ineligible patients in the era of DAA: single center study. 2017 , 23, 74-79	2
593	KASL clinical practice guidelines: management of hepatitis C. 2016 , 22, 76-139	58
592	Management of hepatitis C viral infection in chronic kidney disease patients on hemodialysis in the era of direct-acting antivirals. 2018 , 24, 351-357	0

591	[Distribution of hepatitis C virus genotypes in Jeju Island]. 2008 , 14, 28-35	8
590	[Clinical outcome of pegylated interferon and ribavirin therapy for chronic hepatitis C]. 2008 , 14, 36-45	17
589	[Comparison of therapeutic results between combination therapy of peginterferon alpha-2a plus ribavirin and interferon alpha-2b plus ribavirin according to treatment duration in patients with chronic hepatitis C]. 2008 , 14, 46-57	14
588	[Effects of pegylated interferon and ribavirin in Korean patients with chronic hepatitis C virus infection]. 2008 , 14, 318-30	16
587	[Efficacy of initial treatment with peginterferon alpha-2a versus peginterferon alpha-2b in combination with ribavirin in naive chronic hepatitis C patients living in Daejeon and Chungcheong Province in Korea: a comparative study]. 2008 , 14, 493-502	7
586	Impact of adherence to peginterferon-ribavirin combination therapy in chronic hepatitis C patients on achieving a sustained virologic response. 2009 , 15, 338-49	9
585	[A comparison of 24- vs. 48-week peginterferon plus ribavirin in patients with genotype 1 chronic hepatitis C]. 2009 , 15, 496-503	0
584	[Clinical efficacy and safety of the combination therapy of peginterferon alpha and ribavirin in cirrhotic patients with HCV infection]. 2010 , 16, 38-48	8
583	[Occurrence of diabetic ketoacidosis and autoimmune thyroiditis in a patient treated with pegylated interferon-alpha 2b and ribavirin for chronic hepatitis C]. 2010 , 16, 187-91	2
582	[Peginterferon alfa-2a/ribavirin for 48 or 72 weeks in hepatitis C genotype 1 and 4 patients with slow virologic response]. 2010 , 16, 201-5	2
581	Durability of a sustained virologic response in patients with chronic hepatitis C treated with peginterferon and ribavirin. 2011 , 17, 84	1
580	Durability of a sustained virological response in chronic hepatitis C patients treated with pegylated interferon alfa and ribavirin. 2011 , 17, 183-8	2
579	Peginterferon alpha and ribavirin combination therapy in patients with hepatitis C virus-related liver cirrhosis. 2011 , 17, 220-5	13
578	Recent trends in the treatment of chronic hepatitis C. 2012 , 18, 22-8	12
577	New antiviral agents for hepatitis C. 2012 , 4, 5	26
576	Occult persistence and lymphotropism of hepatitis C virus infection. 2008 , 14, 2789-93	29
575	Treatment responses in Asians and Caucasians with chronic hepatitis C infection. 2008 , 14, 3416-20	40
574	Extended-therapy duration for chronic hepatitis C, genotype 1: the long and the short of it. 2008 , 14, 3621-7	10

573	Antiviral therapy in hepatitis C virus cirrhotic patients in compensated and decompensated condition. 2008 , 14, 6467-72	21
572	Is pegylated interferon superior to interferon, with ribavarin, in chronic hepatitis C genotypes 2/3?. 2008 , 14, 6627-31	8
571	Evolution and predictive factors of thyroid disorder due to interferon alpha in the treatment of hepatitis C. 2009 , 15, 328-33	17
570	Iron increases HMOX1 and decreases hepatitis C viral expression in HCV-expressing cells. 2009 , 15, 4499-510	31
569	APRI as a predictor of early viral response in chronic hepatitis C patients. 2009 , 15, 4923-7	6
568	Do statins reduce hepatitis C RNA titers during routine clinical use?. 2009 , 15, 5020-7	40
567	Costimulatory molecule programmed death-1 in the cytotoxic response during chronic hepatitis C. 2009 , 15, 5129-40	17
566	Ketoprofen, peginterferon 2a and ribavirin for genotype 1 chronic hepatitis C: a phase II study. 2009 , 15, 5946-52	3
565	Psychiatric side effects of pegylated interferon alfa-2b as compared to conventional interferon alfa-2b in patients with chronic hepatitis C. 2005 , 11, 1769-74	48
564	Interferon beta-1a alone or in combination with ribavirin: a randomized trial to compare efficacy and safety in chronic hepatitis C. 2005 , 11, 4484-9	13
563	Improvement of quantitative testing of liver function in patients with chronic hepatitis C after installment of antiviral therapy. 2005 , 11, 5521-4	4
562	Treatment of genotype 2 and 3 chronic hepatitis C virus-infected patients. 2005 , 11, 6188-92	2
561	New combination test for hepatitis C virus genotype and viral load determination using Amplicor GT HCV MONITOR test v2.0. 2005 , 11, 469-75	9
560	Impact of parietal cell autoantibodies and non-organ-specific autoantibodies on the treatment outcome of patients with hepatitis C virus infection: a pilot study. 2005 , 11, 482-7	13
559	Is interferon-beta an alternative treatment for chronic hepatitis C?. 2006 , 12, 2730-6	6
558	Mental and physical symptoms associated with lower social support for patients with hepatitis C. 2006 , 12, 4665-72	42
557	Mental and physical symptoms associated with lower social support for patients with hepatitis C. 2006 , 12, 4665	34
556	Retinal vein thrombosis associated with pegylated-interferon and ribavirin combination therapy for chronic hepatitis C. 2006 , 12, 4908-10	14

555	Screening in liver disease. 2006 , 12, 5272-80	3
554	Triple antiviral therapy in HCV positive patients who failed prior combination therapy. 2006 , 12, 5293-300	5
553	Efficacy of low dose peginterferon alpha-2b with ribavirin on chronic hepatitis C. 2006 , 12, 5554-6	11
552	Treatment of hepatitis C virus genotype 4 with peginterferon alfa-2a: impact of bilharziasis and fibrosis stage. 2006 , 12, 5692-8	37
551	Hepatocellular carcinoma prevention: a worldwide emergence between the opulence of developed countries and the economic constraints of developing nations. 2006 , 12, 7239-49	63
550	Interferon alpha plus ribavirin combination treatment of Japanese chronic hepatitis C patients with HCV genotype 2: a project of the Kyushu University Liver Disease Study Group. 2006 , 12, 784-90	17
549	Triple therapy of interferon and ribavirin with zinc supplementation for patients with chronic hepatitis C: a randomized controlled clinical trial. 2006 , 12, 1265-9	13
548	Genetic diversity of the hepatitis C virus: impact and issues in the antiviral therapy. 2007 , 13, 2416-26	72
547	Sequence diversity of hepatitis C virus: implications for immune control and therapy. 2007 , 13, 4808-17	72
546	Does protracted antiviral therapy impact on HCV-related liver cirrhosis progression?. 2007 , 13, 4903-8	3
545	Recent i.v.-drug users with chronic hepatitis C can be efficiently treated with daily high dose induction therapy using consensus interferon: an open-label pilot study. 2007 , 13, 579-84	7
544	Effects of a 24-week course of interferon-alpha therapy after curative treatment of hepatitis C virus-associated hepatocellular carcinoma. 2007 , 13, 5343-50	35
543	Effect of sustained virological response on long-term clinical outcome in 113 patients with compensated hepatitis C-related cirrhosis treated by interferon alpha and ribavirin. 2007 , 13, 5648-53	67
542	Specifically targeted antiviral therapy for hepatitis C virus. 2007 , 13, 5673-81	42
541	Quasispecies evolution in NS5A region of hepatitis C virus genotype 1b during interferon or combined interferon-ribavirin therapy. 2007 , 13, 1195-203	24
540	Immediate virological response predicts the success of short-term peg-interferon monotherapy for chronic hepatitis C. 2010 , 16, 1506-11	1
539	Alkaline phosphatase predicts relapse in chronic hepatitis C patients with end-of-treatment response. 2010 , 16, 2407-10	5
538	Peginterferon and ribavirin treatment for hepatitis C virus infection. 2011 , 17, 419-32	43

537	Long-term outcome of chronic hepatitis C patients with sustained virological response to peginterferon plus ribavirin. 2011 , 17, 493-8	19
536	"Liverscore" is predictive of both liver fibrosis and activity in chronic hepatitis C. 2011 , 17, 4607-13	4
535	Mutations around interferon sensitivity-determining region: a pilot resistance report of hepatitis C virus 1b in a Hong Kong population. 2011 , 17, 5317-23	4
534	Efficacy and safety of treatment of hepatitis C virus infection in renal transplant recipients. 2012 , 18, 55-63	21
533	Chronic hepatitis C: treat or wait? Medical decision making in clinical practice. 2012 , 18, 1339-47	22
532	Beneficial effects of fucoidan in patients with chronic hepatitis C virus infection. 2012 , 18, 2225-30	29
531	Impact of ribavirin dose on retreatment of chronic hepatitis C patients. 2012 , 18, 2966-72	1
530	Can zinc enhance response interferon therapy for patients with HCV-related liver disease?. 2012 , 18, 3196-200	8
529	Efficacy of MK615 for the treatment of patients with liver disorders. 2012 , 18, 4118-26	11
528	Vaccination with dendritic cells pulsed with hepatitis C pseudo particles induces specific immune responses in mice. 2012 , 18, 785-93	2
527	Vitamin D improves viral response in hepatitis C genotype 2-3 naïve patients. 2012 , 18, 800-5	109
526	Factors associated with early virological response to peginterferon-2a/ribavirin in chronic hepatitis C. 2013 , 19, 1943-52	7
525	Sofosbuvir and ABT-450: terminator of hepatitis C virus?. 2013 , 19, 3199-206	19
524	Are metabolic factors still important in the era of direct antiviral agents in patients with chronic hepatitis C?. 2013 , 19, 6947-56	11
523	Addicts with chronic hepatitis C: difficult to reach, manage or treat?. 2013 , 19, 8011-9	8
522	Pre-treatment role of inosine triphosphate pyrophosphatase polymorphism for predicting anemia in Egyptian hepatitis C virus patients. 2013 , 19, 1387-95	18
521	Management of thrombocytopenia due to liver cirrhosis: a review. 2014 , 20, 2595-605	76
520	Individualization of chronic hepatitis C treatment according to the host characteristics. 2014 , 20, 2839-53	8

519	Chronic hepatitis C genotype 1 virus: who should wait for treatment?. 2014 , 20, 2867-75	6
518	Understanding the interaction of hepatitis C virus with host DEAD-box RNA helicases. 2014 , 20, 2913-26	23
517	Virus-related liver cirrhosis: molecular basis and therapeutic options. 2014 , 20, 6457-69	32
516	Hepatic flares in chronic hepatitis C: spontaneous exacerbation vs hepatotropic viruses superinfection. 2014 , 20, 6707-15	13
515	Impact of hepatitis C virus heterogeneity on interferon sensitivity: an overview. 2014 , 20, 7555-69	34
514	Age-related differences in response to peginterferon alfa-2a/ribavirin in patients with chronic hepatitis C infection. 2014 , 20, 10984-93	18
513	Eligibility of persons who inject drugs for treatment of hepatitis C virus infection. 2014 , 20, 12722-33	22
512	Hepatitis C virus-specific cytotoxic T cell response restoration after treatment-induced hepatitis C virus control. 2015 , 21, 3480-91	17
511	Interferon- β polymorphisms and response to pegylated interferon in Iranian hepatitis C patients. 2015 , 21, 8935-42	20
510	Simeprevir with peginterferon and ribavirin induced interstitial pneumonitis: first case report. 2015 , 21, 1009-13	7
509	Impact of new treatment options for hepatitis C virus infection in liver transplantation. 2015 , 21, 10760-75	23
508	Re-re-treatment of hepatitis C virus: Eight patients who relapsed twice after direct-acting-antiviral drugs. 2015 , 21, 12430-8	4
507	Retreatment with peginterferon and ribavirin in chronic hepatitis C. 2015 , 21, 1994-9	2
506	S-adenosyl-L-methionine modifies antioxidant-enzymes, glutathione-biosynthesis and methionine adenosyltransferases-1/2 in hepatitis C virus-expressing cells. 2016 , 22, 3746-57	9
505	Pleiotropic effects of statins in the diseases of the liver. 2016 , 22, 6201-13	33
504	Impact of hepatitis C virus core mutations on the response to interferon-based treatment in chronic hepatitis C. 2016 , 22, 8406-8413	4
503	Hepatitis C in injection drug users: It is time to treat. 2017 , 23, 3569-3571	21
502	Hepatitis C virus NS5A region mutation in chronic hepatitis C genotype 1 patients who are non-responders to two or more treatments and its relationship with response to a new treatment. 2017 , 23, 4538-4547	5

501	Dramatic response of hepatitis C patients chronically infected with hepatitis C virus genotype 3 to sofosbuvir-based therapies in Punjab, Pakistan: A prospective study. 2017 , 23, 7899-7905	6
500	Recovery of natural killer cells is mainly in post-treatment period in chronic hepatitis C patients treated with sofosbuvir plus ledipasvir. 2018 , 24, 4554-4564	7
499	Mononuclear phagocyte system in hepatitis C virus infection. 2018 , 24, 4962-4973	7
498	Management of betablocked patients after sustained virological response in hepatitis C cirrhosis. 2019 , 25, 2665-2674	3
497	Liver-related effects of chronic hepatitis C antiviral treatment. 2020 , 26, 2931-2947	5
496	Simple scoring system for prediction of hepatocellular carcinoma occurrence after hepatitis C virus eradication by direct-acting antiviral treatment: All Kagawa Liver Disease Group Study. 2020 , 19, 2205-2212	20
495	Assessment of the efficacy of reducing peginterferon alpha-2a and ribavirin dose on virologic response in Koreans with chronic hepatitis C. 2009 , 24, 203-11	9
494	Clinical implication of serum uric acid level in pegylated interferon and ribavirin combination therapy for chronic hepatitis C infection. 2017 , 32, 1010-1017	2
493	Platelet count is associated with sustained virological response rates in treatments for chronic hepatitis C. 2019 , 34, 989-997	1
492	Daclatasvir and asunaprevir combination therapy for patients with chronic hepatitis C virus genotype 1b infection in real world. 2019 , 34, 794-801	3
491	Prise en charge de l'hépatite chronique C: une urgence psychiatrique?. 2009 , 85, 629	0
490	Psychiatric Issues in Patients with Hepatitis C. 2003 , 33, 357-360	6
489	Psychiatric and Substance Use Disorder Comorbidity With Hepatitis C. 2003 , 33, 362-366	4
488	Injection Drug Use and Hepatitis C: From Transmission to Treatment. 2003 , 33, 377-382	9
487	Comanagement of Depression and HCV Treatment. 2003 , 33, 385-391	15
486	Anatomical and Functional Retinal Complications of Combined Sofosbuvir and Ribavirin Therapy in Patients With Chronic Hepatitis C Virus. 2019 , 50, 39-41	1
485	Analysis of the sensitivity of the impact resonance frequency test as a tool to determine the elastic properties of bituminous materials. 1957 , 7, 131	1
484	Hepatitis C treatment at three Norwegian hospitals 2000-2011. 2015 , 135, 2052-8	1

483	Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction. 2005 , 66, 41-8	227
482	Interferon-alpha Treatment of Hepatitis C Patients With Psychiatric Illness: Evidence-Based Risk-Benefit Assessment. 2005 , 7, 74-75	5
481	Study of the effect of combined interferon and ribavirin therapy on the hearing profile of hepatitis C virus patients. 2015 , 31, 237-243	3
480	Sustained virologic response to peginterferon alpha-2a and ribavirin in 335 patients with chronic hepatitis C: a tertiary care center experience. 2008 , 14, 58-65	12
479	Role of hematopoietic growth factors as adjuncts in the treatment of chronic hepatitis C patients. 2008 , 14, 151-7	8
478	Prevalence of thyroid disorders in hepatitis C virus positive patients on interferon and antiviral therapy. 2016 , 6, 245-248	3
477	Interferon-Inducible protein-10 in chronic hepatitis C: Correlations with insulin resistance, histological features & sustained virological response. 2017 , 145, 543-550	2
476	Effect of CBT on Depressive Symptoms in Methadone Maintenance Patients Undergoing Treatment for Hepatitis C. 2011 , 2, 2-10	7
475	Risk factors and genotypes of hepatitis C virus infection in libyan patients. 2008 , 3, 162-5	11
474	Predictors of Complete Early Virological Response to Pegylated Interferon and Ribavirin in Egyptian Patients with Chronic Hepatitis C Genotype 4. 2013 , 03, 78-83	1
473	Impact of past HBV exposure on virological response to combined interferon ribavirin therapy in patients with chronic HCV genotype 4. 2011 , 01, 38-43	2
472	Clinical characteristics of null responders to Peg-IFN α 2b/ribavirin therapy for chronic hepatitis C. 2010 , 2, 401-5	5
471	Safety of pegylated interferon and ribavirin therapy for chronic hepatitis C in patients with sickle cell anemia. 2010 , 2, 180-4	8
470	Severe adverse events during antiviral therapy in hepatitis C virus cirrhotic patients: A systematic review. 2013 , 5, 120-6	22
469	Complementary and alternative medications in hepatitis C infection. 2014 , 6, 9-16	4
468	Telaprevir- and boceprevir-based tritherapies in real practice for F3-F4 pretreated hepatitis C virus patients. 2014 , 6, 660-9	13
467	Treatment of chronic hepatitis C in liver transplant candidates and recipients: Where do we stand?. 2015 , 7, 1606-16	3
466	Predictive factors associated with hepatitis C antiviral therapy response. 2015 , 7, 1617-31	58

465	Psychosocial assessment and monitoring in the new era of non-interferon-alpha hepatitis C virus treatments. 2015 , 7, 2209-13	8
464	Era of direct acting antivirals in chronic hepatitis C: Who will benefit?. 2015 , 7, 2543-50	8
463	Hepatitis C virus: A global view. 2015 , 7, 2676-80	71
462	Comparison of peg-interferon, ribavirin plus telaprevir vs simeprevir by propensity score matching. 2015 , 7, 2841-8	4
461	Evidence-based consensus on the diagnosis, prevention and management of hepatitis C virus disease. 2015 , 7, 616-27	25
460	Antiviral therapies for chronic hepatitis C virus infection with cirrhosis. 2015 , 7, 1133-41	18
459	Is the 25-year hepatitis C marathon coming to an end to declare victory?. 2017 , 9, 921-929	5
458	Liver decompensation predicts ribavirin overexposure in hepatitis C virus patients treated with direct-acting antivirals. 2017 , 9, 1270-1277	3
457	Efficacy and safety of sofosbuvir and ledipasvir in Japanese patients aged 75 years or over with hepatitis C genotype 1. 2017 , 9, 1340-1345	5
456	Future of liver disease in the era of direct acting antivirals for the treatment of hepatitis C. 2017 , 9, 352-367	37
455	Treatment of psychological co-morbidities in common gastrointestinal and hepatologic disorders. 2010 , 1, 64-71	11
454	Association of ITPA polymorphism with outcomes of peginterferon- α plus ribavirin combination therapy. 2013 , 4, 54-60	5
453	Recombinant interferon-Beta-1alpha plus ribavirin for the treatment of chronic HCV infection: a prospective, randomized, comparative pilot study. 2009 , 3, 20-5	5
452	Fatal Neutropenic Enterocolitis during Pegylated Interferon and Ribavirin Combination Therapy for Chronic Hepatitis C Virus Infection. 2009 , 3, 218-21	3
451	Delayed viral clearance of chronic hepatitis C in patients after treatment failure. 2011 , 5, 110-4	3
450	Efficacy and tolerability of peginterferon alpha plus ribavirin in the routine daily treatment of chronic hepatitis C patients in Korea: a multi-center, retrospective observational study. 2012 , 6, 98-106	21
449	Association between ITPA gene polymorphisms and hematological abnormalities in hepatitis C virus-infected patients receiving combination therapy. 2015 , 9, 214-23	4
448	Hepatitis C Virus and Antiviral Drug Resistance. 2016 , 10, 890-895	12

447	Final Report of Unmet Needs of Interferon-Based Therapy for Chronic Hepatitis C in Korea: Basis for Moving into the Direct-Acting Antiviral Era. 2017 , 11, 543-550	6
446	The Role of FGL2 in the Pathogenesis and Treatment of Hepatitis C Virus Infection. 2010 , 1, e0004	13
445	Retreatment of Chronic Hepatitis C Infection with Telaprevir: Preliminary Results in Turkey. 2015 , 32, 266-72	5
444	A significant upsurge of body mass index in patients with chronic hepatitis C successfully treated with direct-acting antiviral regimens. 2019 , 30, 708-713	4
443	Evaluation of an integrated care service facility for people living with hepatitis C in New Zealand. 2012 , 12, e229	11
442	Hepatitis C virus infection and dialysis: 2012 update. 2013 , 2013, 159760	20
441	Role of IL28B genotype in older hepatitis C virus-infected patients. 2013 , 3, 54	3
440	Identification of the most accessible sites to ribozymes on the hepatitis C virus internal ribosome entry site. 2003 , 36, 538-44	13
439	Does prophylactic antidepressant treatment boost interferon-alpha treatment completion in HCV?. 2013 , 2, 139-45	3
438	An Educational Initiative for Pharmacists to Inform Patients about Pegylated-Interferon and Ribavirin Combination Therapy in the Outpatient Clinic. 2012 , 38, 95-110	2
437	A comprehensive long-term prognosis of chronic hepatitis C patients with antiviral therapy: a meta-analysis of studies from 2008 to 2014. 2015 , 15, e27181	7
436	Rapid Virological Response Represents the Highest Prediction Factor of Response to Antiviral Treatment in HCV-Related Chronic Hepatitis: a Multicenter Retrospective Study. 2015 , 15, e18640	6
435	The role of interleukin-28b gene polymorphisms in chinese patients with chronic hepatitis C treated with pegylated interferon and ribavirin. 2014 , 14, e18793	8
434	Efficacy of 24-week pegylated interferon alpha and ribavirin combination therapy in highly selected patients infected with hepatitis C virus genotype 1. 2015 , 15, e24955	6
433	Safety and Efficacy of Adding Ribavirin to Interferon or Peginterferon in Treatment of Hepatitis C Infection in Patients With Thalassemia: A Systematic Review on Randomized Controlled Trials. 2016 , 16, e28537	6
432	Hepatitis C Virus Treatment Revolution: Eastern European Story. 2015 , 15, e28969	7
431	The ITPA and C20orf194 Polymorphisms and Hematological Changes During Treatment With Pegylated-Interferon Plus Ribavirin in Patients With Chronic Hepatitis C. 2016 , 16, e35278	4
430	Effectiveness and safety of first-generation protease inhibitors in real-world patients with hepatitis C virus genotype 1 infection in Brazil: a multicenter study. 2017 , 72, 378-385	3

429	Clinical Profiles of Chronic Hepatitis C in a Major County Medical Center Outpatient Setting in United States. 2004 , 1, 92-100	8
428	A practical approach to managing patients with HCV infection. 2006 , 3, 63-8	6
427	The role of hepatitis C virus genotyping in evaluating the efficacy of INF-based therapy used in treating hepatitis C infected patients in Libya. 2013 , 1, 3	4
426	Genotypes of hepatitis C virus in relapsed and non-respondent patients and their response to anti-viral therapy in district Mardan, Khyber Pakhtunkhawa, Pakistan. 2015 , 16, 1037-40	6
425	Inhibition of viral RNA-dependent RNA polymerases with clinically relevant nucleotide analogs. 2021 , 49, 315-354	2
424	Aging impairs fibrosis-4 index after sustained virologic response by direct-acting antivirals in chronic hepatitis C infection. 2021 , 27, 100566	0
423	Chronic Hepatitis C. 2022 , 163-201	
422	Serum Fetoprotein level at treatment completion is a useful predictor of hepatocellular carcinoma occurrence more than one year after hepatitis C virus eradication by direct-acting antiviral treatment. 2021 ,	1
421	Verbesserung der virologischen Ansprechrage durch Therapie mit pegyliertem Interferon alpha-2-b plus Ribavirin nach Lebertransplantation bei Hepatitis-C-Zirrhose. 2003 , 345-347	
420	L'effet immunomodulateur du VHC dans l'volution vers la chronicit' de l'hpatite C : vers de nouvelles approches thrapeutiques. 2003 , 187, 1147-1161	1
419	Viral response to therapy: viral dynamics. 2004 , 157-173	
418	Verordnungsprofil der Internisten. 2004 , 1013-1041	
417	Current and future therapy of chronic hepatitis. 2004 , 51-75	
416	Neue Arzneimittel. 2004 , 24-87	6
415	Problems inherent to antiviral therapy. 2004 , 203-238	
414	Current standard of care in hepatitis C virus infection. 2004 , 141-156	
413	Characterization of the Interferon Alpha Response Against HCV in Hepatoma Cells. 2004 , 123-130	
412	Hepatitis C. 2004 , 117-143	

- 411 Antiviral Treatment of Chronic Hepatitis B and C : Current Update. **2005**, 48, 440
- 410 The Usefulness of Combination Treatment with Interferon .BETA. Administered Twice-daily Followed by Interferon .ALPHA.-2b plus Ribavirin in Chronic Hepatitis C. **2005**, 46, 498-505
- 409 Ribavirin monotherapy increases sustained response rate in relapsers of end treatment virologic responders. **2005**, 11, 1663-7
- 408 Management of HIV/AIDS in Correctional Settings. **2005**, 449-487 2
- 407 Genotype of hepatitis virus. 3. Hepatitis C virus.. **2005**, 46, 480-485
- 406 Purification and Characterization of HCV RNA-dependent RNA Polymerase from Korean Genotype 1b Isolate: Implications for Discovery of HCV Polymerase Inhibitors. **2005**, 26, 285-291
- 405 État des connaissances sur l'hépatite C : épidémiologie, prise en charge et traitements actuels. **2005**, 189, 375-387
- 404 Challenges and Controversies in the Management of Hepatitis C Virus Infection (Part 1). **2005**, 2005,
- 403 [Efficacy and safety of peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C virus infection]. **2006**, 59, 415-9
- 402 Looking to the Future. **2006**, 101, S19-S25 2
- 401 Serum HCV core antigen level is a useful prediction marker of serum HCV RNA negative at 24-week-treatment with peginterferon and ribavirin in patients with chronic hepatitis C. **2006**, 47, 411-412
- 400 An early prognosis for the treatment of Chronic Hepatitis C patients with Pegylated Interferon-.ALPHA.2b plus Ribavirin-Monitoring analysis by the serum HCV core antigen values-. **2006**, 47, 355-356
- 399 [Treatment options for chronic hepatitis C virus infection]. **2006**, 59, 560-6
- 398 Hepatitis C: a challenge to hepatologists and to the liver transplantation team. **2006**, 21 Suppl 1, 15-8
- 397 Current Treatment of Hepatitis C and Hepatocellular Carcinoma. **2006**, 2, 108-114
- 396 Challenges and Controversies in the Management of Hepatitis C Virus Infection (Part 2). **2006**, 2006,
- 395 Prevention of Viral Hepatitis. **2007**, 127-155 1
- 394 Hepatitis B and C Viruses. **2007**, 411-424

- 393 Efficacy of a tailored regimen of peginterferon α 2b/ribavirin therapy for chronic hepatitis C, in which the treatment was maintained for 44 weeks after HCV RNA became undetectable at 5-24 weeks post initiation. **2007**, 48, 380-381
- 392 [A case of vasculitis in chronic hepatitis C patient treated with pegylated interferon alpha-2a and ribavirin]. **2007**, 13, 419-22
- 391 [Short-term therapy with pegylated interferon plus ribavirin for the chronic hepatitis C genotype 2 patients]. **2007**, 13, 341-8 1
- 390 Treatment of Chronic Hepatitis C Virus Infection in Older Adults. **2007**, 13, 432
- 389 Chronic Hepatitis. **2007**, 237-256
- 388 [Treatment of hepatitis C in patients on renal replacement therapy]. **2007**, 148, 489-94
- 387 Treatment of Hepatitis C Virus Infection in Patients before and after Renal Transplantation. **2007**, 1, 225-234
- 386 Experiences on Antiviral Treatment for Chronic Viral B and C Hepatitis in Hungary (1998-2004). A Nation-Wide Study. **2007**, 1, 207-219
- 385 Interferon in the Treatment of Viral Hepatitis. On the 50th Anniversary of Interferon's Discovery. **2007**, 1, 271-279
- 384 The Role and the Possibilities of Natural Interferon Treatment for Chronic Hepatitis C: Our Experiences with Natural Interferon Treatment for Patients Debarred from Combined Antiviral Therapy due to the STOP Rule. **2007**, 1, 331-339 1
- 383 Hepatitis C for addiction professionals. **2007**, 4, 34-41 1
- 382 Transplantation. **2008**, 631-704
- 381 Pegylated interferon α 2b/ribavirin combination therapy for elderly patients with chronic hepatitis C with high viral load of HCV genotype 1b. **2008**, 49, 145-152
- 380 Four-week pegylated interferon alpha-2a monotherapy for chronic hepatitis C with genotype 2 and low viral load: a pilot, randomized study. **2008**, 14, 7220-4 3
- 379 The Effectiveness of Combination Therapy with Peginterferon α 2a and Ribavirin in Chronic Hepatitis C. **2008**, 44, 72 1
- 378 Osmotic fragility of erythrocyte for the prediction of Ribavirin induced anemia in patients with chronic hepatitis C viral infection. **2008**, 49, 6-13
- 377 Nadir platelet and neutrophil counts during the course of PEG-IFN α 2b plus ribavirin combination therapy can be predicted by the values at week one: Towards achieving better efficacy. **2008**, 49, 239-247
- 376 A case of chronic hepatitis C in which a 72-week course of pegylated interferon and ribavirin combination therapy resulted in relapse but a subsequent interferon monotherapy could induce sustained virological response. **2008**, 49, 495-500

- 375 [Treatment of chronic hepatitis C: efficacy of initial treatment of peginterferon alpha-2a versus peginterferon alpha-2b plus ribavirin in naive chronic hepatitis C patients]. **2008**, 14, 443-5
- 374 Therapeutic Strategies Targeting the Innate Antiviral Immune Response. **2008**, 223-251
- 373 Antiviral Agents. **2008**, 29-36
- 372 0-2/0-4 ratios are predictor of virological non-response to pegylated interferon alpha-2b plus ribavirin therapy for patients with hepatitis C virus of genotype 1b and high viral load. **2008**, 49, 452-453
- 371 [Effectiveness of peg-interferon and ribavirin for hepatitis C in a patient with hypertension and diminished kidney function]. **2008**, 149, 889-92
- 370 Antiviral treatment for hepatitis C cirrhosis: is the effort justified?. **2008**, 149, 427-8
- 369 Les troubles psychiatriques liés au traitement de l'hépatite chronique C. **2009**, 80-92
- 368 Comorbidities in Black Patients with HIV/AIDS. **2009**, 159-177
- 367 État des lieux de la prise en charge psychiatrique et psychologique des patients VHC+ et VIH/VHC+ en France. **2009**, 8-15
- 366 INFECTIOUS HEPATITIS. **2009**, 527-547
- 365 Pegylated interferon alpha 2b for chronic hepatitis C.
- 364 Hepatitis B and C Viruses. **2009**, 53-66
- 363 State-of-the-Art Lecture: Treatment of hepatitis C. **2009**, 105-119
- 362 Pegylated interferon alpha 2a for chronic hepatitis C.
- 361 9 Virale hepatitis. **2009**, 83-99
- 360 Response-guided therapy in Japanese chronic hepatitis C patients infected with genotype 1b and high viral load. **2009**, 50, 687-702
- 359 HEPATITIS C VIRUS. **2009**, 2380-2394
- 358 Rapid virological response obtained by natural IFN for a patient of chronic hepatitis C with a high viral load of HCV genotype 1b who is refractory to peg-interferon + ribavirin combination therapy. **2009**, 50, 590-592

357 Pegylated Interferons in the Adjuvant Treatment of Melanoma. **2009**, 555-564

356 Anti-HCV Agents in Development. **2009**, 159-183

355 ANTIVIRAL AGENTS. **2009**, 3245-3271

354 Two HCV-related chronic hepatitis patients with Peg-interferon α 2a induced generalized rash. **2009**, 50, 565-570

2

353 Current and Future Therapy of Chronic Hepatitis C. **2009**, 71-96

352 Support of Patients During Antiviral Therapy for Hepatitis B and C. **2009**, 337-351

351 Pegylated interferon alpha 2a for chronic hepatitis C.

350 Interferon Signaling. **2010**, 189-200

2

349 Pegylated interferon alpha 2b for chronic hepatitis C.

348 Viral Hepatitis. **2010**, 100-106

347 Les nouveaux traitements anti-VHC, comment les utiliser? De la virologie à la clinique. **2010**, 233-237

346 Chapter 19 Chronic Liver Disease. **2010**,

0

345 Estimation of the Number of Sustained Viral Responders by Interferon Therapy Using Random Numbers with a Logistic Model. **2010**, 509-516

344 Viral Hepatitis. **2010**, 539-551.e1

343 Hepatitis C. **2010**, 1313-1335.e6

1

342 Use of hematopoietic growth factor in the management of hematological side effects associated to antiviral treatment for HCV hepatitis. **2010**, 2, e2010003

4

341 Drugs to treat viral hepatitis. **2010**, 1471-1476

340 Viral Illnesses. **2010**, 1700-1722

339 Hepatitis. **2010**, 608-616

338 A case of hepatitis C related cirrhosis with sustained virological response by a long-term, intermittent use of low-dose natural interferon-alpha. **2010**, 51, 6-12

1

337 Hepatitis C Virus.

336 Viral Hepatitis. **2010**, 315-327

335 Antiviral Therapy. **2010**, 210-225

334 Clearance of hepatitis C virus RNA from serum in HIV/hepatitis C virus coinfection indicates eradication from peripheral blood mononuclear cells. **2010**, 24, 1267-71

5

333 Baseline anti-NS4a antibodies in combination with on-treatment quantitative HCV-RNA reliably identifies nonresponders to pegylated interferon-ribavirin combination therapy after 4 weeks of treatment. **2010**, 22, 1443-8

1

332 Interferon Alfa. **2010**, 2959-2975

331 Drug-Induced Endocrine Autoimmunity. **2011**, 157-179

330 Viral Dynamic Modeling and Simulations in HIV and Hepatitis C. **2011**, 227-250

329 Liver. **2011**, 773-803

328 Leber-, Gallenwegs- und Pankreaserkrankungen. **2011**, 445-528

327 Molecular Detection and Characterization of Hepatitis C Virus. **2011**, 557-577

326 Comment optimiser le traitement de l'hépatite chronique virale C?. **2011**, 155-156

325 Viral Hepatitis C. **2011**, 427-432

2

324 Molecular Microbiology. **2011**, 27-59

7

323 Hepatitis C Virus. **2011**, 1437-1455

1

322 [Clubfoot in Uganda]. **2011**, 131, 8

- 321 Completion of chronic hepatitis C virus treatment in interferon-induced major depressive disorder with psychotic features. **2011**, 8, 381-3 2
- 320 The anti-viral effect and the influence on the values of ALT and AFP by low-dose PEG-IFN α treatment for prevention of cancer in patients with chronic hepatitis C. **2011**, 52, 94-101 1
- 319 Antiviral Agents. **2011**, 1687-1709
- 318 Digital ischemic necrosis caused by pegylated interferon in a patient with hepatitis C. **2011**, 2, 6-8 1
- 317 Antiviral therapy in patients after treatment for hepatitis C-related hepatocellular carcinoma. **2011**, 5, 77-81
- 316 [Syndrome distribution among patients with chronic hepatitis C and interventions of integrated traditional Chinese and Western medicine: study protocol]. **2011**, 9, 365-73
- 315 Hepatitis C: a patient's journey from a psychiatrist's perspective. **2011**, 17, 340-349
- 314 Epidemiology of Chronic HCV. **2012**, 3-11
- 313 Measuring HCV RNA and Assessing Virologic Response. **2012**, 149-157
- 312 Sex and Gender Differences in Gastroenterology and Hepatology. **2012**, 65-82
- 311 Long-Term Course of Patients with Mixed Cryoglobulinemia. **2012**, 219-226
- 310 Mutations and the Development of Anti-viral Resistance. **2012**, 227-249
- 309 The Genetics of Virologic Response. **2012**, 183-192
- 308 Response-Guided Therapy. **2012**, 159-169
- 307 Hepatitis C. 582-652
- 306 Treatment with Interferon and Ribavirin. **2012**, 115-130
- 305 Peginterferon, Ribavirin and Anti-viral Triple Therapy. **2012**, 251-260
- 304 Genotype 1: Standard Treatment. 65-73

303 Hepatitis C Genotype 4 Therapy: Progress and Challenges. 113-126

302 Individually Tailored Treatment Strategies in Treatment-naïve Chronic Hepatitis C Genotype 1 Patients. 74-83

301 Altered Dosage or Durations of Current Antiviral Therapy for HCV Genotypes 2 and 3. 97-103

300 Antivirals in Cirrhosis and Portal Hypertension. 132-139

299 Hepatitis C Virus Genotypes. 12-16

1

298 Cytopenias: How they Limit Therapy and Potential Correction. 160-168

297 Standard Therapy for Genotypes 2/3. 90-96

296 Genotype 1 Relapsers and Non-Responders. 84-89

295 A reduced dose of ribavirin does not influence the virologic response during pegylated interferon alpha-2b and ribavirin combination therapy in patients with genotype 1 chronic hepatitis C. **2012**, 18, 272-8

1

294 Response-guided therapy based on reaction to the initial dose using administration of peginterferon α 2a alone or in combination with ribavirin in naïve patients with chronic hepatitis C of serotype 2 and high viral loads. **2012**, 53, 18-27

293 Study of peginterferon alfa-2b plus ribavirin combination therapy in type C compensated liver cirrhosis. **2012**, 53, 803-813

292 The importance of a prior psychiatric examination in pegylated interferon and ribavirin combination treatment for chronic hepatitis C. **2012**, 59, 39-44

291 Chronic Hepatitis. **2012**, 171-186.e4

290 Novel biosensor-based microarray assay for detecting rs8099917 and rs12979860 genotypes. **2012**, 18, 6481-8; discussion p. 6487

1

289 A Case of Anti-Cyclic Citrullinated Peptide Antibody-Positive Rheumatoid Arthritis Following Peginterferon Alpha-2A and Ribavirin Therapy for Chronic Hepatitis C. **2012**, 83, 287

288 Experience of long-term low dose pegylated interferon therapy for chronic hepatitis C patients who cannot treat with standard of care therapy. **2012**, 53, 699-706

287 Chronic viral hepatitis C. 610-617

286 The A, B, Cs (+ D + E) of hepatitis. **2012**, 18, 75-84

- 285 Structure based virtual screening of inhibitors for binding at the allosteric site of HCV RNA dependent RNA polymerase. **2012**, 8, 716-9
- 284 Chronic Viral Hepatitis in Adults and Children: Hepatitis C. 208-225
- 283 Therapie der chronischen Hepatitis C. **2012**, 34,
- 282 Pegylated interferon and ribavirin combination therapy for chronic hepatitis C associated with thyroid dysfunction. **2013**, 54, 731-740
- 281 Liver. **2013**, 929-959
- 280 Leber, Gallenwege, Pankreas. **2013**, 144-169
- 279 Efficacy and safety of pegylated interferon^α-2a plus ribavirin treatment in refractory chronic hepatitis C patients -a multi-center study in Kyushu-. **2013**, 54, 266-276
- 278 Development Overview of Pegasys[®] (Pegylated interferon alpha -2a(40kD)). **2013**, 28, 189-196
- 277 Targeting Interferon- α to the Liver: Apolipoprotein A-I as a Scaffold for Protein Delivery. 441-452
- 276 Future directions in hepatitis C therapy. **2013**, 98-111
- 275 Hepatitis C Virus Testing. **2014**, 57-80
- 274 Pegylated interferon and ribavirin in the retreatment of chronic hepatitis C in Korea. **2013**, 7, 585-93
- 273 Treatment of Hepatitis C Before Liver Transplantation. **2014**, 1-14
- 272 Molecular-Genetic Testing in Hepatocellular Carcinoma and Its Premalignant Conditions. **2014**, 211-258
- 271 Improved Sustained Virological Response Following Treatment with Pegylated-Interferon Alpha-2b Compared with Alpha-2a, Both with Ribavirin, for Chronic Hepatitis C Infection with Genotypes 2 and 3. **2014**, 05, 111-117
- 270 Pharmacometrics of Viral Infections. **2014**, 259-295
- 269 Establishment of a Practical Workflow Using a Next Generation Sequencer to Search for Novel SNPs Associated with the Anti-HCV Treatment Response. **2014**, 60, 568-575
- 268 Liver Disease among Renal Transplant Recipients. **2014**, 511-536

267 Sequelae of Chronic Viral Hepatitis. 371-388

266 Plasticity of the Hepatitis C Virus Genome. 178-190

265 Clinical Aspects of Hepatitis C Virus Infection. 241-264

264 Evaluation of Safety and Pharmacokinetic Behavior of Unipeg[®] in Healthy Human Volunteers. **2014**, 4, 220-227

263 Epidemiology of Virus Infection and Human Cancer. **2015**, 23-47

1

262 Two Types of Viral Hepatitis, Two Different Treats from Pharma -What[®] After the Liver Meeting[®] 2014?. **2015**, 2,

261 Treatment results and factors affecting sustained virological response in chronic hepatitis C patients in Northern India. **2015**, 5, 24-30

260 Antiviral Drugs against Hepatitis Viruses. **2015**, 563-575.e3

259 Interferon- β polymorphisms in pegylated-interferon- α plus ribavirin therapy for genotype-2 chronic hepatitis C. **2015**, 21, 3904-11

258 Chronische Hepatitis. **2015**, 1-10

257 Importance of virological response in the early stage of telaprevir-based triple therapy for hepatitis C. **2015**, 7, 2688-95

256 Protease Inhibitor Resistance. **2015**, 1-17

255 Miscellaneous Antiviral Agents (Interferons, Imiquimod, Pleconaril). **2015**, 576-580.e2

254 . **2015**, 13,

253 Can laboratory parameters be predictive factors for treatment effectiveness of patients suffering from viral hepatitis C?. **2015**, 69, 91-98

252 Hepatic Disease. 121-133

251 Hepatitis C Virus Infection. 1939-1957

250 Acute Viral Hepatitis. 1886-1915

- 249 Association of the Treatment Induced Clearance of Hepatitis C Virus Infection with the IL28B Gene Polymorphisms. **2015**, 1, 005-008
- 248 Cryoglobulins and Cryoglobulinemia. **2016**, 633-645 1
- 247 Viral Variation and Response to Therapy. **2016**, 243-256
- 246 Tackling HCV-3 in Asia: Breakthroughs for Efficient and Cost-effective Treatment Strategies. **2016**, 6, 35-42
- 245 [Direct Acting Antivirals for Treatment of Hepatitis C Infection in Patients with Advanced Liver Disease]. **2016**, 67, 58-60
- 244 21. Chronic Liver Disease. **2016**,
- 243 Chronic Hepatitis B, C, and D. 69-95
- 242 Association of IL28B Genotypes and Baseline Serum Interferon-Inducible- Protein-10 Levels with Treatment Response in Hepatitis C Virus Patients in China. **2016**, 10, 446-55 2
- 241 Interferon-Free Treatments for Chronic Hepatitis C Genotype 1 Infection. **2016**, 4, 97-112 4
- 240 Immune Activation in the Liver by Nucleic Acids. **2016**, 4, 151-7 5
- 239 Current and Emerging Therapeutic Regimens for Patients with Chronic Hepatitis C Infection. **2016**, 3, 58-69
- 238 A real-world intention-to-treat analysis of a decade's experience of treatment of hepatitis C with interferon-based therapies. **2016**, 5, 2061 1
- 237 The Role of MicroRNA in Hepatitis C Virus Replication. **2013**, 1, 125-30
- 236 Genetic Variation in Interleukin-28B and Response to Peg-IFNα/ RBV Combination Therapy in Patients with Hepatitis C Virus Infection. **2016**, 10,
- 235 Resistance to Cyclophilin Inhibitors. **2017**, 59-85
- 234 Sexually Transmitted Infections and Male Infertility: Old Enigma, New Insights. **2017**, 183-212 1
- 233 Is the 25-year hepatitis C marathon coming to an end to declare victory?.
- 232 The Impact of Interleukin-28B rs12979860 Polymorphism on Peginterferon-alpha and Ribavirin Combination Therapy in Iranian Patients with Hepatitis C Virus Genotype 1 Infection. **2017**, 1,

- 231 Molecular Characterization of HCV and Introduction of Biorisk Management CWA 15793-2008 at DHQ Divisional Headquarters Teaching Hospital & MBBS Medical College, Chattar Parri, Mirpur District AJK. **2017**, 4,
- 230 Frequency of Hypothyroidism in Patients with Hepatitis C on Standard Interferon Therapy. **2017**, 2, 57-60
- 229 Sofosbuvir/simeprevir versus sofosbuvir/ribavirin regimen in Egyptian patients with hepatitis C virus. **2018**, 8, 6-11
- 228 Treatment of Hepatitis C with Pegylated Interferon Alpha-2a and Ribavirin: Experience from Benin. **2018**, 08, 275-283 1
- 227 Efficacy of direct-acting antiviral treatment for chronic hepatitis C: A single hospital experience. **2018**, 10, 88-94 0
- 226 A Closing Chapter: Hepatitis C Genotype 3 Elimination in Liver Transplant; Sofosbuvir/Daclatasvir in a Hard-to-Treat Population. **2018**, 16, 61-67 2
- 225 Appraisal of circulating biochemical markers and antioxidative activity in interferon intolerant HCV patients. **2018**, 5,
- 224 ORGANIZUOJANTI PNEUMONIJA. KLINIKINIS ATVEJIS. **2018**, 28, 66-70 1
- 223 Hepatitis C Virus and Innate Interferon Response: Pathogen Biology, Drug Resistance, Novel Drug Targets, and Therapeutic Strategies. **2019**, 233-249
- 222 Definition of the profiles of hepatitis C virus patients based on the identification of risky practices in Spain. **2019**, 111, 731-737 2
- 221 Erythrocyte Membrane Protein Band 3 Predicts Interferon Ribavirin-Induced Anemia. **2019**, 08, 5-16
- 220 Impact of Direct Acting Antivirals on Survival in Patients with Chronic Hepatitis C and Hepatocellular Carcinoma.
- 219 Neurocognitive impairment and cerebral metabolic alterations induced by direct hepatitis C virus neuroinvasion: implications on quality of life. **2019**, 60,
- 218 Chronic hepatitis C: modern condition of the problem. **2019**, 23, 36-46 1
- 217 Pangenotypic treatment regimens for chronic hepatitis C. **2019**, 65, 553-563
- 216 PROFILE OF HCV GENOTYPES AND HIV-SUBTYPES AMONG HIV-COINFECTED PATIENTS IN SOUTHERN BRAZIL. **2019**, 56, 344-350 1
- 215 [Antiviral therapy of chronic hepatitis C: 30 years success story]. **2019**, 91, 110-115 1
- 214 Hepatitis C virus (HCV) : Development of anti-HCV agents and anti-HCV therapy. **2020**, 132, 131-143

- 213 Detection and distribution of genotypes of Hepatitis C in a tertiary care hospital. **2020**, 9, 5249-5251 o
- 212 Emerging Management of Hepatitis C in Transplant. **2020**, 1-20
- 211 Restoration of HBV-specific CD8 T-cell responses by sequential low-dose IL-2 treatment in non-responder patients after IFN- α therapy. **2021**, 6, 376 4
- 210 Twenty-year follow-up of an outbreak of hepatitis C in a small rural town of Argentina: The O'Brien Project. **2021**, 100577 o
- 209 Hepatitis in the clinics Treatment options. **2008**, 1-20
- 208 Chronic hepatitis C: Portrait of a silent epidemic and the etiologic agent. **2008**, 95-120
- 207 Krankheiten der Leber und Gallenwege. **2008**, 409-419
- 206 Current therapy of hepatitis C. 109-114
- 205 Hepatitiden. **2005**, 779-804
- 204 Akute und chronische infektiöse Hepatitiden. **2005**, 819-828
- 203 Treatment of Chronic Hepatitis C in Difficult-to-Treat Patients in the Clinical Setting. **2008**, 192-214
- 202 Effects of Combined IFN-Alpha/Ribavirin Treatment in HCV Disease-Related Progression. **2008**, 215-236
- 201 Mechanisms of Interferon Action and Resistance in Chronic Hepatitis C Virus Infection: Lessons Learned from Cell Culture Studies. **2008**, 16-38
- 200 Treatment of Chronic Hepatitis C with Different Genotypes. **2008**, 130-147 2
- 199 Interferon-Based Therapy for Hepatitis C Virus Infections. **2008**, 168-191
- 198 Prophylaxe und Therapie der Hepatitis A, B und C. **2007**, 107-116
- 197 Akute und chronische infektiöse Hepatitiden. **2007**, 901-910
- 196 Impact of different anti-HCV regimens on platelet count during treatment in Egyptian patients. **2020**, 10,

195	Hepatitis C Infection in Hemodialysis Patients. 2018 , 44, 107-112	2
194	Clinical applications of molecular biology for infectious diseases. 2006 , 27, 39-51	48
193	Paternal use of ribavirin-interferon alpha 2B combination therapy before conception. 2005 , 51, 1623-5	3
192	A case of cutaneous vasculitis with underlying hepatitis C and cryoglobulinaemia. 2008 , 77, 51-3	3
191	Early experience with chronic hepatitis C in Northern Ireland: epidemiology and response to monotherapy. 2004 , 73, 25-31	1
190	Treatment of intravenous drug users with chronic hepatitis C: treatment response, compliance and side effects. 2007 , 11, 196-8	7
189	Racial differences in hepatitis B and hepatitis C and associated risk behaviors in veterans with severe mental illness. 2004 , 96, 43-52	14
188	Sustained virological response rate to pegylated interferon plus ribavirin for chronic hepatitis C in African Americans: results in treatment-naïve patients in a university liver clinic. 2005 , 97, 1703-7	12
187	Use of fMRI to predict psychiatric adverse effects of interferon treatment for Hepatitis C - preliminary report. 2007 , 3, 655-67	2
186	Antiviral combination therapy with interferon/peginterferon plus ribavirin for patients with chronic hepatitis C in Germany: a health technology assessment commissioned by the German Agency for Health Technology Assessment. 2003 , 1, Doc07	1
185	Management of chronic hepatitis C treatment failures: role of consensus interferon. 2009 , 3, 141-50	7
184	Management of chronic hepatitis C: consensus guidelines. 2007 , 21 Suppl C, 25C-34C	49
183	On-treatment predictions of success in peg-interferon/ribavirin treatment using a novel formula. 2010 , 16, 89-97	2
182	Guidelines for the Prevention and Treatment of Opportunistic Infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics. 2009 , 58, 1-166	86
181	Modelling hepatitis C virus kinetics: the relationship between the infected cell loss rate and the final slope of viral decay. <i>Antiviral Therapy</i> , 2009 , 14, 459-64	1.6 16
180	Antiviral potency analysis and functional comparison of consensus interferon, interferon-alpha2a and pegylated interferon-alpha2b against hepatitis C virus infection. <i>Antiviral Therapy</i> , 2008 , 13, 851-62	1.6 7
179	Treatment options for HCV nonresponders and relapse patients. 2010 , 6, 1-12	1
178	Skin rash during chronic hepatitis C therapy. 2010 , 6, 323-5	4

177	Hepatitis C Virus Therapy-related Skin Manifestations. 2010 , 6, 326-8	1
176	Health-related quality of life in Greek chronic hepatitis C patients during pegylated interferon and ribavirin treatment. 2010 , 14, 122-5	7
175	Hepatitis C (chronic). 2010 , 2010,	
174	Management of recurrent hepatitis C following liver transplantation. 2010 , 6, 637-45	7
173	Treatment, care and support for people co-infected with HIV and hepatitis C: a scoping review. 2009 , 3, e184-95	1
172	The practical management of treatment failure in chronic hepatitis C: a summary of current research and management options for refractory patients. 2007 , 3, 4-32	2
171	Mechanism of action of ribavirin in the treatment of chronic hepatitis C. 2007 , 3, 218-25	48
170	Emerging therapies for chronic hepatitis C virus. 2008 , 4, 729-34	1
169	Hepatitis C Virus-related Mixed Cryoglobulinemia: Pathogenesis, Clinical Manifestations, and New Therapies. 2007 , 3, 695-703	12
168	IL-28B As a Predictor of Sustained Virologic Response in Patients with Chronic Hepatitis C Virus Infection. 2011 , 7, 366-73	5
167	Effect of ribavirin alone or combined with silymarin on carbon tetrachloride induced hepatic damage in rats. 2007 , 2, 19-27	6
166	The optimal dose of ribavirin for chronic hepatitis C: From literature evidence to clinical practice: The optimal dose of ribavirin for chronic hepatitis C. 2011 , 11, 240-6	10
165	Which is the IDEAL peginterferon for Hepatitis C: a meta-analysis of both pegylated interferons in the treatment of HCV-infected patients. 2010 , 10, 229-30	
164	Advances in the treatment of hepatitis C virus infection. 2012 , 8, 91-101	8
163	Viral hepatitis in Hawai'i--differing perspectives. 2010 , 69, 3-20	2
162	Evolution of viral RNA in a Chinese patient to interferon/ribavirin therapy for hepatitis C. 2012 , 24, 353-60	
161	Management of hepatitis C virus infection: the basics. 2012 , 20, 154-61	14
160	A SPECIAL MEETING REVIEW EDITION: Advances in the Treatment of Hepatitis C Virus Infection From EASL 2013: The 48th Annual Meeting of the European Association for the Study of the Liver April 24-28, 2013 Amsterdam, The Netherlands Special Reporting on: Simeprevir Plus Peginterferon/Ribavirin Is Associated with a High SVR12 Rate in Treatment-Naïve Patients with Genotype 1 Hepatitis C Virus Infection Addition of Simeprevir to Peginterferon/Ribavirin Is Associated with Faster Resolution of Fatigue in Treatment-Naïve Patients with Genotype 1 Hepatitis C Virus Infection. 2013 , 9, 1-18	6

159	Balapiravir plus peginterferon alfa-2a (40KD)/ribavirin in a randomized trial of hepatitis C genotype 1 patients. 2012 , 11, 15-31	18
158	Impact of new therapeutics for hepatitis C virus infection in incarcerated populations. 2013 , 21, 27-35	23
157	Success of antiviral therapy in chronic hepatitis C infection relates to functional status of myeloid dendritic cells. 2013 , 138, 766-78	4
156	Hepatitis C treatment & management. 2014 , 7, 31-6	1
155	Sofosbuvir plus ribavirin as a treatment alternative for chronic HCV genotype 2 or 3 patients unable to benefit from standard therapy. 2013 , 9, 679-81	
154	Commentary: sofosbuvir for treatment of hepatitis C virus genotype 2 or 3 infection in patients without treatment options. 2013 , 9, 682-3	
153	Frontiers in the treatment of hepatitis C virus infection. 2014 , 10, 90-100	7
152	Estimation of average diagnosis and treatment costs of hepatitis C. 2012 , 5, 139-45	6
151	Using statistical models to assess medical cost of hepatitis C virus. 2012 , 5, S31-6	4
150	Statistical count models for prognosis the risk factors of hepatitis C. 2013 , 6, 41-7	1
149	HCV infection treatment: a future full of hope. 2013 , 6, 1-5	2
148	Random effect model for identifying related factors to virological response in HCV patients. 2013 , 6, S65-9	
147	Evaluated outcomes in patients with Chronic Hepatitis C. 2013 , 6, S58-64	2
146	Statin efficacy in the treatment of hepatitis C genotype I. 2014 , 19, S1-4	2
145	Genotype 4 HCV infection is difficult to cure with pegylated interferon and ribavirin. Results from a Greek Nationwide Cohort Study. 2014 , 18, 57-64	5
144	Hepatocellular carcinoma in the world and the middle East. 2010 , 2, 31-41	30
143	Pegaferon in hepatitis C: Results of a Multicenter Study. 2011 , 3, 110-4	8
142	Ribavirin induced anaemia: the effect of vitamin D supplementation on erythropoietin and erythrocyte indices in normal Wistar rat. 2014 , 7, 2667-76	11

141	Interleukin-28B (rs12979860) gene variation and treatment outcome after peginterferon plus ribavirin therapy in patients with genotype 1 of hepatitis C virus. 2014 , 19, 1062-7	4
140	Is response-guided therapy being applied in the clinical setting? The hepatitis C example. 2015 , 8, 22-8	2
139	Vitamin D and chronic hepatitis C: effects on success rate and prevention of side effects associated with pegylated interferon- α and ribavirin. 2015 , 8, 10284-303	2
138	Viekira Pak (Ombitasvir, Paritaprevir, and Ritonavir Tablets; Dasabuvir Tablets): All-Oral Fixed Combination Approved for Genotype 1 Chronic Hepatitis C Infection. 2015 , 8, 142-7	60
137	Once-a-Day Harvoni (Ledipasvir plus Sofosbuvir), a New Oral Combination for the Treatment of Patients with Genotype 1 Chronic Hepatitis C Infection. 2015 , 8, 54-8	8
136	Rs12979860 and rs8099917 single nucleotide polymorphisms of interleukin-28B gene: simultaneous genotyping in caucasian patients infected with hepatitis C virus. 2013 , 54, 83-6	7
135	Antiviral Therapy in Elderly Patients With Hepatitis C Virus Infection. 2015 , 11, 294-346	4
134	HIV-HCV Coinfection. 2006 , 2, 357-365	
133	Update on the Use of Consensus Interferon in Difficult-to-Treat Hepatitis C Patients: A Review of Selected Posters From Digestive Disease Week May 20-25, 2006 Los Angeles, Calif. With commentary by: Fred Poordad, MDCedars-Sinai Medical Center Los Angeles, Calif. 2006 , 2, 1-12	
132	Advances in the Treatment of Hepatitis B and Hepatitis C Nonresponders: A Report of Symposia Presented at the 15th Conference of the Asian Pacific Association for the Study of the Liver August 18-21, 2005 Bali, Indonesia. 2006 , 2, 1-16	
131	Treatment Related Hematologic Changes in a Population of Iranian Patients with Chronic Hepatitis C Infection from 2009 to 2014. 2017 , 46, 1386-1394	1
130	Noninvasive Assessment of Fibrosis Regression in Hepatitis C Virus Sustained Virologic Responders. 2017 , 13, 587-595	7
129	Increasing hepatitis C screening in a large integrated health system: science and policy in concert. 2018 , 24, e134-e140	4
128	Positive and Negative Predictive Factors for Treatment Response in Patients with Chronic Viral C Hepatitis. 2017 , 43, 318-324	
127	Heart Transplantation Outcomes in Patients With Hepatitis C Virus Infection: Potential Impact of Newer Antiviral Treatments After Transplantation. 2017 , 34, S40-S48	
126	The State of Hepatitis C Care in the VA. 2015 , 32, 20S-24S	
125	Phase I/II study protocol to assess safety and efficacy of adoptive cell therapy with anti-PD-1 plus low-dose pegylated-interferon-alpha in patients with metastatic melanoma refractory to standard of care treatments: the ACTME trial. 2020 , 10, e044036	1
124	Development and Validation of Head-space Gas Chromatographic Method in Tandem with Flame ionized detection for the determination of Residual solvents in Simeprevir API Synthesis. 2021 , 5175-5181	

- 123 Perioperative Management of Hepatitis C in Patients Undergoing Total Joint Arthroplasty. **2021**, 9, 0
- 122 Aptamer-Based Antibacterial and Antiviral Therapy against Infectious Diseases. **2021**, 1
- 121 Chronic Viral Hepatitis. **2003**, 24, 399-410 1
- 120 Are There Still Difficult-to-Treat Patients with Chronic Hepatitis C in the Era of Direct-Acting Antivirals?. *Viruses*, **2022**, 14, 6.2 1
- 119 Hepatitis C virus: A critical approach to who really needs treatment.. **2022**, 14, 1-44
- 118 Development of Pharmaceutical Nanomedicines: From the Bench to the Market.. **2022**, 14, 11
- 117 Machine learning for mathematical models of HCV kinetics during antiviral therapy. **2021**, 108756 2
- 116 Nurse practitioners as primary care site champions for the screening and treatment of hepatitis C virus.. **2022**,
- 115 Effect of Silymarin as an Adjunct Therapy in Combination with Sofosbuvir and Ribavirin in Hepatitis C Patients: A Miniature Clinical Trial.. **2022**, 2022, 9199190 1
- 114 The knowledge on HCV. **2022**, Publish Ahead of Print, 0
- 113 Hepatitis C Virus NS3/4A Inhibition and Host Immunomodulation by Tannins from : A Structural Perspective.. **2022**, 27, 1
- 112 The Impact of Direct-Acting Antiviral Therapy on the Risk of Recurrence after Curative Resection in Patients with Hepatitis-C-Virus-Related Early Stage Hepatocellular Carcinoma.. **2022**, 58, 0
- 111 Phase I/II study protocol to assess safety and efficacy of adoptive cell therapy with anti-PD-1 plus low-dose pegylated-interferon-alpha in patients with metastatic melanoma refractory to standard of care treatments: the ACTME trial. **2020**, 10, e044036 0
- 110 Synergistic Interferon-Alpha-Based Combinations for Treatment of SARS-CoV-2 and Other Viral Infections.. *Viruses*, **2021**, 13, 6.2 4
- 109 Low Incidence of Hepatocellular Carcinoma after Antiviral Therapy in Patients with Chronic Hepatitis C and Hemophilia.. **2022**, 11,
- 108 Clinical and Molecular Basis of Hepatocellular Carcinoma after Hepatitis C Virus Eradication.. **2022**, 11, 1
- 107 Hesperidin identified from Citrus extracts potently inhibits HCV genotype 3a NS3 protease.. **2022**, 22, 98 1
- 106 Cell Trafficking at the Intersection of the Tumor-Immune Compartments.. **2022**, 1

105	Fighting Enteroviral Infections to Prevent Type 1 Diabetes.. 2022 , 10,		1
104	PEGylated Nanoparticles as a Versatile Drug Delivery System. 2022 , 309-341		1
103	Diastereoselective Synthesis of 2'-Dihalopyrimidine Ribonucleoside Inhibitors of Hepatitis C Virus Replication.. 2022 , 7, 1452-1461		0
102	Pharmacodynamic and therapeutic pilot studies of single-agent ribavirin in patients with human papillomavirus-related malignancies.. 2022 , 128, 105806		0
101	The combination of PD-1 blockade with interferon- γ has a synergistic effect on hepatocellular carcinoma.. 2022 ,		1
100	The curing regimens of HCV: A SWOT analysis.. <i>Antiviral Therapy</i> , 2022 , 27, 13596535211072672	1.6	0
99	Hepatitis C virus eradication ameliorates the prognosis of advanced hepatocellular carcinoma treated with sorafenib.. 2022 ,		0
98	Interferon-alfa: um interferente end�rino. 2021 , 95-122		
97	Viral Dynamics and Pharmacokinetics of Peginterferon Alpha-2A and Peginterferon Alpha-2B in Naive Patients with Chronic Hepatitis C: A Randomized, Controlled Study. <i>Antiviral Therapy</i> , 2004 , 9, 491-497	1.6	68
96	Hepatitis C Virus-Rna Clearance in HIV-Coinfected Patients with Chronic Hepatitis C Treated with Pegylated Interferon plus Ribavirin. <i>Antiviral Therapy</i> , 2004 , 9, 505-509	1.6	21
95	Clinical Outcome to Interferon Therapy in Chronic Hepatitis C: Insights from Mechanistic Studies. <i>Antiviral Therapy</i> , 2004 , 9, 637-639	1.6	
94	Pkr Gene Expression and Response to Pegylated Interferon plus Ribavirin Therapy in Chronic Hepatitis C. <i>Antiviral Therapy</i> , 2004 , 9, 763-770	1.6	8
93	Depressive Symptoms after Initiation of Interferon Therapy in Human Immunodeficiency Virus-Infected Patients with Chronic Hepatitis C. <i>Antiviral Therapy</i> , 2004 , 9, 905-909	1.6	21
92	Mitochondrial Effects of a 24-Week Course of Pegylated-Interferon plus Ribavirin in Asymptomatic HCV/HIV Co-Infected Patients on Long-Term Treatment with Didanosine, Stavudine or Both. <i>Antiviral Therapy</i> , 2004 , 9, 969-977	1.6	1
91	The Role of Hepatitis C Virus (HCV) in Mitochondrial Dna Damage in HIV/HCV-Coinfected Individuals. <i>Antiviral Therapy</i> , 2005 , 10, 109-115	1.6	5
90	Area-Under-The-Curve for Peginterferon Alpha-2A and Peginterferon Alpha-2B is Not Related to Body Weight in Treatment-Naive Patients with Chronic Hepatitis C. <i>Antiviral Therapy</i> , 2005 , 10, 201-205	1.6	7
89	Open, Randomized, Multicentre Italian Trial on Peg-Ifn plus Ribavirin versus Peg-Ifn Monotherapy for Chronic Hepatitis C in HIV-Coinfected Patients on Haart. <i>Antiviral Therapy</i> , 2005 , 10, 309-317	1.6	28
88	Oligonucleotide-Based Therapeutic Options against Hepatitis C Virus Infection. <i>Antiviral Therapy</i> , 2006 , 11, 273-287	1.6	7

87	Incidence and Risk Factors for Mitochondrial Toxicity in Treated HIV/HCV-Coinfected Patients. <i>Antiviral Therapy</i> , 2005 , 10, 423-429	1.6	25
86	Future Therapies for Hepatitis C. <i>Antiviral Therapy</i> , 2006 , 11, 397-408	1.6	21
85	Impact of Steatosis on Long-Term Histological Outcome in Chronic Hepatitis C after Antiviral Therapy. <i>Antiviral Therapy</i> , 2006 , 11, 483-489	1.6	12
84	Evolution of Hepatitis C Virus Quasispecies during Therapy with IL2 Combined to Alpha Interferon and Ribavirin. <i>Antiviral Therapy</i> , 2005 , 10, 499-504	1.6	1
83	Mitochondrial Dna Depletion in HIV-Infected Patients is More Pronounced with Chronic Hepatitis C and Enhanced following Treatment with Pegylated Interferon plus Ribavirin. <i>Antiviral Therapy</i> , 2005 , 10, 557-561	1.6	5
82	The Clinical Utility of Using Catrimox-14-Treated Whole Blood in Detecting Hepatitis C Virus RNA. <i>Antiviral Therapy</i> , 2005 , 10, 535-541	1.6	2
81	Amino Acid Variations in Hepatitis C Virus P7 and Sensitivity to Antiviral Combination Therapy with Amantadine in Chronic Hepatitis C. <i>Antiviral Therapy</i> , 2006 , 11, 507-519	1.6	31
80	Results of a Study of Prolonging Treatment with Pegylated Interferon-2A plus Ribavirin in HIV/HCV-Coinfected Patients with No Early Virological Response. <i>Antiviral Therapy</i> , 2006 , 11, 473-482	1.6	14
79	Impact of Ribavirin Exposure on Early Virological Response to Hepatitis C Therapy in HIV-Infected Patients with Chronic Hepatitis C. <i>Antiviral Therapy</i> , 2005 , 10, 657-662	1.6	18
78	A Randomized, Double-Blind, Placebo-Controlled Dose-Escalation Trial of Merimepodib (VX-497) and Interferon-2n Previously Untreated Patients with Chronic Hepatitis C. <i>Antiviral Therapy</i> , 2005 , 10, 635-643	1.6	22
77	Defective Synthesis of Granulocyte-Colony Stimulating Factor in Pegylated Interferon-2-Treated Chronic Hepatitis C Patients with Declining Leukocyte Counts. <i>Antiviral Therapy</i> , 2006 , 11, 637-640	1.6	4
76	Treating Hepatitis C in HIV-Infected Patients: Where are We Now?. <i>Antiviral Therapy</i> , 2005 , 10, 691-694	1.6	
75	The Impact of Haematopoietic Growth Factors on the Management and Efficacy of Antiviral Treatment in Patients with Hepatitis C Virus. <i>Antiviral Therapy</i> , 2005 , 10, 769-776	1.6	26
74	Baseline Factors associated with Haematological Toxicity that Leads to a Dosage Reduction of Pegylated Interferon-2a and Ribavirin in HIV- and HCV-Coinfected Patients on HCV Antiviral Therapy. <i>Antiviral Therapy</i> , 2005 , 10, 841-847	1.6	12
73	Resistance of Hepatitis C Virus to Ns3/4A Protease Inhibitors: Mechanisms of Drug Resistance Induced by R155Q, A156T, D168A and D168V Mutations. <i>Antiviral Therapy</i> , 2006 , 11, 847-856	1.6	30
72	Low-level HCV Viraemia after Initial Response during Antiviral Therapy: Transcription-Mediated Amplification Predicts Treatment Failure. <i>Antiviral Therapy</i> , 2007 , 12, 423-428	1.6	4
71	The Magnitude of Week 4 HCV RNA Decay on Pegylated Interferon/Ribavirin Accurately Predicts Virological Failure in Patients with Genotype 1. <i>Antiviral Therapy</i> , 2007 , 12, 401-406	1.6	5
70	Evolution of T-cell Responses to Hepatitis C Virus (HCV) during Pegylated Interferon plus Ribavirin treatment in HCV-Monoinfected and in HCV/HIV-Coinfected Patients. <i>Antiviral Therapy</i> , 2007 , 12, 459-468	1.6	7

69	Rapid virological response at week 4 predicts response to pegylated interferon plus ribavirin among HIV/HCV-coinfected patients. <i>Antiviral Therapy</i> , 2007 , 12, 523-529	1.6	15
68	Premature Treatment Discontinuation in HIV/HCV-Coinfected Patients Receiving Pegylated Interferon plus Weight-Based Ribavirin. <i>Antiviral Therapy</i> , 2007 , 12, 469-476	1.6	11
67	Dynamics of Apoptotic Activity during Antiviral Treatment of Patients with Chronic Hepatitis C. <i>Antiviral Therapy</i> , 2007 , 12, 779-787	1.6	6
66	Effect of Ribavirin on the Hepatitis C Virus (JFH-1) and its Correlation with Interferon Sensitivity. <i>Antiviral Therapy</i> , 2007 , 12, 805-813	1.6	20
65	Lack of Rapid Virological Response Predicts Interferon- α /Ribavirin Therapy Failure in HCV Genotype 2 Patients: A Single-Centre Study. <i>Antiviral Therapy</i> , 2007 , 12, 1033-1040	1.6	7
64	Early Monitoring of Ribavirin Serum Concentration is not Useful to Optimize Hepatitis C Virus treatment in HIV-Coinfected Patients. <i>Antiviral Therapy</i> , 2007 , 12, 1217-1224	1.6	12
63	Predictors of Severe Haematological Toxicity Secondary to Pegylated Interferon plus Ribavirin Treatment in HIV-HCV-Coinfected Patients. <i>Antiviral Therapy</i> , 2007 , 12, 1225-1236	1.6	25
62	Ribavirin considerations in treatment optimization. <i>Antiviral Therapy</i> , 2008 , 13, 23-30	1.6	13
61	Effect of Antiviral Treatment on Serum Markers of Liver Fibrosis in HIV/Hepatitis C virus-Coinfected Patients: The Fibrovic 2 Study [ANRS HC02]. <i>Antiviral Therapy</i> , 2009 , 14, 211-219	1.6	19
60	Should Treatment of Hepatitis B Depend on Hepatitis B virus Genotypes? A Hypothesis Generated from an Explorative Analysis of Published Evidence. <i>Antiviral Therapy</i> , 2008 , 13, 211-220	1.6	84
59	Modelling Hepatitis C virus Kinetics: The Relationship between the Infected Cell Loss rate and the Final Slope of Viral Decay. <i>Antiviral Therapy</i> , 2009 , 14, 459-464	1.6	25
58	Very Early Viral Kinetics on Interferon Treatment in Chronic Hepatitis C virus Genotype 4 Infection. <i>Antiviral Therapy</i> , 2008 , 13, 581-589	1.6	3
57	Virological response at 4 weeks to predict outcome of hepatitis C treatment with pegylated interferon and ribavirin. <i>Antiviral Therapy</i> , 2009 , 14, 501-511	1.6	44
56	Antiviral Treatment for Chronic Hepatitis C in Illicit drug Users: A Systematic Review. <i>Antiviral Therapy</i> , 2009 , 14, 467-479	1.6	8
55	Distinct Hepatitis C virus Kinetics in HIV-Infected Patients Treated with Ribavirin plus Either Pegylated Interferon α a or α b. <i>Antiviral Therapy</i> , 2008 , 13, 511-517	1.6	5
54	Rapid decrease of wild-type hepatitis C virus on telaprevir treatment. <i>Antiviral Therapy</i> , 2009 , 14, 591-595	1.6	30
53	Prediction of Sustained Virological Response by Ribavirin Plasma Concentration at Week 4 of Therapy in Hepatitis C virus Genotype 1 Patients. <i>Antiviral Therapy</i> , 2008 , 13, 607-611	1.6	48
52	Naturally occurring substitutions conferring resistance to hepatitis C virus polymerase inhibitors in treatment-naïve patients infected with genotypes 1b. <i>Antiviral Therapy</i> , 2009 , 14, 723-730	1.6	11

51	Pegylated Interferon- α 2b plus Ribavirin: An Efficacious and well-Tolerated Treatment Regimen for Patients with Hepatitis C virus Related Histologically Proven Cirrhosis. <i>Antiviral Therapy</i> , 2008 , 13, 663-673	1.6	30
50	Dynamic Evolution of Therapy for Chronic Hepatitis C: How will Novel Agents be Incorporated into the Standard of Care?. <i>Antiviral Therapy</i> , 2008 , 13, 747-760	1.6	11
49	Antiviral Potency Analysis and Functional Comparison of Consensus Interferon, Interferon- α 2a and Pegylated Interferon- α 2b against Hepatitis C virus Infection. <i>Antiviral Therapy</i> , 2008 , 13, 851-862	1.6	16
48	IP-10 Correlates with Hepatitis C Viral Load, Hepatic Inflammation and Fibrosis and Predicts Hepatitis C Virus Relapse or Non-Response in HIV/HCV Coinfection. <i>Antiviral Therapy</i> , 2008 , 13, 969-976	1.6	65
47	Differences in Virological Response to Pegylated Interferon and Ribavirin between Hepatitis C Virus (Hcv)-Monoinfected and HCV/Hiv-Coinfected Patients. <i>Antiviral Therapy</i> , 2008 , 13, 1047-1055	1.6	13
46	Safety, pharmacokinetics and antiviral effect of BILB 1941, a novel hepatitis C virus RNA polymerase inhibitor, after 5 days oral treatment. <i>Antiviral Therapy</i> , 2009 , 14, 23-32	1.6	50
45	Management of Hepatitis C virus Genotype 2 or 3 Infection: Treatment Optimization on the Basis of Virological Response. <i>Antiviral Therapy</i> , 2009 , 14, 143-154	1.6	14
44	The pattern of pegylated interferon- α 2b and ribavirin treatment failure in cirrhotic patients depends on hepatitis C virus genotype. <i>Antiviral Therapy</i> , 2009 , 14, 577-584	1.6	28
43	Virological Effects of Isis 14803, An Antisense Oligonucleotide Inhibitor of Hepatitis C Virus (HCV) Internal Ribosome Entry Site (IRES), on HCV Ires in Chronic Hepatitis C Patients and Examination of the Potential Role of Primary and Secondary HCV Resistance in the Outcome of Treatment. <i>Antiviral Therapy</i> , 2004 , 9, 953-968	1.6	27
42	Viral Interaction and Responses in Chronic Hepatitis C and B Coinfected Patients with Interferon-Alpha plus Ribavirin Combination Therapy. <i>Antiviral Therapy</i> , 2005 , 10, 125-133	1.6	58
41	Response to Interferon-Based Therapies in HIV-Infected Patients with Chronic Hepatitis C Due to Genotype 4. <i>Antiviral Therapy</i> , 2005 , 10, 167-170	1.6	8
40	Impaired Response to Interferon- α 2B plus Ribavirin in Cirrhotic Patients with Genotype 3A Hepatitis C Virus Infection. <i>Antiviral Therapy</i> , 2006 , 11, 797-802	1.6	14
39	A Sustained Virological Response to Interferon or Interferon/Ribavirin Reduces Hepatocellular Carcinoma and Improves Survival in Chronic Hepatitis C: A Nationwide, Multicentre Study in Taiwan. <i>Antiviral Therapy</i> , 2006 , 11, 985-994	1.6	133
38	Optimizing outcomes in patients with hepatitis C virus genotype 1 or 4. <i>Antiviral Therapy</i> , 2008 , 13, 9-16	1.6	22
37	A Phase I/II Study Evaluating Escalating Doses of Recombinant Human Albumin-Interferon- α 2 Fusion Protein in Chronic Hepatitis C Patients who have Failed Previous Interferon-Based Therapy. <i>Antiviral Therapy</i> , 2006 , 11, 35-45	1.6	46
36	Outcome of Chronic Hepatitis C Patients who Required Early Termination of Pegylated Interferon- α 2 plus Ribavirin Combination Therapy. <i>Antiviral Therapy</i> , 2006 , 11, 1015-1020	1.6	23
35	Optimizing Treatment Outcomes in Chronic Hepatitis C: Management of Non-Response. <i>Antiviral Therapy</i> , 2006 , 11, 955-970	1.6	1
34	Response-Guided Therapy: Optimizing Treatment now and in the Future. <i>Antiviral Therapy</i> , 2008 , 13, 1-2	1.6	179

33	Hepatitis C virus therapy to date. <i>Antiviral Therapy</i> , 2008 , 13, 3-8	1.6	18
32	HCV Treatment in Decompensated Disease. <i>Current Hepatology Reports</i> ,	1	
31	Breakthroughs in hepatitis C research: from discovery to cure. <i>Nature Reviews Gastroenterology and Hepatology</i> ,	24.2	5
30	Direct-Acting Antivirals as Primary Treatment for Hepatitis C Virus-Associated Indolent Non-Hodgkin Lymphomas: The BAiT Study of the Fondazione Italiana Linfomi. <i>Journal of Clinical Oncology</i> ,	2.2	0
29	Los beneficios de los nuevos antivirales pangenotípicos de acción directa en pacientes con enfermedad mental grave e infección por el virus de la hepatitis C: resultados de una revisión bibliográfica. <i>Gastroenterología Y Hepatología</i> , 2022 ,	0.9	0
28	Targeting non-structural proteins of Hepatitis C virus for predicting repurposed drugs using QSAR and machine learning approaches. <i>Computational and Structural Biotechnology Journal</i> , 2022 , 20, 3422-3438	6.8	1
27	Small molecule NS5B RdRp non-nucleoside inhibitors for the treatment of HCV infection: A medicinal chemistry perspective. <i>European Journal of Medicinal Chemistry</i> , 2022 , 114595	6.8	0
26	Galectin-9 and Interferon-Gamma Are Released by Natural Killer Cells upon Activation with Interferon-Alpha and Orchestrate the Suppression of Hepatitis C Virus Infection. <i>Viruses</i> , 2022 , 14, 1538	6.2	0
25	Hepatitis C and Psychiatry. 2005 , 3, 194-202		
24	Safety and effectiveness of direct-acting antivirals in patients with chronic hepatitis C and chronic kidney disease.		0
23	Hepatocellular carcinoma, decompensation, and mortality based on hepatitis C treatment: A prospective cohort study. 2022 , 28, 4182-4200		
22	Treatment of Hepatitis C Virus Prior to Posterior Lumbar Fusion. Publish Ahead of Print,		
21	Hepatitis C virus, insulin resistance, and diabetes: A review.		1
20	Genomic divergence of Hepatitis C virus towards common prescribed interferon regimens on sustained virologic response (SVR) ?. 2022 , 12, 59-64		0
19	Basic biotechnology applications in viral diseases. 2022 , 105-113		0
18	Hepatitis C. 2022 ,		0
17	Direct antiviral agents (DAAs) and their use in pregnant women with hepatitis C (HCV). 1-12		0
16	Longitudinal Assessment of Multiple Immunological and Inflammatory Parameters during Successful DAA Therapy in HCV Monoinfected and HIV/HCV Coinfected Subjects. 2022 , 23, 11936		0

- 15 Effectiveness of hepatitis C antiviral treatment and feasibility of hepatitis C elimination goal. ○
- 14 "Like a pickle that's been unpickled" Emotional, identity and behavioural transformations throughout hepatitis C treatment. **2022**, 17, e0272401 ○
- 13 Effectivity of repurposed drugs against SARS-CoV-2 infections, A hope for COVID 19: inhibitor modelling studies by docking and molecular dynamics. **2022**, 8, e12327 ○
- 12 2-Thiouridine is a broad-spectrum antiviral nucleoside analogue against positive-strand RNA viruses. ○
- 11 Mathematical Processing of Absorption as Green Smart Spectrophotometric Methods for Concurrent Assay of Hepatitis C Antiviral Drugs, Sofosbuvir and Simeprevir: Application to Combined Pharmaceutical Dosage Forms and evaluation of the method greenness. ○
- 10 Genotype 4 hepatitis C virus-a review of a diverse genotype. **2023**, 68, 54-59 ○
- 9 Repeated Measurement of FIB-4 to Predict Long-Term Risk of HCC Development Up to 10 Years After SVR. Volume 9, 1433-1443 ○
- 8 Pilot Outreach Program in Remedis—the Promising Step toward HCV Elimination among People Who Inject Drugs. **2023**, 20, 501 ○
- 7 Direct-acting antivirals sofosbuvir and daclatasvir attenuate carbon tetrachloride-induced liver fibrosis in mice. **2023**, 7, 71-81 ○
- 6 Decade of optimizing therapy with direct-acting antiviral drugs and the changing profile of patients with chronic hepatitis C. 29, 949-966 ○
- 5 Treating Hepatitis C Prior to Total Hip Arthroplasty is Cost-effective: A Markov Analysis. **2023**, ○
- 4 Eliminaci3n del virus de la hepatitis C en un centro penitenciario: una experiencia de 18 a3os. **2023**, ○
- 3 Outcomes and Follow-Up after Hepatitis C Eradication with Direct-Acting Antivirals. **2023**, 12, 2195 ○
- 2 The transmission risk factors of hepatitis B and C infection in dental treating and tattooing among hemodialysis patients. **2023**, 418-422 ○
- 1 Elimination of hepatitis C virus in a prison: An 18-year experience. **2023**, ○